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About the Health Information and Quality Authority (HIQA) 
The Health Information and Quality Authority (HIQA) is an independent statutory 
authority established to promote safety and quality in the provision of health and 
social care services for the benefit of the health and welfare of the public. 
HIQA’s mandate to date extends across a wide range of public, private and voluntary 
sector services. Reporting to the Minister for Health and engaging with the Minister 
for Children and Youth Affairs, HIQA has responsibility for the following: 
 Setting standards for health and social care services — Developing 
person-centred standards and guidance, based on evidence and international 
best practice, for health and social care services in Ireland. 
 
 Regulating social care services — The Office of the Chief Inspector within 
HIQA is responsible for registering and inspecting residential services for older 
people and people with a disability, and children’s special care units.  
 
 Regulating health services — Regulating medical exposure to ionising 
radiation. 
 
 Monitoring services — Monitoring the safety and quality of health services 
and children’s social services, and investigating as necessary serious concerns 
about the health and welfare of people who use these services. 
 
 Health technology assessment — Evaluating the clinical and cost-
effectiveness of health programmes, policies, medicines, medical equipment, 
diagnostic and surgical techniques, health promotion and protection activities, 
and providing advice to enable the best use of resources and the best 
outcomes for people who use our health service. 
 
 Health information — Advising on the efficient and secure collection and 
sharing of health information, setting standards, evaluating information 
resources and publishing information on the delivery and performance of 
Ireland’s health and social care services. 
 
 National Care Experience Programme — Carrying out national service-
user experience surveys across a range of health services, in conjunction with 
the Department of Health and the HSE.    
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1 Introduction 
1.1 Background to the request 
In August 2018, the Health Information and Quality Authority (HIQA) commenced 
work on a health technology assessment (HTA) on a pre-exposure prophylaxis 
(PrEP) programme for populations at substantial risk of sexual acquisition of the 
human immunodeficiency virus (HIV). The HTA was requested by the Clinical Lead in 
Sexual Health at the Health Service Executive (HSE), with the endorsement of the 
Department of Health.  
PrEP is a form of HIV prevention whereby oral anti-retrovirals (most commonly a 
combination of tenofovir and emtricitabine) are taken by individuals at substantial 
risk of HIV acquisition to prevent infection. There were 492 new HIV diagnoses 
notified in Ireland in 2017, giving rise to a notification rate of 10.3 per 100,000 
population (based on Irish census data).(1) The National Sexual Health Strategy 
2015–2020 has called for a comprehensive restructuring of its HIV prevention 
initiatives, with Priority Action 3 calling for “the appropriate use of antiretroviral 
therapy in HIV prevention”.(2) It is envisaged that PrEP is made available as part of 
an overall HIV prevention package, with an overarching aim of reaching zero HIV 
transmissions.  
There is increasing evidence that PrEP is safe and effective at preventing HIV in 
those at risk of infection. A number of countries (including France and Scotland) 
have introduced national PrEP programmes to combat the spread of HIV. Individuals 
taking PrEP must be monitored closely for side effects and require frequent testing 
for HIV (in addition to other sexually transmitted infections [STIs]). Individuals 
taking PrEP are also offered advice and support regarding safer sex practices and 
adherence to treatment is reinforced. PrEP refers to the antiretroviral medication 
itself, whereas a PrEP programme includes holistic assessment, preventive PrEP 
treatment, education and advice for individuals at substantial risk of infection.  
The aim of this assessment is to examine the clinical and cost-effectiveness of 
introducing a PrEP programme in Ireland. Based on the available evidence, the HTA 
will inform decision making by the Department of Health and the HSE. 
1.2 Terms of reference 
Informed by this HTA, the Minister for Health and the HSE will make decisions 
regarding the potential introduction of a PrEP programme in Ireland.  
The Terms of Reference, agreed with the Department of Health and the HSE, are to: 
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 describe the epidemiology of HIV infection in Ireland 
 examine the clinical effectiveness and safety of oral pre-exposure prophylaxis 
(PrEP) to reduce sexual acquisition of HIV in individuals at substantial risk of 
infection 
 review the evidence of the cost-effectiveness of PrEP 
 evaluate the cost-effectiveness and budget impact of introducing a PrEP 
programme in Ireland 
 estimate the organisational and resource implications of a PrEP programme in 
Ireland 
 consider the wider ethical or societal implications that the introduction of PrEP 
may have for patients, the general public or the health care system. 
1.3 Overall approach 
Following an initial scoping of the technology, the Terms of Reference of this 
assessment were agreed between HIQA, the Department of Health and the HSE.  
HIQA convened an Expert Advisory Group comprising representation from relevant 
stakeholders, including the Department of Health, the HSE, the Health Protection 
Surveillance Centre, clinicians with specialist expertise in HIV and sexual health, the 
National Centre for Pharmacoeconomics and relevant advocacy groups. The role of 
the Expert Advisory Group is to inform and guide the process, provide expert advice 
and information, and to provide access to data where appropriate. A full list of the 
membership of the Expert Advisory Group is available in the acknowledgements 
section of this report.  
The Terms of Reference of the Expert Advisory Group are to: 
 contribute to the provision of high quality and considered advice by the Authority 
to the Health Service Executive 
 contribute fully to the work, debate and decision making processes of the group 
by providing expert guidance, as appropriate 
 be prepared to provide expert advice on relevant issues outside of group 
meetings, as requested 
 provide advice to the Authority regarding the scope of the analysis 
 support the Evaluation Team led by the Authority during the assessment process 
by providing expert opinion and access to pertinent data, as appropriate 
 review the project plan outline and advise on priorities, as required 
 review the draft report from the Evaluation Team and recommend amendments, 
as appropriate 
 contribute to the Authority’s development of its approach to HTA by participating 
in an evaluation of the process on the conclusion of the assessment. 
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HIQA appointed an Evaluation Team comprising staff from the Health Technology 
Assessment Directorate to carry out the assessment. 
The Terms of Reference of the HTA were reviewed by the Expert Advisory Group at 
its first meeting. Draft findings on the epidemiology of HIV in Ireland and the clinical 
effectiveness and safety of PrEP were also discussed at that meeting. Considerations 
regarding the cost-effectiveness, budget impact, organisational, social and ethical 
implications of providing a PrEP programme in Ireland were discussed at the second 
meeting of the group. Draft versions of this report were circulated for review by the 
Expert Advisory Group before a final draft report was prepared for public 
consultation. After the public consultation is complete, a final version of this report 
will be circulated for review by the Expert Advisory Group before it is submitted to 
the Board of HIQA for approval. The completed assessment will be submitted to the 
Minister for Health and the Health Service Executive as advice and published on the 
HIQA website. 
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2 Description of technology 
Key points
 Pre-exposure prophylaxis (PrEP) is a HIV prevention strategy that uses 
antiretroviral medications to protect HIV-negative people from acquiring HIV.  
 The World Health Organisation (WHO) recommends oral pre-exposure 
prophylaxis (PrEP) containing tenofovir as an additional prevention choice for 
people at substantial risk of HIV infection as part of combination HIV 
prevention approaches. The WHO defines ‘substantial risk’ as a risk of HIV 
acquisition that is greater than 3 per 100 person-years in the absence of PrEP. 
 Once daily oral tenofovir/emtricitabine as a fixed dose combination tablet has 
been licensed and available for use as PrEP in Ireland since 2016. While 
licensed, it is not reimbursed through the Primary Care Reimbursement 
Service. Therefore, individuals with a valid prescription for PrEP must pay for it 
themselves.  
 Policy provision for PrEP is contained in the National Sexual Health Strategy 
2015–2020. The strategy recommends a comprehensive restructuring of HIV 
prevention initiatives, with Priority Action 3 calling for “the appropriate use of 
antiretroviral therapy in HIV prevention”. 
 The HSE Sexual Health and Crisis Pregnancy Programme (SHCPP) has 
developed clinical guidance documents (including eligibility criteria) and 
national standards for PrEP use in Ireland. These recommend that PrEP 
medications should be provided as part of a holistic programme that includes 
frequent monitoring for adherence and side effects, testing for HIV and other 
sexually transmitted infections (STIs), and counselling and advice on safer sex 
practices. 
 Twelve countries have introduced national PrEP programmes. France became 
the first country in Europe to provide PrEP through its public health system in 
2015. Elsewhere in Europe, Belgium, Norway, Portugal and Scotland also 
provide PrEP through national programmes. PrEP has also been made available 
in a large number of other countries through demonstration projects, 
implementation projects or clinical trials. 
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2.1 Background  
Pre-exposure prophylaxis (PrEP) is a HIV prevention strategy that uses antiretroviral 
medications to protect HIV-negative people from acquiring HIV. In addition to PrEP, 
these antiretroviral medications are prescribed to prevent the onward transmission 
of HIVin the following cases: 
 as post-exposure prophylaxis (PEP) following occupational or sexual exposure 
(PEPSE) to HIV by a person who is HIV-negative 
 by HIV positive people, as early and effective antiretroviral treatment 
suppresses the viral load decreasing the risk of virus transmission (treatment-
as-prevention [TasP]). 
It is intended that antiretroviral medicines are used in addition to other effective 
prevention strategies, including HIV/STI testing and treatment, provision of 
condoms, health promotion and risk reduction education around sexual behaviour, 
and support and education around alcohol and substance misuse. 
In 2012, the World Health Organization (WHO) first made conditional 
recommendations on PrEP use in serodifferent couples (where one partner is HIV 
negative and the other HIV positive) and men/transgender women who have sex 
with men. They recommended PrEP delivery through demonstration projects to 
ascertain its optimal delivery approaches. Subsequently, in 2014, the WHO 
developed consolidated HIV guidelines for key populations, including gay, bisexual 
and other men who have sex with men (MSM), people who inject drugs (PWID), sex 
workers, transgender people, and people in prisons and other closed settings. In this 
assessment, the term MSM will include gay, bisexual and other men who have sex 
with men. The primary populations that the planned PrEP programme intends to 
engage include both MSM and trans women who have sex with men. 
In 2016, WHO issued updated consolidated guidelines.(3) The following 
recommendation was made: 
Oral pre-exposure prophylaxis (PrEP) containing TDF [tenofovir disoproxil 
fumarate] should be offered as an additional prevention choice for people at 
substantial risk of HIV infection as part of combination HIV prevention 
approaches (strong recommendation, high quality evidence).  
Substantial risk was defined by WHO as a risk of HIV acquisition that was greater 
than three per 100 person-years in the absence of PrEP. 
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2.2 Regulatory status of PrEP  
In the US, the Food and Drug Administration (FDA) approved in 2012 a once daily 
oral fixed-dose combination pill containing tenofovir disoproxil fumarate and 
emtricitabine (Truvada®) for use as PrEP to prevent sexual acquisition of HIV-1.(4) 
The US Centers for Disease Control and Prevention (CDC) subsequently released 
clinical guidelines on the use of PrEP in 2014.(5) These guidelines recommended PrEP 
use in individuals at substantial risk of sexually acquired HIV. 
In August 2016, Truvada® was officially granted marketing authorisation in Europe 
for use as PrEP.(6) Treatment is indicated in combination with safer sex practice to 
reduce the risk of sexually-acquired HIV-1 infection in adults at high risk. The 
marketing authorisation allows for the marketing of Truvada® for PrEP in all 28 
countries of the EU, subject to national regulatory authority approval of required 
pharmacovigilance materials in each country. In 2017, the EMA extended the use of 
Truvada® for PrEP to include adolescents over the age of 13 at substantial risk. In 
July 2017, Truvada® came off patent, and a number of generic formulations have 
since become available in Ireland. 
2.3 Product information 
Much of the product information in this section is listed in the Summary of Product 
Characteristics (SmPC) of marketed PrEP medications in Ireland.(7-9) The 
formulations of the tenofovir /emtricitabine fixed dose combinations licensed and 
marketed for use as PrEP in Ireland differ. Each tablet of the Truvada® formulation 
contains 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate, which 
is equivalent to 245 mg of its active metabolite, tenofovir disoproxil. Sources may 
express this as Truvada 200 mg/245 mg (disoproxil dose) or Truvada 200 mg/300 
mg (disoproxil fumarate dose). Generic formulations contain emtricitabine and 
alternative tenofovir disoproxil salts, such as tenofovir disoproxil maleate or 
phosphate. For the remainder of this HTA, tenofovir disoproxil refers to the active 
component of the salt of tenofovir (tenofovir disoproxil fumarate, maleate or 
phosphate) and tenofovir/emtricitabine refers to oral tenofovir disoproxil and 
emtricitabine fixed dose combination medication for use as PrEP to prevent HIV 
acquisition. 
2.3.1 Mechanism of action 
Emtricitabine is a nucleoside analogue of cytidine. Tenofovir disoproxil, which is 
converted in vivo to tenofovir, is a nucleotide analogue of adenosine 
monophosphate. Both emtricitabine and tenofovir have activity against HIV-1, HIV-2 
and hepatitis B virus. Following phosphorylation by cell enzymes, emtricitabine and 
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tenofovir both competitively inhibit HIV-1 reverse transcriptase. This results in DNA 
chain termination. By inhibiting HIV-1 from replicating as it enters the body, it is 
thought that tenofovir/emtricitabine prevents the virus from establishing permanent 
infection.  
The time to onset of protection after starting tenofovir/emtricitabine is unknown and 
the treatment is not always effective in preventing the acquisition of HIV. The 
effectiveness in reducing the risk of acquiring HIV is strongly correlated with 
adherence, as demonstrated by measurable drug levels in blood. It should, 
therefore, only be used for PrEP as part of an overall HIV prevention strategy, 
including consistent and correct condom use, knowledge of HIV status and regular 
testing for other sexually transmitted infections. The effectiveness and safety of 
emtricitabine/tenofovir disoproxil when taken as PrEP in preventing acquisition of 
HIV is reviewed in detail in Chapter 4. 
2.3.2 Dosing schedule 
The recommended dose of tenofovir/emtricitabine for treating or preventing HIV is 
one tablet, taken orally, once daily. To optimise the absorption of tenofovir, it is 
recommended that the treatment is taken with food. 
While only licensed as a daily regimen, event-based dosing has been suggested in 
certain jurisdictions due to the success of one trial that confirmed the safety and 
effectiveness of event based (also known as ‘on demand’) PrEP(10) (see Chapter 4 for 
further details). The recommendation is as follows: take two pills before sex as a 
double dose (two pills) and a single pill 24 and 48 hours after. If sex continues as 
multiple episodes, individuals should continue taking one pill every 24 hours for the 
days condomless anal sex is occurring, and, after the last episode of condomless 
anal sex, continue taking PrEP for two more days. Event-based dosing is only 
recommended for those at risk of HIV through anal sex and not vaginal sex due to 
the fact that evidence for event-based dosing is specific to the MSM group.(10) 
2.3.3 Adverse events 
The safety data contained in the SmPC for tenofovir/emtricitabine are largely derived 
from its use as treatment in people who are HIV positive. The risk of adverse effects 
when tenofovir/emtricitabine is used for PrEP is less well described. The most 
frequently reported adverse reactions considered possibly or probably related to 
treatment with emtricitabine or tenofovir are nausea (12%) and diarrhoea (7%).  
The SmPC for tenofovir/emtricitabine states that emtricitabine and tenofovir are 
primarily excreted by the kidneys. Renal failure, renal impairment, elevated 
creatinine, hypophosphataemia and proximal tubulopathy have been reported with 
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the use of tenofovir for treating HIV infection. Creatinine clearance should be 
calculated in all individuals before starting tenofovir/emtricitabine for either 
treatment or prevention, and renal function should also be monitored during use. 
Tenofovir/emtricitabine for use as PrEP is not recommended in people with 
creatinine clearance less than 60 ml/min. There are also cautions around use in 
people with impaired renal function and use of nephrotoxic medicines.  
Small decreases in bone mineral density of the hip and spine were seen in a study of 
treatment with tenofovir in people who were antiretroviral-naive, but there was no 
increased risk of fractures or evidence for clinically relevant bone abnormalities. 
People with chronic hepatitis B or C treated with antiretroviral therapy are at an 
increased risk for severe and potentially fatal hepatic adverse reactions.   
Emtricitabine and tenofovir individually and in combination have shown activity 
against hepatitis B virus in pharmacodynamic studies, and discontinuation of 
tenofovir/emtricitabine in people infected with hepatitis B virus may be associated 
with severe acute exacerbations of hepatitis. 
Tenofovir/emtricitabine alone does not constitute a complete regimen for treating 
HIV, and resistant mutations have emerged in people with undetected HIV infection 
who are only taking this treatment as dual therapy. It should, therefore, only be 
used for PrEP in people who have been confirmed to be HIV negative, and this 
should be reconfirmed at frequent intervals (for example, at least every three 
months) using a combined antigen/antibody test. PrEP is contraindicated in people 
with unknown or positive HIV-1 status.  
2.4 PrEP use in Ireland 
Two PrEP monitoring clinics are operational in Ireland: one at the Gay Men’s Health 
Service and another at the Mater Misericordiae University Hospital. These clinics do 
not dispense PrEP. A number of other STI clinics also prescribe PrEP, as well as GPs 
and primary care centres. While daily oral tenofovir disoproxil/emtricitabine as PrEP 
is licensed for the prevention of sexually acquired HIV in Ireland, PrEP is not 
reimbursed through the Primary Care Reimbursement Service (PCRS). Therefore, 
while individuals can redeem their prescriptions for PrEP though community 
pharmacies, they must pay for it themselves. There is also evidence that some 
individuals are ordering PrEP online.  
Policy provision for PrEP is contained in the National Sexual Health Strategy 2015–
2020.(2) The strategy recommends a comprehensive restructuring of HIV prevention 
initiatives, with Priority Action 3 calling for “the appropriate use of antiretroviral 
therapy in HIV prevention”. The HSE Sexual Health and Crisis Pregnancy Programme 
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(SHCPP) has responsibility for implementing this strategy. To inform its work, SHCPP 
convened a multisectoral working group to develop recommendations in relation to 
the use of HIV PrEP in Ireland (the PrEP Working Group).   
This group, with community representation, developed clinical guidance documents 
and national standards in relation to the use of PrEP in Ireland. These standards were 
reviewed by SHCPP’s Sexual Health Strategy Implementation Group and SHCPP’s 
Clinical Advisory Group and they will inform future work on the preparedness of STI 
clinics to implement PrEP programmes in line with these standards. In time, if PrEP is 
available through the HSE, it is intended that the finalised standards will be used in all 
centres providing PrEP. 
2.4.1 Eligibility criteria 
The PrEP Working Group has developed evidence-based eligibility criteria for PrEP in 
Ireland and provides guidance on its provision as well as the assessment and 
monitoring of those at risk of HIV. Guidelines from the British Association for Sexual 
Health and HIV (BASHH) and the British HIV Association (BHIVA) were used as a 
reference, particularly in relation to evidence around PrEP dosing schedules and 
clinical monitoring of those on PrEP.(11)  
Indications for PrEP per the PrEP Working Group 
Three populations were identified by the PrEP Working Group as being eligible for 
PrEP to prevent the sexual transmission of HIV: 
1. MSM or transgender women having sex with men at substantial risk. 
Individuals must be HIV negative, sexually active with likelihood of remaining 
sexually active in the next three months, and report at least one of the 
following: 
 condomless anal sex with at least two casual partners over the 
last six months  
 an episode of documented or reported acute STI over the last 12 
months (excluding anogenital warts and non-primary herpes 
simplex virus) 
 documented or reported use of HIV post-exposure prophylaxis 
following sexual exposure (PEPSE) over the last 12 months 
 engagement in chemsex over the last six months. 
2. HIV negative individuals having condomless sex with a HIV positive person 
who is not stably suppressed on antiretroviral therapy, specifically when the 
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person living with HIV:  
 is not on antiretroviral therapy 
 has initiated antiretroviral therapy but is not yet on treatment for 
six months with virological suppression (an individual is 
considered virologically suppressed when the viral load is less 
than 200 copies/mL) 
 has loss of virological control on antiretroviral therapy and the risk 
of HIV transmission has been deemed by a consultant physician 
specialising in HIV medicine to be substantial and warrant PrEP 
for the HIV negative partner. 
3. Other HIV negative heterosexual men, heterosexual women and transgender 
 men considered by a senior clinician specialising in HIV medicine to be at 
 substantial risk for sexual acquisition of HIV. 
The following individuals are not eligible for PrEP: 
 individuals in a monogamous relationship with a HIV positive partner who 
is confirmed to be stably suppressed on antiretroviral therapy for at least 
six months  
 individuals in a monogamous relationship with a partner who is known to 
be HIV negative  
 individuals unwilling to attend for follow up. 
 
The PrEP Working Group does not recommend PrEP for the prevention of HIV 
through injection drug use. People who inject drugs may nonetheless be at risk of 
sexual acquisition of HIV and, therefore, may otherwise meet the eligibility criteria 
for PrEP. 
PrEP in pregnancy 
The PrEP Working Group recommends that pregnant females at substantial risk of 
sexual acquisition of HIV should be informed of the protective effect of PrEP in 
averting HIV infection and informed of the available information in relation to the 
safety of use of tenofovir disoproxil and emtricitabine in pregnancy. Females at 
substantial risk of HIV who meet eligibility criteria should be offered PrEP as part of 
combination HIV prevention regardless of pregnancy status or risk of conception. 
However, pregnancy status should be established in females being considered for 
PrEP and in women taking PrEP.  
PrEP contraindications (at baseline or during follow up) 
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PrEP comprises dual antiretroviral therapy and is, therefore, not indicated in 
individuals who are HIV positive. It is also contraindicated in circumstances of poor 
adherence with continued high risk exposure, as individuals who seroconvert are at 
increased risk of developing antiretroviral resistance. Therefore, PrEP is 
contraindicated in individuals who: 
 are HIV positive 
 have an undocumented HIV status 
 are poorly adherent to PrEP (that is, less than four days per week of a daily 
dosing schedule) with continued high risk exposure 
 are allergic to tenofovir or emtricitabine. 
Impact of suppressive antiretroviral therapy on risk of HIV acquisition  
As indicated above, PrEP is indicated in HIV negative individuals who engage in 
condomless anal sex with a HIV positive person only when the HIV positive person is 
not stably suppressed on antiretroviral therapy. When the HIV-infected partner is 
suppressed on antiretroviral therapy, PrEP is not indicated. The HPTN 052 clinical 
trial(12) and the HIV Partner cohort study(13) underpin the efficacy of suppressive 
antiretroviral therapy in preventing onward transmission of HIV in serodifferent 
sexual couples over a range of different sexual exposure types. The results of the 
HIV Partner cohort study, where the health outcomes of partners of HIV positive 
individuals on suppressive antiretroviral therapy were measured, are given in Table 
2.1 below. Note that while the incidence of HIV was zero in all comparisons, the 
upper 95% Confidence Interval was high (and above 3 per 100 couple-years) for 
some. This reflects low number of couples in the analysis of these comparisons (for 
example, the upper limit of 12.71 per 100 couple-years in the ‘anal sex with 
ejaculation in heterosexual women’ was based on 29 couple-years of data, compared 
with 1,238 couple-years for the overall group). 
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Table 2.1.  Efficacy of suppressive antiretroviral therapy in preventing 
onward transmission of HIV in serodifferent couples, by sexual 
exposure type 
 Number of 
infections 
HIV incidence per 
100 couple years 
Upper limit 
95% CI 
Overall 0 0 0.3 
Heterosexual women 
Any sex 0 0 0.97 
Vaginal sex ejaculation 0 0 1.50 
Vaginal sex no 
ejaculation 
0 0 1.55 
Anal sex ejaculation 0 0 12.71 
Anal sex no ejaculation 0 0 8.14 
Heterosexual men 
Any sex 0 0 0.88 
Insertive anal sex 0 0 7.85 
MSM 
Any sex 0 0 0.84 
Insertive anal sex 0 0 1.00 
Receptive anal sex 
ejaculation 
0 0 2.70 
Receptive anal sex no 
ejaculation 
0 0 1.68 
Source: HIV PARTNER observational study  
2.4.2 Components of a PrEP programme 
PrEP medications should be provided as part of a holistic programme that includes 
frequent monitoring for adherence and side effects, testing for HIV and other STIs, 
and counselling and advice on safer sex practices. Clinical management guidance, 
national standards for a PrEP programme and a monitoring framework have been 
developed by the PrEP Working Group.  
2.4.2.1 Clinical management guidance 
The PrEP Working Group outlines four key stages in the assessment and monitoring 
of individuals on PrEP:  
Stage 1: Identification of people at high risk of HIV, determination of eligibility 
  for PrEP and baseline assessment 
Stage 2: The starting PrEP visit 
Stage 3: Subsequent visits 
Stage 4: Continuing PrEP visits (after one year). 
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The following sections outline the key elements that have been identified for each of 
these stages.  
Stage 1: Identification of people at high risk of HIV, determination of eligibility 
  for PrEP and baseline assessment 
The guidelines noted that some people may recognise their risk of HIV and self-refer 
for PrEP assessment and some may have been referred for PrEP assessment.  
Consultations should be able to identify people at substantial risk of HIV (and eligible 
for PrEP) from their sexual history, history of STIs, history of PEPSE (post-exposure 
prophylaxis after sexual exposure) use and history of chemsex (use of drugs such as 
methamphetamine, mephedrone or gamma hydroxybutyrate [GHB] during sex). 
Table 2.2 lists these key elements in a patient’s history 
Table 2.2. Key elements in patients’ sexual history 
Elements of consultation Notes 
Last sex 
 
 Type of sex (anal, vaginal, oral and active, 
passive or both) 
 Use of condoms 
Number of sexual partners in 
the last 3 months 
 Type of sex (anal, vaginal, oral and active, 
passive or both) 
 Use of condoms  
For MSM or trans women 
having sex with men 
Number of condomless anal sex partners in the 
last 6 months 
HIV status of sexual partners 
 
If partner is HIV positive, document treatment 
status and virological suppression status 
STIs in the last 12 months   
PEPSE in the last 12 months  
Use of chemsex in the last 6 
months 
 
PEPSE=post-exposure prophylaxis after sexual exposure 
‘Slamming’=injection drug use during sexual episodes, typically methamphetamine, mephedrone or GHB 
 
For individuals at high risk of HIV, the guidelines recommend that consultation 
should include the additional elements listed in Table 2.3. 
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Table 2.3. Consultation requirements — individuals at high risk 
Elements of consultation Notes, additional actions 
Provision of information on 
HIV/STI risk reduction 
 
Safer sex practices, provision of condoms, brief 
intervention regarding alcohol, drugs (including 
information around safer injecting and needle 
exchange for individuals ‘slamming’ drugs) and 
further support/referral if required 
Documentation of medical 
conditions 
Renal conditions and other medical conditions 
that may impair renal function, for example, 
diabetes mellitus and hypertension 
Bone conditions or risk factors for low bone 
mineral density 
Documentation of current 
medication(s) 
If PrEP is being considered, medications that may 
be nephrotoxic 
Documentation of drug 
allergy status 
 
Clinical examination as 
required 
 
Appropriate investigations 
including 
 
 4th generation venous blood HIV test 
 HBV testing, directed by history unless 
documented as HBV immune 
 HAV IgG testing if previous vaccination not 
reported or not documented as HAV immune 
 syphilis serology 
 HCV testing  
 chlamydia and gonorrhea NAAT testing from 
all relevant anatomical sites (can be self-taken 
or provider taken) 
 where indicated gonorrhea culture from 
urethra, pharynx and rectum 
Provide treatment as 
required, including PEPSE 
 
Provide vaccination as 
indicated 
Hepatitis A and B, HPV (if aged under 26 years) 
 
PEPSE=post-exposure prophylaxis after sexual exposure; HBV=hepatitis B virus; HAV=hepatitis A virus; HCV=hepatitis C virus; 
IgG=immunoglobulin G; NAAT=nucleic acid amplification test; HPV=human papilloma virus 
If found to be eligible for PrEP, the guidelines recommend that consultation should 
include the elements listed in Table 2.4.  
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Table 2.4. Consultation requirements — individuals eligible for PrEP 
Elements of consultation Notes, additional actions 
Assess and document PrEP 
eligibility  
 
Discuss PrEP and provide written 
information and offer/arrange 
starting PrEP visit and document 
patient’s decision.  
The starting PrEP visit must be within four 
weeks of the baseline HIV test and, if not, 
a repeat HIV test must be performed. For 
patients requiring PEPSE, arrangements 
should be made for the starting PrEP visit 
at the end of the PEPSE course. 
Check serum creatinine and eGFR  
PEPSE=post-exposure prophylaxis after sexual exposure; eGFR=estimated glomerular filtration rate 
 
Stage 2: Starting PrEP visit 
Table 2.5 lists the guideline recommendations for the key elements of the first PrEP 
visit (when PrEP is initiated). 
Table 2.5. Key elements of starting PrEP visit 
Elements of consultation Notes, additional actions 
Confirm previously documented 
eligibility criteria 
 
Reiterate HIV/STI risk reduction 
strategies 
 
Safer sex practices, provision of 
condoms, brief intervention regarding 
alcohol, drugs and further 
support/referral if required 
Confirm HIV negative 4th generation 
venous blood HIV test within last 
four weeks 
Determine if need for repeat HIV test at 
four weeks (for example, if there is 
concern individual is in HIV window 
period at time of test or if individual has 
just completed PEPSE) 
Check results from previous visit Treat STIs, offer vaccination where 
required 
Check serum creatinine and eGFR 
results  
 
Review medical history and determine 
when next creatinine check indicated 
Discuss PrEP and document patients 
decision regarding starting 
Discuss lead in times, adherence and 
dosing schedule 
Address any queries in relation to 
PrEP and follow up 
 
Prescribe one to three months 
tenofovir disoproxil /emtricitabine 
one tablet once daily or event-based 
dosing, if appropriate  
 
Confirm contact details and 
preferred mechanism for contacting 
where need arises 
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PEPSE=post-exposure prophylaxis after sexual exposure 
Stage 3: Subsequent visits 
Patients must return every three months following PrEP initiation. Table 2.6 lists the 
key elements outlined in the guidelines of these subsequent visits. 
Table 2.6. Key elements of subsequent PrEP visit 
Elements of consultation Notes, additional actions 
Determine if still taking 
PrEP 
If no longer taking, determine and document 
reason(s) for stopping 
Reassess eligibility criteria Document if still eligible or no longer eligible 
Reiterate HIV/STI risk 
reduction 
 
Safer sex practices, provision of condoms, brief 
intervention regarding alcohol, drugs and further 
support/referral if required 
Take sexual history Document sexual exposure history in last three 
months. Determine if symptoms of STI. 
Examination as required   
Investigations 
 
 4th generation venous blood HIV test 
syphilis serology 
 HCV testing (annually unless otherwise 
indicated)  
 chlamydia and gonorrhea NAAT testing 
from all relevant anatomical sites (can be 
self-taken or provider taken) 
 where indicated, gonorrhea culture from 
urethra, pharynx and rectum 
Vaccination follow up as 
required 
 
HCV=hepatitis C virus; NAAT=nucleic acid amplification test 
Stage 4: Continuing PrEP 
In addition to the requirements of ‘subsequent’ visits, the guidelines recommend a 
‘continuing visit’ beyond one year which will require the elements listed in Table 2.7. 
The additional laboratory investigation is measurement of creatinine and estimated 
glomerular filtration rate (yearly). 
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Table 2.7. Key elements of continuing PrEP visits 
Elements of consultation Notes, additional actions 
Measure serum creatinine, eGFR if indicated Clinical assessment checklist 
available for frequency of renal 
monitoring and 
recommendations in the 
setting of impaired renal 
function  
Assess and document dosing schedule and 
adherence  
Reinforce adherence where 
required 
Prescribe three months tenofovir 
disoproxil/emtricitabine one tablet once 
daily or for event-based dosing if 
appropriate  
 
Confirm contact details and preferred 
mechanism for contacting where need arises 
 
eGFR=estimated glomerular filtration rate 
2.4.2.2 National standards for PrEP 
The PrEP Working Group has developed a set of national standards for the provision 
of PrEP as part of combination HIV prevention strategies in Ireland. The standards 
represent best practice and outline the responsibilities of services, service managers, 
service providers and healthcare professionals, as well as establishing the 
expectations of service users. The standards are in line with the goals of the 
National Sexual Health Strategy regarding sexual health services, specifically 
“Equitable, accessible and high quality sexual health services, which are targeted 
and tailored to need”. 
Six standards were developed. They relate to:  
1. Access  
2. Service Configuration and Structure  
2.1. Availability of appropriate combination HIV prevention and STI 
 management tools   
2.2. Links to other services  
2.3. Surveillance, monitoring and evaluation  
3. Clinical Assessment and Management  
4. Management of Results  
5. Information Governance  
6. Patient and Public Engagement. 
2.4.2.3 PrEP monitoring framework 
The PrEP Working Group has also developed a PrEP monitoring framework 
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document that fulfills PrEP Standard 2.3: Surveillance, monitoring and evaluation. 
The following quality standards are included: 
1. Disease Surveillance: It is a core requirement that all PrEP services meet 
statutory disease notification and surveillance requirements within a 
reasonable timeframe. 
2. PrEP monitoring and evaluation: It is a core requirement that all PrEP 
services participate in national monitoring and evaluation requirements for 
PrEP within a reasonable timeframe. 
2.5 International PrEP programmes 
As mentioned previously, daily oral PrEP using a fixed dose combination of 
emtricitabine/tenofovir is licensed in all EU/EEA member states by the European 
Commission (2016) and in the US by the FDA (2012).  
Many countries offer PrEP through dedicated programmes, such as national 
programmes, demonstration projects, implementation projects and clinical trials. 
Overall, PrEP is available in 49 countries worldwide through one or more of these 
programmes. Appendix 1 lists all countries where PrEP is available through a 
dedicated programme. 
Twelve countries provide PrEP through national programmes, and four countries are 
planning to introduce national programmes (see Table 2.8 and Figure 2.1). France 
became the first country in Europe to offer PrEP through its public health system in 
2015.(14) It did this through an ‘emergency recommendation for temporary use’, 
which became permanent in April 2017. Other European countries that have national 
programmes in place include Belgium, Norway, Portugal and Scotland. Northern 
Ireland introduced a pilot PrEP clinic based in the Belfast Trust in August 2018.(15)  
Table 2.8. Countries with ongoing or planned national programmes  
Ongoing National PrEP Programmes 
Country Relevant guideline/policy document 
Belgium HIV plan 2014–2019 Belgium(16) 
Brazil Clinical Protocol and Therapeutic Guidelines for Management of 
HIV Infection in Adults (2018)(17) 
Canada 1. Canadian guideline on HIV pre-exposure prophylaxis and 
nonoccupational postexposure prophylaxis(18) 
2. Guidance for the use of PrEP in British Columbia (2016)(19) 
France ANSM Pre-exposure Prophylaxis Guidelines (2017)(20) 
Kenya Framework for the Implementation of Pre-Exposure Prophylaxis 
of HIV In Kenya (2017)(21) 
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New Zealand Australasian Society for HIV, Viral Hepatitis and Sexual Health 
Medicine HIV pre-exposure prophylaxis: clinical guidelines(22) 
Norway Not identified 
Portugal Not identified 
Scotland Scottish Medicines Consortium Truvada Assessment (2017)(23) 
Thailand Thailand National Guidelines on HIV/AIDS Treatment and 
Prevention 2017(24) 
Uganda 1. National HIV AND AIDS Strategic Plan 2015/2016 - 
2019/2020(25) 
2. Consolidated Guidelines for Prevention and Treatment of HIV 
in Uganda (2016)(26) 
USA National HIV/AIDS Strategy for the United States: Updated to 
2020(27) 
Wales Preparing for PrEP full report 2017(28) 
Planned National PrEP Programmes 
Country Guideline 
Botswana Not identified 
Israel Not identified 
Namibia National Guidelines For Antiretroviral Therapy (2016) 
Taiwan Taiwan National Pre-Exposure Prophylaxis Guidelines (2016) 
Source: Global Advocacy for HIV prevention (AVAC) 2018 
Figure 2.1. Countries with ongoing or planned national programmes  
 
Countries are: Belgium, Brazil, Canada, France, Kenya,  Norway, New Zealand, Thailand, Portugal, Uganda, Scotland & NI (UK), 
and USA  
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2.6 Discussion 
Pre-exposure prophylaxis (PrEP) is the most recent development in the field of HIV 
prevention. It involves the pre-emptive use of oral antiretroviral therapy in HIV 
negative people to reduce the risk of HIV infection. In their latest guidelines, WHO 
recommends that oral PrEP containing tenofovir disoproxil is offered as part of a 
comprehensive HIV prevention programme to people at ‘substantial risk of HIV 
infection’.(3) PrEP is available in 49 countries worldwide and over ten countries have 
implemented national programmes for PrEP delivery. 
Policy provision for PrEP in Ireland is contained in the National Sexual Health 
Strategy 2015–2020.(2) The strategy recommends a comprehensive restructuring of 
HIV prevention initiatives, with Priority Action 3 calling for “the appropriate use of 
antiretroviral therapy in HIV prevention”. 
Once daily oral tenofovir/emtricitabine as a fixed dose combination tablet has been 
licensed and available for use as PrEP in Ireland since 2016. While evidence exists 
for other dosing schedules (such as event-based(29)), only daily dosing is licensed. 
PrEP differs from a PrEP programme in that a programme provides PrEP as part of a 
holistic service that includes frequent monitoring for adherence and side effects, 
testing for HIV and other STIs, and counselling and advice on safer sex practices. 
While licensed, PrEP is not reimbursed through the Primary Care Reimbursement 
Service. Therefore, individuals with a valid prescription for PrEP must pay out-of-
pocket at community pharmacies. Additionally, some users are obtaining PrEP 
online. This raises concerns regarding potential inequity in that access to PrEP is 
limited to those who can afford to pay. Additionally, those acquiring PrEP online may 
not be enrolled in a programme and are, therefore, not undergoing testing for HIV 
and other STIs, monitoring for side effects and obtaining advice on safer sex 
practices.  
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3 Epidemiology of HIV in Ireland 
Key points  
 HIV is a notifiable disease in Ireland. All new diagnoses notified in Ireland are 
reported nationally by the Health Protection Surveillance Centre (HPSC). 
 There were 492 diagnoses of HIV notified in Ireland in 2017, representing a 
rate of 10.3 per 100,000 population. An increasing proportion (39%) of 
diagnoses in Ireland in 2017 was in people known to be previously diagnosed 
HIV positive abroad and the majority of these (88%) had transferred their care 
to Ireland.  
 Of the 492 new diagnoses, just over half (53%) were among gay, bisexual and 
other men who have sex with men (MSM). The proportion of MSM previously 
diagnosed HIV positive before arrival in Ireland has increased from 16% of 
cases in 2012 to 42% in 2017. Of those previously diagnosed HIV positive 
abroad in 2017, 91% were transferring their care to Ireland. Among MSM 
without a previous HIV positive diagnosis, there was a 3% decline in diagnoses 
between 2016 and 2017 and a 14% decline between 2015 and 2016.  
 Heterosexuals accounted for 33% (163) of diagnoses in 2017, an increase of 
13% compared with 2016. Of these, 41% were previously diagnosed positive in 
another country, of whom 85% had transferred their HIV care to Ireland. 
Overall, 61% of heterosexual cases were born in sub-Saharan Africa.  
 There were 17 (4%) diagnoses among people who inject drugs (PWID) in 
2017, a decrease from the numbers in 2016 (21) and from 2014-2015 when 
there was an outbreak of HIV in Dublin among homeless drug users. 
 The prevalence of HIV in Ireland is not known, but was estimated in 2018 to be 
7,205 people (95% Confidence Interval: 6,456 to 8,056). 
 While comparing favourably with the WHO European region, Ireland has yet to 
meet the UNAIDS has set ’90-90-90’ targets for HIV diagnosis and treatment 
(90% of people with HIV know their status, 90% of those who know their 
status on ART, 90% of those on ART virally suppressed [<200copies/µl]). In 
Ireland it is estimated that 87% know their status, of which 83% (95% CI: 
74.5% to 93.0%) are on antiretroviral therapy (ART) and 95% are virally 
supressed. 
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 The Men who have sex with men Internet Survey Ireland 2015 (MISI 2015) was 
a large-scale community based survey among adult MSM living in Ireland. This 
survey estimated that the HIV prevalence in MSM who have been tested is 
7.8%, with an overall prevalence (tested and untested) of 5%. This is very 
similar to UK MSM prevalence (7.7%). 
 Only 67% of MSM were sure of their HIV status in the MISI 2015 survey. Of 
HIV positive men, 79% were currently on ART, and of those on ART, 91% were 
virally suppressed. 
 Very little data were identified on other populations at substantial risk, such as 
PWID, sex workers or prisoners. 
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3.1 Introduction 
HIV infection is a notifiable disease in Ireland and is of major public health 
importance. The objective of this chapter is to describe the epidemiology of HIV 
infection in Ireland. First the notification rate of HIV infection is described (Section 
3.2) and then the number of people living with HIV in Ireland (i.e., the prevalence of 
HIV infection) is described (Section 3.3). Finally, the proportion of gay, bisexual and 
other men who have sex with men (MSM) who may be eligible for PrEP is described 
(Section 3.4).  
Most of the data on the epidemiology of HIV in Ireland come from published reports 
by the Health Protection Surveillance Centre (HPSC) including collaborations 
between the HPSC and the HSE’s Sexual Health and Crisis Pregnancy Programme 
(SHCPP) and the Joint United Nations Programme on HIV and AIDS (UNAIDS). 
Important published survey data include the Men who have sex with men Internet 
Survey Ireland 2015 (MISI 2015)(30) and the Healthy Ireland Survey 2017.(31)  
3.2 HIV notifications in Ireland 
3.2.1 HIV testing and case definition 
HIV infection became a notifiable disease in Ireland in September 2011. As a 
consequence, all clinicians and clinical directors of laboratories have a statutory 
obligation to notify all new diagnoses of HIV to the Health Protection Surveillance 
Centre (HPSC).(32) Acquired immunodeficiency syndrome (AIDS) is not a notifiable 
disease; however, the stage of infection should be reported on HIV surveillance 
forms for all new HIV diagnoses. From January 2012 onwards, only AIDS-defining 
illnesses that occur at the time of HIV diagnosis have been recorded and included in 
reports by the HPSC. 
Fourth generation assays that simultaneously test for anti-HIV antibodies and the 
p24 antigen are recommended for HIV screening. Assays available in Europe have 
excellent sensitivities (99.78–100%) and specificities (99.5–99.93%).(33) Following a 
reactive screening test for HIV, confirmatory testing should always be undertaken in 
a laboratory with experience in HIV confirmation. In Ireland, the National Virus 
Reference Laboratory (NVRL) undertakes all HIV confirmatory testing. Since January 
2015 (for HSE East) and January 2016 (for all other HSE areas), the NVRL notify 
new diagnoses of HIV based on confirmatory testing on a single sample (previously 
two separate samples were required) and then notify the relevant Department of 
Public Health).(1)  
Once the NVRL confirms a new diagnosis, they enter relevant information into the 
Computerised Infectious Disease Reporting (CIDR) system.(34) The CIDR is a 
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confidential name-based surveillance system for managing infectious disease 
notifications in Ireland. CIDR has received ISO 27001 accreditation which is a 
European certification for best practice in information security and system 
availability.  
All HIV-exposed infants are referred to the Rainbow Clinic at Our Lady’s Children’s 
Hospital in Crumlin. Once a new paediatric HIV diagnosis has been confirmed by the 
clinic, it is notified directly by the Rainbow Clinic to the relevant Department of 
Public Health. Paediatric infections are not notified to the CIDR by the NVRL.  
3.2.2 Notification rate in 2017  
Due to the fact that data on HIV diagnoses in 2018 are provisional at present (see 
Section 3.2.2), the most recent year with complete data is 2017. Data presented in 
this section are taken from the HIV in Ireland 2017 Annual Epidemiological Report, 
published by the HPSC.(35)  
There were 492 new HIV diagnoses notified in Ireland in 2017, giving rise to a 
notification rate of 10.3 per 100,000 population (based on Irish census data). The 
notification rate for the period 2015 to 2017 ranged from 10.1 to 10.5 per 100,000. 
Prior to this, there was a large increase (30%) in notifications between 2014 and 
2015. A change in the case definition for surveillance which was introduced in 2015 
in HSE East (and all other HSE areas in 2016) may partly explain this increase. 
Previously, confirmatory testing by the NVRL was required on two separate samples 
prior to notification. From January 2015 onwards, confirmatory testing by NVRL on 
one sample was sufficient prior to notification.  
In 2017, 76% (n=376) of HIV diagnoses were in men and 24% (n=116) were in 
women, with a male to female ratio of 3.2. Men had higher age-specific rates than 
women in all age groups. The median age of adult cases at HIV diagnosis was 35 
years (range: 18 to 75 years). Eight percent of HIV diagnoses were in young people 
(15-24 years) and 14% were in those aged 50 years and older. Additional 
demographic data related to diagnoses in 2017 is provided in Appendix 2. 
Information on probable route of transmission was available for 90% (n=442) of 
diagnoses. Among all notifications, sex between men was the predominant mode of 
HIV transmission (53%). Notifications among MSM decreased by 4% between 2016 
and 2017. Heterosexuals accounted for 33% of diagnoses, an increase of 13% 
compared with 2016. Four per cent of notifications were among people who inject 
drugs (PWID). There were no cases where the route of transmission was reported as 
mother to child transmission (MTCT).  
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In terms of region of birth, 26% (n=130) of people diagnosed with HIV were born in 
Ireland, 63% (n=308) born outside of Ireland and 11% (n=54) did not have 
information on country of birth. Geographic origin varied by route of transmission. 
The majority (66%) of MSM were born in Ireland or Latin America. The majority of 
heterosexual females (74%) were born in sub-Saharan Africa with roughly equal 
proportions of heterosexual males born in Ireland (43%) and sub-Saharan Africa 
(40%). The majority of PWID (76%) were born in Ireland or Central and Eastern 
Europe. 
Figure 3.1, below, demonstrates the trends in the rate of notification for Irish born 
and migrants over the last fifteen years (2003-2017). The rate of diagnosis among 
those born in Ireland has remained stable since 2003, ranging from 3.4 to 4.2 per 
100,000. There has been much greater fluctuation in the rate among migrants, 
increasing from 18.4 in 2011 to 38.4 per 100,000 in 2016, reversing a previous 
downward trend. 
Figure 3.1. Trend in rate of HIV diagnosis by migrant status, 2003 to      
2017 
 
 
HSE East (counties Dublin, Wicklow and Kildare) consistently reports higher 
diagnosis rates than other regions. In 2017, 346 new HIV cases (70%) were 
diagnosed in people living in HSE East giving a rate of 20.2 per 100,000 population. 
This was almost twice the national rate (10.3 per 100,000).  
Notifications of HIV to the HPSC include all people who are diagnosed HIV positive 
for the first time in Ireland and include a number of people who have been 
previously diagnosed HIV positive abroad. The number previously positive has 
continued to increase in recent years, from 15% (n=51) in 2012(36)  to 39% (n=192) 
in 2017.(35) 
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Figure 3.2 demonstrates the trend of “previous positive” and “new diagnosis” (not 
previously positive or unknown) for the last six years (2012-2017). In 2017, the 
number of cases with no previous history of HIV diagnosis abroad (new diagnoses) 
decreased by 4% compared with 2016 (from 313 to 302 cases). Since 2015, data 
have been collected on whether a person has transferred their HIV care from 
another country to a service within Ireland. Thirty four percent of people diagnosed 
in 2017 were “transfer of care”. This represents 88% of those who were previously 
diagnosed HIV positive abroad. 
Figure 3.2.  Trend in HIV notifications by history of previous positive  
diagnosis, 2012 to 2017 
  
3.2.2.1 HIV infection by risk group 
This section reports characteristics of HIV diagnoses by risk group. Further 
demographic characteristics of these groups are provided in Appendix 2. 
Men who have sex with men (MSM) 
MSM remain the population most affected by HIV in Ireland. In 2017, the HPSC were 
notified of 262 HIV cases among MSM, representing 53% of all notifications they 
received that year. The majority of these men were born abroad (68%), with the 
highest number of these from Latin America (55%).  
0
50
100
150
200
250
300
350
400
2012 2013 2014 2015 2016 2017
Trend in HIV diagnoses by history of previous positive diagnosis, 2012 
to 2017 
Not Previous Positive/Unknown Previous Positive
Draft: Health technology assessment of a PrEP programme for populations at substantial risk of 
sexual acquisition of HIV 
Health Information and Quality Authority 
Page 37 of 244  
Forty two percent of the notifications received by the HPSC in 2017 in MSM had a 
previous HIV diagnosis abroad and 91% of these had transferred their HIV care from 
abroad to Ireland. Therefore, 58% of notifications in the MSM group were new 
diagnoses (n=151). Among MSM without a previous HIV positive diagnosis, there 
was a small reduction in diagnoses in recent years (14% reduction in notifications 
between 2015 and 2017). 
Heterosexuals 
Heterosexual transmission accounted for 33% (n=163) of HIV notifications to the 
HPSC in 2017, with 100 (61%) among females and 63 (39%) among males. Similar 
to the MSM group, 41% of heterosexual cases notified to the HPSC were previously 
diagnosed HIV positive abroad and 85% of these people transferred their care to 
Ireland. The majority of heterosexual cases were born in sub-Saharan Africa (61%), 
an area of the world which has a generalised HIV epidemic. 
People who inject drugs (PWID) 
There were 17 notifications (4% of all diagnoses) among PWID in 2017, 14 (71%) 
among males and three (29%) among females. This is a decrease compared with 
the number of diagnoses among PWID in 2016 (n=21). This continues the decrease 
in new cases compared with 2014 (n=27) and 2015 (n=49) when there was an 
outbreak of HIV among homeless PWID living in Dublin. The outbreak was declared 
over in February 2017. Of note, parenteral transmission of HIV is out of scope of this 
HTA and only HIV infection in PWID where the risk factor is sexual is considered. 
3.2.2.2 Morbidity and mortality 
Co-infections 
Co-infections with other sexually transmitted infections (STIs) are common at time 
of diagnosis. Among MSM, 23% were co-infected with an acute bacterial STI 
(chlamydia, gonorrhoea and/or early infectious syphilis) in 2017. Over 70% of PWID 
were co-infected with hepatitis C and 7% of heterosexuals were co-infected with 
tuberculosis. 
Clinical stage of infection at diagnosis 
Of all HIV notifications in 2017, 52% (n=255) were asymptomatic, 12% (n=61) 
were symptomatic (non-AIDS), 6% (n=29) had an AIDS-defining illness, 2% (n=11) 
had an acute seroconversion illness and the clinical stage was not reported for the 
remaining 27% (n=135). Of the 29 people with an AIDS-defining illness at the time 
of HIV notification, 13 were MSM, 12 were heterosexual, one was a PWID and the 
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risk group for three was unknown.  
 
Late presentation and advanced infection 
Late diagnosis refers to a CD4 count of less than 350 cells per microlitre at diagnosis 
or an AIDS-defining illness at diagnosis (excluding those with acute HIV infection). 
Advanced infection refers to a CD4 count of less than 200 cells per microlitre at 
diagnosis or an AIDS-defining illness at diagnosis (excluding those with acute 
infection). 
Where information on CD4 count or AIDS defining illness at diagnosis was available, 
41% of all notifications in Ireland in 2017 were classified as late presenters and 22% 
as having advanced HIV infection. The proportion presenting late and the proportion 
presenting with advanced infection was higher than 2016 (late presenter: 38%; 
advanced stage: 19%). Among the people who did not have a previous positive 
diagnosis, the proportion who presented late was 55% including 32% who 
presented with advanced HIV infection. 
Deaths 
Data on deaths are obtained from either clinician’s reports via enhanced surveillance 
forms or from data reported to the Central Statistics Office (CSO). Of note, it is not 
possible to link these two sources of information. Data from enhanced surveillance 
forms in 2017 documented that three people (all male) died at the time of HIV 
notification. 
Data from CSO Vital Statistics reported that there were 11 deaths reported to the 
CSO in 2017 where the cause of death was AIDS or HIV, seven males and four 
females.  
3.2.3 Historical notifications 
Between 1982 to the end of 2017, a total of 8,826 HIV notifications were received in 
Ireland.(35) However, this number does not represent the number of people living 
with HIV in Ireland, as it does not take factors such as death and migration into 
account (see Section 3.3 for prevalence estimates). 
UNAIDS estimated that 7,205 people (95% confidence intervals: 6,456-8,056) were 
living with HIV in Ireland at the end of 2017 with 13% of these people unaware of 
their infection.(37) 
Table 3.1 and Figure 3.3 give the historical number of notifications by risk group 
(that is, probable route of transmission).  
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Table 3.1.  Number and proportion of HIV notifications by risk group,  
2003 to 2017 
Risk 
group 
MSM PWID Heterosexual Mother 
to child 
Unknown
/other 
Total 
Year N % N % N % N % N %  
2003 76 19 50 12.5 222 55.4 11 2.7 42 10.5 401 
2004 63 17.6 74 20.7 179 50 3 0.8 39 10.9 358 
2005 60 18.4 67 20.6 171 52.5 3 0.9 25 7.7 326 
2006 89 25.2 59 16.7 181 51.3 2 0.6 22 6.2 353 
2007 91 23.3 55 14.1 165 42.2 6 1.5 74 18.9 391 
2008 105 26 40 9.9 190 47 7 1.7 62 15.3 404 
2009 138 34.9 30 7.6 162 41 5 1.3 60 15.2 395 
2010 134 40.6 23 7 127 38.5 9 2.7 37 11.2 330 
2011 145 44.5 17 5.2 125 38.3 3 0.9 36 11 326 
2012 166 49 17 5 131 38.6 5 1.5 20 5.9 339 
2013 158 46.3 21 6.2 132 38.7 3 0.9 27 7.9 341 
2014 184 48.8 27 7.2 126 33.4 2 0.5 38 10.1 377 
2015 248 51.3 49 10.1 130 26.9 5 1 51 10.6 483 
2016 261 51.4 21 4.1 140 27.6 3 0.6 83 16.3 508 
2017 262 53.3 17 3.5 163 33.1 0 0.0 50 10.2 492 
Source: HIV in Ireland 2017 Annual Epidemiological Report, published by the HPSC 
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Figure 3.3. Historical HIV notifications in Ireland, 2003-2017, by possible route of transmission 
 
Source: HIV in Ireland 2017 Annual Epidemiological Report, published by the HPSC 
 
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
MSM 76 63 60 89 91 105 138 134 145 166 158 184 248 261 262
PWID 50 74 67 59 55 40 30 23 17 17 21 27 49 21 17
Heterosexual 222 179 171 181 165 190 162 127 125 131 132 126 130 140 163
Mother to child 11 3 3 2 6 7 5 9 3 5 3 2 5 3 0
Total 401 358 326 353 391 404 395 330 326 339 341 377 483 508 492
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3.2.4 Recent infection 
In order to monitor the ongoing transmission of HIV, it is important to determine the 
proportion of new diagnoses which are recent HIV infections. Recent Infection 
Testing Algorithms (RITA) attempt to differentiate recent from longer standing 
infections. They combine results of recent infection assays and supplementary 
laboratory and clinical information that together are used to classify a HIV infection 
as likely to be recent or not recent. In addition, the HIV p24 antigen test which is 
designed to detect a protein (the p24 protein) associated with HIV can be used to 
indicate acute infection with HIV.  
The HPSC reports recent infections in Ireland using the Recent Infection Testing 
Algorithm (RITA) or a p24 antigen positive status.(38) In 2017, it was estimated that 
13% of HIV diagnoses (of those tested) were likely to be recent infections (within 
four months), using the RITA or a p24 antigen positive status. By probable routes of 
transmission, MSM had the highest proportion of likely recent cases (16%) followed 
by PWID (14%). Higher proportions of likely recent infections were also seen in 
young people (15-24 years) (29%); people born in Ireland (23%); and people who 
acquired their infection in Ireland (28%). 
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3.3 Prevalence of HIV in Ireland 
Limited data were retrieved on the prevalence of HIV in Ireland. In the absence of 
national prevalence data, estimates are based on three sources: a study by Tuite et 
al. (2015)(39), a national treatment audit (2018)(40) and modelling estimates carried 
out by UNAIDS (2018).(37) 
3.3.1 Study by Tuite et al. 2015  
The earliest study to estimate the national prevalence of HIV in Ireland was 
published in 2015.(39) The primary objective of the study was to retrospectively 
identify the number of patients accessing specialist ambulatory care for HIV infection 
in Ireland over a 12-month period between July 2009 and June 2010.  
The six sites for specialist adult (age 17 or over) HIV care in Ireland were audited: 
St James's Hospital, Mater Misericordiae University Hospital and Beaumont Hospital 
(all in Dublin) and Cork University Hospital, Galway University Hospital and Limerick 
Regional Hospital (outside of Dublin). In Ireland, all newly diagnosed adult patients 
are referred to one of these six centres for care. In total, 3,254 patients were 
identified as accessing specialist ambulatory over this period; 81.1% accessed care 
in Dublin (53.6% at St James’s Hospital, 16.5% at Mater Misericordiae University 
Hospital, 11.0% at Beaumont Hospital), whilst 18.8% accessed care outside of 
Dublin (11.2% at Cork University Hospital, 5.2% at University College Hospital 
Galway and 2.4% at Limerick Regional Hospital).  
For known HIV cases, the crude prevalence rate amongst 15 to 59-year olds was 
estimated at 1.09 per 1,000 nationally and 2.25 per 1,000 in the Dublin area.  
A limitation of this study, however, was that patients who did not receive outpatient 
care, either because they are not engaged in care or they only accessed inpatient 
care, were not captured by the audit. There is a large discrepancy between the 
number of patients identified and the number of new diagnoses ever reported to the 
HPSC at the time of the study (n=6,979). Even taking into consideration natural 
attrition due to reported deaths (505 recorded deaths at the time of the study) and 
emigration, there remained a large proportion of patients unaccounted for. 
3.3.2 Treatment audit – 2018  
In 2018, a national audit of all patients who attended HIV treatment services in the 
previous year was undertaken, using standardised definitions recommended by the 
European Centre for Disease Prevention and Control (ECDC).(40) This study included 
the six specialist treatment centres previously audited, in addition to St Vincent’s 
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University Hospital, Dublin, and the joint paediatric HIV service of Our Lady's 
Children's Hospital, Crumlin and Temple St. Children’s University Hospital, Dublin. 
This large-scale audit measured the total number of patients attending HIV services 
in 2017. Additionally, treatment outcomes were documented: the proportion of 
patients who were receiving antiretroviral therapy (ART) and the proportion of 
patients who were virally suppressed were recorded.  
A total of 5,317 patients attended HIV services in 2017, significantly higher than 
previously recorded. Of these, 98.3% (n=5,227) were on ART and 95.4% (n=4,986) 
of these were virally suppressed (defined as fewer than 200 copies of HIV RNA per 
millilitre of blood). Additionally, 90.6% (n=4,735) of those on ART had an 
undetectable viral load (defined as fewer than 50/mL HIV RNA copies). Viral 
suppression greatly reduces the risk of onward HIV transmission.(41) 
3.3.3 UNAIDS 2018   
In 2018, the Joint United Nations Programme on HIV and AIDS (UNAIDS) modeled 
HIV incidence curves to provide the most comprehensive estimate of the prevalence 
of HIV (both diagnosed and undiagnosed) in Ireland to date.(37) This was 
accomplished by close collaboration between UNAIDS and the HPSC and the CSO. 
To develop the estimates for Ireland, the HPSC provided HIV case-reporting data 
and other data including the number of adults and children on ART and the number 
of women accessing services for the prevention of mother-to-child transmission 
(PMTCT). UNAIDS also used vital registration data (deaths) from the CSO. UNAIDS 
modeled this data using their ‘Spectrum’ software, an epidemiological modeling tool 
that was designed to assist countries in mapping their HIV epidemic.  
UNAIDS Spectrum estimated that the total population in Ireland living with HIV was 
7,205 (95% CI: 6,456 to 8,056) in 2017. By gender, approximately 2,400 women 
(95% CI: 2,200 to 2,700) and 4,800 men (95% CI: 4,100 to 5,400) were living with 
HIV (aged 15+). This represented 0.2% of all adults, between 0.1 and 0.2% of all 
women and between 0.2 and 0.3% of all men. 
The proportion living with diagnosed HIV was estimated at 87.1% (n=6,276 people, 
95% CI: 5,623 to 7,017) and the proportion with undiagnosed HIV was 12.9% 
(n=929 people; 95% CI: 833 to 1,039). Of the estimated 6,276 (95% CI: 5,623 to 
7,017) people diagnosed with HIV, an estimated 83.3% (95% CI: 74.5% to 93.0%) 
were on antiretroviral therapy (ART).  
Of the 5,227 people on ART, 95.4% were virally suppressed (data obtained from the 
2018 Treatment Audit). Therefore, it was estimated that 73% (95% CI: 65 to 81%; 
approximately 5,200 people) of all people living with HIV were receiving ART and 
Draft: Health technology assessment of a PrEP programme for populations at substantial risk of 
sexual acquisition of HIV 
Health Information and Quality Authority  
Page 44 of 244  
69% (n=5,000) were virally suppressed.  
The inputs were modified in an iterative process between HPSC and UNAIDS so that 
the best fit to the data could be obtained. A limitation of this type of epidemiological 
modeling is that it is particularly sensitive to inward and outward migration. This is 
of particular relevance in Ireland where a large proportion of people newly 
diagnosed with HIV in Ireland are not born in Ireland and there is considerable 
inward and outward migration of HIV positive people. The SPECTRUM modeling tool 
is being improved on an ongoing basis and UNAIDS are currently working to 
determine how the model can better account for migration. 
3.3.4 Additional estimates by risk group 
3.3.4.1 MSM 
The 2017 Healthy Ireland survey, which is a nationally representative probability 
based survey, found that 4% of men had reported that their last sex was with a 
man.(31) In 2018, there were 1,802,395 men aged between 16 and 80 in Ireland.(42) 
Applying Healthy Ireland figures results in approximately 72,096 MSM in Ireland. The 
2015 Healthy Ireland survey reported a higher estimate (6%).(43) Another survey of 
young people (My World Survey National Study of Youth Mental Health, 2012) 
reported that 4% of respondents were gay and a further 4% were bisexual.(44) 
These data, however, relate to both males and females aged 12 to 19 years. 
HIV prevalence data in the MSM group in Ireland were obtained from the MISI 2015 
survey.(30) MISI 2015 was a large-scale community based survey among adult MSM 
living in Ireland. It focused on HIV and STI testing, sexual behaviour, substance use, 
access to and use of HIV prevention interventions (condoms and PEP), knowledge 
about HIV and STIs, and awareness and impact of Irish health promotion materials. 
The survey was open for online self-completion by men 18 years and older for 13 
weeks between 1 March and 31 May 2015. The analysis included 3,090 responses. 
More than a third of respondents (36.7%) had never tested for HIV and 61.6% had 
not tested for HIV in the last year. A total of 4.9% of respondents had been 
diagnosed with HIV. Of those who ever tested for HIV, 7.8% were HIV positive and 
among those who tested in the last 12 months, 1.5% were HIV positive. Two thirds 
of men (67%) were definite about their HIV status, either positive or negative. 
However, the remaining third were unsure of their HIV status; 29% thought it was 
probably negative, 0.2% thought probably positive and 4% didn’t know. The 
proportion of men who were unsure was significantly higher among those who never 
tested (38%) compared with those who had previously tested negative (32%).  
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HIV prevalence was highest in the 40 to 49 age category (13.6%). In terms of area 
of residence, prevalence was highest in Dublin (8.1%). Of HIV positive men, 79% 
surveyed were currently on ART, and of those on ART, 91% were virally suppressed. 
Of the HIV positive men, 41% had been diagnosed late (CD4 count < 350 cells per 
microlitre) including 22% diagnosed with advanced HIV infection (CD4 count < 200 
cells per microlitre). 
Table 3.2 outlines the key characteristics of the MSM group in Ireland. Almost five 
per cent of respondents had been diagnosed with HIV. Of those who ever tested for 
HIV, 7.8% were HIV positive and among those who tested in the last 12 months, 
1.5% were HIV positive.  
  
Draft: Health technology assessment of a PrEP programme for populations at substantial risk of 
sexual acquisition of HIV 
Health Information and Quality Authority  
Page 46 of 244  
Table 3.2. Prevalence estimates in MSM group 
Epidemiological parameter Value Source  
Male MSM prevalence 4% Healthy Ireland survey 2017(2) 
Population size estimate 72,096 Source: CSO male population estimates 2018 
(males aged 16 to 80) and 4% MSM estimate 
from Healthy Ireland Survey 2017 
HIV prevalence  7.8%* Source: MISI MSM Internet Survey 2015 
(proportion who ever had a HIV test who 
tested positive) 
Knowledge of HIV status** 67% Source: MISI MSM Internet Survey 2015 
ART coverage 79%  Source: MISI MSM Internet Survey 2015 
ART who are virally 
suppressed 
91%  Source: MISI MSM Internet Survey 2015 
ART – antiretroviral therapy; HIV – human immunodeficiency virus, MSM – men who have sex with men. 
*Of those tested 
**Two thirds of men (67%) were definite about their HIV status, either positive or negative. 
3.3.4.2 People who inject drugs 
The estimated population of PWID in Ireland was 19,000 in 2014. (45) Of note, only 
sexual transmission of HIV is considered in this assessment. However, due to the 
higher prevalence of HIV in this group, PWID may also be at increased risk of sexual 
acquisition of HIV. 
Over a 20 year period from 1997 to 2017, depending on the population and setting 
chosen, the HIV prevalence rate in PWID in Ireland ranges from 1% to 19% across 
studies.(46) It is evident that certain areas within Dublin’s inner city have very high 
rates (19%) of HIV among PWID.(47) The most recent peer-reviewed study indicated 
a prevalence rate of 8%.(48) It is clear that although HIV prevalence among PWID 
has been measured by a number of studies, there is a lack of recent and nationally 
representative data. 
An estimated 60.5% of all PWID have access to prescribed opioid substitution 
therapy and the average number of needles and syringes distributed per person who 
injects drugs is 168 per year.  
3.3.4.3 Sex workers 
Little is known on the scale of sex work in Ireland. Keller et al. studied sex workers 
over a 12-month period between December 2007 and December 2008.(49) The 
authors reported that there is a minimum of 1,000 women in indoor prostitution in 
Ireland at any one time. Global AIDS Monitoring 2018 (part of UNAIDS) estimated 
that 80% of sex workers were knowledgeable about their HIV status and 80% used 
condoms.(50) No up-to-date data on the number of sex workers living with HIV were 
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identified. 
3.3.4.4 Prisoners 
There were 3,738 prisoners in Ireland in November 2017.(51) HIV prevalence in this 
group is estimated to be 1.9%.(52) Therefore, approximately 71 prisoners may have 
HIV in Ireland. The rate of Hepatitis C and HIV co-infection is 1.3%, indicating 
sharing needles was the likely route of HIV transmission for the majority of this 
group.  
3.3.5 International comparison 
UNAIDS provides global epidemiological data on HIV. Ireland is in the 
Western/Central Europe and North America region for the purposes of analyses. 
Table 3.3 compares Ireland with the overall region in terms of HIV incidence and 
prevalence.(53) Overall prevalence is somewhat lower in Ireland relative to the rest of 
this region. 
Table 3.3. Ireland and regional comparison 
Epidemiological 
parameter 
Ireland Regional  
(West/Central Europe 
and N America) 
HIV incidence  (all ages) 0.1 per 1,000** 0.07 per 1,000* 
HIV incidence  (age 15 to 
49) 
0.2 per 1,000**Ŧ 0.15 per 1,000* 
HIV prevalence  (age 15 
to 49) 
0.2%* 0.3%* 
Source: UNAIDS 2018 and HPSC. 
*Relates to 2017 data. 
**Relates to 2016 data  
ŦActual data are for 15 to 44 year olds 
The most up-to-date data on regional comparisons for HIV treatment identified was 
an ECDC presentation on the HIV continuum of care in Europe and Central Asia, July 
2018.(54) Table 3.4 compares Ireland to the WHO European region and WHO 
Western Europe for HIV diagnosis and treatment parameters. 
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Table 3.4. Ireland and Europe comparison 
Epidemiological parameter Ireland WHO European 
region 
WHO Western 
Europe 
Proportion of people with 
HIV who know their status 
87.1% 80% 86%  
(range: 74 to 93%) 
Proportion of people who 
know their status on ART 
83.3% 64% 90%  
(range: 58 to 
100%) 
Proportion of people on ART 
who are virally suppressed 
95.4% 85% 92%  
(range: 32 to 98%) 
Source: ECDC 2018 
Key: ART – antiretroviral treatment; HIV – human immunodeficiency virus. 
 
UNAIDS has set ’90-90-90’ targets for each of the three variables in Table 3.4 (90% 
of people with HIV know their status, 90% of those who know their status on ART, 
90% of those on ART virally suppressed). Ireland has not reached the 90% target 
for the first two. However, Ireland compares favourably to the WHO European 
region as a whole, achieving higher figures for all targets. Ireland has achieved 
comparable success compared with the WHO Western Europe region, although 
significant variation between countries was noted. 
Table 3.5 compares the MSM group in Ireland to select countries in the WHO 
Western Europe region and the USA, per UNAIDS 2018. Note that in Table 3.5, the 
proportion of MSM who know their HIV status is presented, which is not the same as 
the proportion with HIV who know their status (this estimate is presented in Table 
3.4 for the general population). The proportion of MSM who know their status was 
obtained from MISI data, which noted 36.7% had never tested for HIV (and 61.6% 
had not tested for HIV in the last year). 
Table 3.5. International comparison, MSM group  
Epidemiological 
parameter 
Ireland UK France Spain Germany USA 
HIV prevalence 7.8%* 7.7% 14% 11.3% 7.5% 14.5% 
Proportion of MSM 
who know their HIV 
status 
63.3% 88% 48.8% NR NR NR 
Proportion of 
people who know 
their status on ART 
78.9% 84.1
% 
77.8% NR 87.6% NR 
Condom use 56.9% 60% 44.5% 76.5% 65.8% 42% 
Source: UNAIDS 2018. 
Key: ART – antiretroviral treatment; HIV – human immunodeficiency virus. 
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*Of those tested 
These data indicate that Ireland most closely resembles the UK (MSM prevalence of 
7.8% in Ireland compared with 7.7% in the UK). 
3.4 MSM sexual behaviour data 
A substantial volume of sexual behavior data among MSM was collected in MISI 
2015.(30) Overall, 96% of those responding to the MISI survey reported ever having 
sex with a man with 90% reporting sex with a man in the last 12 months. Among 
respondents who reported ever having sex with a man, 71% had condomless anal 
intercourse (CAI), 55% had CAI within the last 12 months and 47% had CAI within 
the last six months. Fifty-five percent of respondents had sex with one or more 
steady male partners in the last 12 months. Of the respondents who had CAI with a 
steady male partner in the last 12 months, 15% had non-concordant CAI (that is, 
where HIV status is different or unknown). For men who had CAI with a non-steady 
partner, 54% had non-concordant CAI. 
In April 2017, the HSE SHCPP and the HPSC estimated the population likely to avail 
of a PrEP programme in the first year of its availability in Ireland in its report HIV 
Pre-Exposure Prophylaxis (PrEP) in Ireland: PrEP estimates for populations at risk of 
sexual acquisition of HIV, or the ‘PrEP Cascade’, using the MISI 2015 dataset.(55) In 
this report, French PrEP eligibility criteria were applied to the MISI dataset, with 
some adaptations. An estimated 23% (95% CI: 22.7 to 23.3%) of respondents were 
found to be eligible, or 706 out of 3,045 respondents (further details are presented 
in Table 3.6). 
Table 3.6. French PrEP eligibility criteria applied to MISI dataset 
Survey questions MISI data N 
(%) 
Aged 18-64 years 3,045 (100) 
Man/transman 3,045 (100) 
Never received an HIV test result/last test was 
negative* 
2,870 (94) 
CAI with 2 or more non-steady partners in last 12 
months** 
370 (12) 
Diagnosed with an STI in last 12 months 243 (8) 
Ever treated with PEP*** 119 (4) 
Use of crystal meth, GHB/GBL, mephedrone, ketamine 
in last 12 months**** 
181 (6) 
Eligible for PrEP‡ 706 (23) 
Draft: Health technology assessment of a PrEP programme for populations at substantial risk of 
sexual acquisition of HIV 
Health Information and Quality Authority  
Page 50 of 244  
*Number of men who reported to be HIV negative or did not know their HIV status  
**French implementation guidance is CAI with two or more partners in the past six months 
***Using MISI variable "ever used PEP" as a proxy for multiple PEP as in French PrEP eligibility 
criteria 
**** French PrEP eligibility criteria broader in terms of drugs, and narrower in terms of their 
use during sex “use of drugs during sexual intercourse” 
‡Number eligible for PrEP based on overlapping survey responses 
While the design of the MISI 2015 was robust and comparable to similar 
international studies enrolling MSM, there are a number of limitations to the 
methodological approach and the sampling strategy that should be considered when 
interpreting the findings. The convenience sampling strategy used will have 
introduced selection bias, as participants who took part in the survey are more likely 
to have access to gay social media, social networks and gay social settings. 
Additionally, the survey was only provided in English. 
Since then, in 2017, Ireland participated in a pan-European MSM survey, the 
European Men who have sex with men Internet Survey (EMIS 2017), the results of 
which are expected later this year. EMIS 2017 was an online cross-sectional 
behavioural surveillance survey of MSM, conducted across Europe and elsewhere 
including Ireland, and available in 33 languages. The overall aim of EMIS 2017 was 
to generate data useful for the planning of HIV and STI prevention and care 
programmes and for the monitoring of national progress in this area by describing 
the level and distribution of HIV transmission risk and precautionary behaviours. 
In Chapter 6, Section 6.2.1, the target population for PrEP in Ireland is estimated. 
One necessary parameter is the proportion of MSM who would be considered eligible 
for PrEP (as in, at substantial risk of sexual acquisition of HIV). Following discussion 
at the EMIS Ireland 2017 Steering committee meeting on 25 March 2019, there was 
agreement that the EMIS Ireland 2017 dataset should be used to provide the most 
up to date percentage of MSM at substantial risk of sexually acquired HIV and 
therefore eligible for PrEP. The following results were provided to HIQA by the EMIS 
Ireland 2017 Steering committee (please see the acknowledgements section of the 
report for additional details relating to the EMIS Ireland 2017 study). 
The EMIS Ireland 2017 report included 2,083 qualifying cases of men/trans-men 
aged between 17 and 74 with respondents from each county in Ireland. Fewer than 
1% identified as trans-men. Figure 3.4 shows the distribution of ages across the 
entire sample.  
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Figure 3.4. Age distribution of respondents (N=2,083) 
 
The median age of respondents was 33 years (range 17 to 74 years) and the mean 
was 34.7 years. Table 3.7 outlines the distribution of respondents by age group. 
Table 3.7. Distribution of respondents by age group (N=2,083) 
Age group Number Percentage 
<25 469 22.5 
25-39 968 46.5 
40-54 484 23.2 
≥55 162 7.8 
Seventy five percent of respondents were born in Ireland and 25% were born 
abroad. Of those born abroad, 38% were born in European countries (excluding 
Ireland and the UK) and 26% were born in the UK (see Table 3.8). Eighteen percent 
of men born abroad were from Latin America and the Caribbean. Respondents not 
born in Ireland were born in 65 different countries. The most common countries of 
birth were England (n=80), Brazil (n=62), Northern Ireland (n= 34), Poland (n=29) 
and Germany (n=25).  
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Table 3.8. Distribution of respondents born outside of Ireland by 
region of birth as per WHO classification (N=514, missing n=3) 
Region of birth Number Percentage 
Europe (excluding Ireland and UK) 193 37.5 
United Kingdom 134 26.1 
Latin America & Caribbean 95 18.5 
Canada, USA 30 5.8 
Western Pacific Region (excluding Australia 
and New Zealand) 
29 5.6 
African region 16 3.1 
South East Asia 8 1.6 
Eastern Mediterranean 7 1.4 
Western Pacific Region: Australia and New 
Zealand 
2 0.4 
For use in this HTA, the EMIS study authors applied Irish PrEP eligibility criteria (as 
above) to the Irish portion of responses for the purposes of economic modelling. 
Table 3.9 shows the number and percentage of MSM at substantial risk for sexually 
acquired HIV and eligible for PrEP using the Irish criteria. The number eligible for 
PrEP based on overlapping survey responses was 647 (31%). Note that a number of 
adjustments to the Irish PrEP eligibility criteria had to be made based on the EMIS 
Ireland 2017 dataset.  
Table 3.9. Eligibility for PrEP using the EMIS Ireland 2017 dataset 
Criteria used EMIS 2017 
N (%) 
Aged ≥ 17 years  2,083 (100) 
Man/ transman 2,083 (100) 
Sexually active 2,083 (100) 
Never tested for HIV/last HIV test negative 1,929 (93) 
ONE of the following  
CAI with ≥ 2 non-steady partners last 12 
months* 
457 (24) 
STI diagnosis in last 12 months 252 (13) 
Ever had ≥2 treatments of PEP ** 42 (2) 
Use of stimulant drugs during sex last 6 
months*** 
181 (9) 
Eligible for PrEP† 647/2083 (31) 
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* Irish eligibility criteria is CAI with two or more casual partners in the past six months. 
** Irish eligibility criteria is reported use of PEP over last 12 months 
***The stimulant drugs included in this definition were: ecstasy/MDMA, cocaine, amphetamine (speed), crystal 
methamphetamine (Tina, Pervitin), mephedrone and ketamine. Irish eligibility criteria define drugs used during sex as “crystal 
meth, GHB/GBL, mephedrone and ketamine” 
† Number eligible for PrEP based on overlapping survey responses  
Note that the results of EMIS and MISI are not directly comparable, as different 
eligibility criteria for PrEP were used to identify the eligible population. Other reasons 
why the two surveys are not directly comparable include differences in study design 
(for example, MISI was only available in English and EMIS was available in 33 
languages), differences in the age profile of the respondents, and other 
demographic factors such as differences in the proportion who were born in Ireland. 
It is, nonetheless, of concern that high risk behaviour has increased in the MSM 
group in Ireland over a relatively short time period. The number who reported ‘CAI 
with two or more non-steady partners in past 12 months’ doubled, from 12% in 
MISI 2015 to 24% in EMIS 2017. A smaller increase was noted for acute STI 
diagnoses and there may have been an increase in chemsex use. 
3.5 Discussion 
In general, good-quality data were retrieved on overall population-based estimates 
of HIV notifications and HIV prevalence in Ireland, including epidemiological data 
specific to the men who have sex with men (MSM) group. Estimates were also 
retrieved on the proportion of MSM likely to avail of PrEP in Ireland, if a programme 
were introduced. Unfortunately, very limited data were identified on other groups at 
substantial risk of HIV acquisition. 
HIV infection remains a significant public health threat in Ireland. The HIV 
notification rate in Ireland has remained relatively stable between 2015 and 2017, 
following a large increase between 2014 and 2015. A change in the case definition 
used by the HPSC (whereby confirmatory HIV testing required only one sample as 
opposed to two) and a rise in HIV testing may partly explain the increase compared 
with the previous year. The rate of HIV in Ireland is high compared with other 
countries in Western Europe, many of which have seen declines in their HIV rates in 
recent years.(47) This highlights the need to consider combination prevention 
approaches in order to halt transmission of HIV. 
Migration plays an important role in the changing epidemiology of HIV in Ireland. 
Overall, 63% of the notifications to the HPSC in 2017 were for individuals born 
outside Ireland (compared with 26% born in Ireland and 11% unknown country of 
birth). In the MSM group, 61% of the notifications received in 2017 were for 
individuals born outside Ireland, with the highest number from Latin America. 
Additionally, there has been an increase in the proportion of notifications who were 
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previously diagnosed HIV positive abroad: in 2017, these comprised 39% of all 
notifications. A majority of these had transferred their care to Ireland (88%). The 
proportion of MSM previously diagnosed HIV positive before arrival in Ireland has 
increased from 16% of cases in 2012 to 42% in 2017. Of those previously diagnosed 
HIV positive abroad in 2017, 91% were transferring their care to Ireland. 
 
Between 2015 and 2017 there was a slight increase in HIV notifications among MSM 
(from 248 to 262). However, among MSM without a previous HIV positive diagnosis, 
there was a 14% reduction in notifications. This highlights that while notifications 
overall have risen in recent years, this does not reflect a true increase in HIV 
transmission due to the fact that many notifications in Ireland were already known 
to be HIV positive prior to arrival in the country. Nonetheless, given over 150 new 
diagnoses of HIV in MSM this would suggest that current HIV prevention strategies 
are insufficient to halt the spread of HIV, emphasising the need to consider 
combined prevention approaches that includes PrEP. 
Given the increasing number of cases new to Ireland already known to be HIV 
positive, it is essential to focus on early engagement in care and immediate initiation 
of ART (or optimisation of therapy in those transferring care). The HSE recommends 
immediate ART initiation regardless of HIV count.(56) In addition to the clinical 
benefits of early ART initiation, viral suppression reduces onward HIV transmission. 
Maintaining an undetectable viral load is highly effective at preventing onward HIV 
transmission.(41)  
It was noted that significant regional variation exists in Ireland, with HSE East 
consistently reporting higher rates than other regions. Regional variation in 
transmission rates has implications for the organisation of care. 
HIV notifications reported by the HPSC accurately reflect all new cases of HIV 
infection that are detected by the health system in Ireland. However, the variable 
and often long time lag between infection and diagnosis means that HIV case 
surveillance does not directly reflect current patterns of virus transmission or 
incidence. Trends in HIV notifications reported by the HPSC may reflect true trends 
in incident infections, trends in uptake of HIV testing or both. Most individuals self-
present for HIV testing, with the exception of certain groups, such as voluntary 
routine opt-out antenatal HIV testing (introduced nationally in April 1999(57)), opt-out 
emergency department testing for HIV, Hepatitis B and Hepatitis C (introduced at St 
James’s Hospital in July 2015)(58) and routine testing of health care workers and 
blood donors. HIV incidence data is therefore incomplete and it is notable that more 
than a third of MSM in Ireland have never had a HIV test.  
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Significant work was undertaken in 2018 to estimate the prevalence of HIV in 
Ireland, which included modelling undertaken by UNAIDS (in collaboration with the 
HPSC and the SHCPP)(37) and a comprehensive national treatment audit.(40) In 
summary, 7,205 (95% CI: 6,456 to 8,056) people are estimated to be living with 
HIV in Ireland; 87.1% which are aware of their HIV status and 83.3% have initiated 
ART (UNAIDS 2018 data). Of these, 95.4% are virally suppressed (2018 treatment 
audit). UNAIDS has set a target of 90% for each of these three measures. While not 
achieving this target for the first two goals, Ireland compares favourably to the WHO 
Europe region as a whole.  
UNAIDS used Spectrum, an epidemiological modeling tool, to calculate these 
estimates and has been calculating global HIV estimates since 2002. While there 
have been improvements in estimates over time, resulting from enhanced 
availability, quality and completeness of country data and modifications in modeling 
software, the quality of the results still depends on the quality of input data. There 
are concerns that the model does not capture sudden changes and that it does not 
adequately capture issues of migration, a significant contributor to the HIV epidemic 
in Ireland. Estimates also vary significantly according to the assumptions used in the 
model. It is notable that in Greece, a separate modeling tool created by the ECDC 
generated different estimates for people living with HIV, with the Spectrum 
estimates being lower and not capturing a recent HIV outbreak that occurred among 
people who inject drugs. 
Regarding populations at significantly elevated risk of HIV acquisition, very little data 
were identified in any group other than MSM. Healthy Ireland, a nationally 
representative survey, found that 4% of men had reported that their last sex was 
with a man in 2017.(31) The true MSM proportion may be higher however, as the 
question posed by Healthy Ireland may not capture all bisexual men. The Men who 
have sex with men Internet Survey Ireland 2015 (MISI 2015) was a large-scale 
community based survey among adult MSM and provided a wealth of data on HIV 
and sexual behaviour in MSM in Ireland. Overall, 63.3% of respondents had ever 
had a test for HIV and 7.8% of those were HIV positive. Of HIV positive men, 79% 
surveyed were currently on ART, and of those on ART, 91% were virally suppressed. 
HIV prevalence and sexual behaviour in Irish MSM was found to be broadly 
comparable between Ireland and other Western European countries, in particular 
MSM in the UK.(59)  
Two internet surveys were identified that gathered sexual behaviour data on MSM in 
Ireland (MISI 2015 and EMIS 2017 [unpublished data]). Provisional data from EMIS 
suggest an increase in high risk sexual behaviour in the MSM group compared with 
MISI (for example, CAI with two or more non-steady partners in the previous 12 
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months doubled, from 12% to 24%). A smaller increase was noted for acute STI 
diagnoses and there may have been an increase in chemsex use. Note that the 
results of EMIS and MISI are not directly comparable, as different eligibility criteria 
for PrEP were used to identify the eligible population. Other reasons why the two 
surveys are not directly comparable include differences in study design (for example, 
MISI was only available in English and EMIS was available in 33 languages), 
differences in the age profile of the respondents, and other demographic factors 
such as differences in the proportion who were born in Ireland.  
These results of surveys like MISI and EMIS must be interpreted with caution due to 
the fact that they are not nationally representative samples and the sampling 
strategy should be considered carefully when interpreting the findings. The 
convenience sampling strategy used will have introduced selection bias, as 
participants who took part in the survey are more likely to have access to gay social 
media, social networks and gay social settings. In addition, as behaviour is self-
reported, recall bias, social desirability bias and interpretation bias may be 
introduced. It is also possible that internet surveys under-represent populations such 
as migrants and older MSM. On the other hand, internet surveys may be better at 
exploring small subgroups and hidden behaviour (behaviours that are difficult to 
report, such as deliberately risky or violent behaviour). In any case, trends can be 
obtained when comparing with previous similar surveys and allows comparison with 
international surveys with similar design.  
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4 Systematic review of clinical effectiveness and 
 safety of PrEP 
Key points 
 A systematic review undertaken to assess the clinical effectiveness and safety of 
oral PrEP retrieved 15 randomised control trials (RCTs) that compared PrEP with 
placebo, delayed PrEP or with another PrEP medication or dosing schedule. Four 
distinct patient populations were assessed. Six RCTs enrolled MSM, five enrolled 
heterosexual participants, three enrolled serodifferent couples and one enrolled 
people who inject drugs.  
 Included studies involved 25,051 participants encompassing 38,289 person-years 
of follow-up data. Of the 15,062 participants that received active drug in the 
intervention arms of trials, 8,239 (55%) received tenofovir/emtricitabine fixed 
dose combination and 6,823 (45%) received single agent tenofovir.  
 Studies were conducted in high-, middle- and low-income countries. Prevalence 
of HIV varied widely across studies, with the highest rates noted in sub-Saharan 
Africa (23.1% in Botswana). Follow-up periods ranged from 17 weeks to 6.9 
years.  
 Overall, RCTs were judged to have a low risk of bias.  
 Adherence varied greatly across studies. Plasma drug monitoring was considered 
the most objective measurement for adherence assessment: adherence by this 
measurement ranged from 25% to 88%. Trial-level adherence greater than 80% 
was selected a priori as ‘high’ adherence for the purpose of analyses. 
 PrEP was found to be highly effective in preventing HIV acquisition in MSM with 
a risk reduction of 75% across all trials (relative risk (RR) 0.25, 95% confidence 
interval (CI): 0.1 to 0.61; data from six RCTs, high-quality evidence). In trials 
with adherence above 80%, risk was reduced by 86% (RR 0.14, 95% CI: 0.06 to 
0.35; data from three RCTs, high-quality evidence). 
 PrEP was found to be effective in preventing HIV acquisition in HIV-uninfected 
partners of serodifferent couples, with a risk reduction of 75% (RR 0.25, 95% 
CI: 0.14 to 0.46; data from two RCTs, high-quality evidence).  
 PrEP was found to be effective in preventing heterosexual HIV transmission in 
one trial where adherence was high (RR 0.39, 95% CI 0.18 to 0.83; high-quality 
evidence). PrEP was not found to be effective in trials enrolling heterosexual 
participants where adherence was low. 
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 PrEP was found to be effective in preventing HIV transmission in people who 
inject drugs in the only trial retrieved that enrolled drug users, which was 
conducted in Bangkok. Risk was reduced by 49% (RR 0.51, 95% CI: 0.29 to 
0.92; high-quality evidence). This trial may not be directly applicable to the Irish 
context due demographic differences and the high prevalence of HIV in people 
who inject drugs in Thailand. 
 A meta-regression found that efficacy was strongly associated with trial-level 
adherence (p<0.001). On average, an increase in adherence of 10% increased 
efficacy by 13%. 
 PrEP was found to be safe. PrEP did not increase the risk of ‘any’ adverse event 
(RR 1.01, 95% CI: 0.99 to 1.03), serious adverse events (RR 0.91, 95% CI 0.74 
to 1.13) or death (RR 0.83, 95% CI: 0.6 to 1.15) compared with placebo.  
 Adverse events were common in trials (78% of patients reported 'any' adverse 
event), while serious adverse events and deaths were rare. A reduction in 
creatinine clearance was noted in some trials; however, this returned to baseline 
upon discontinuation of study drug. No deaths occurred that were attributable 
to PrEP. 
 Eleven trials measured changes in sexual behaviour. Studies showed either no 
change in condom use throughout the duration of the study (n=4 studies) or 
increases in condom use (n=4 studies). There was no difference in condom use 
between intervention and control arms.  
 Six studies showed no change in the number of sexual partners throughout the 
duration of the study, four studies showed a slight reduction in number of 
sexual partners and one showed an increase. There was no difference between 
intervention and control arms. 
 Five studies recorded changes in the incidence of STIs; no studies reported an 
increase in STIs or a between-group difference in STI diagnoses. 
 In the only study to enrol intravenous drug users, a reduction in intravenous 
drug use, needle sharing and number of sexual partners was observed over the 
course of the study. 
 Patients randomised to receive PrEP who had acute HIV infection at enrolment 
were at increased risk of developing resistance mutations to the study drug (RR 
3.3, 95% CI: 1.17 to 8.27; high-quality evidence). Most conferred resistance to 
emtricitabine. 
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Summary of findings table: Efficacy of PrEP 
Patient or population: HIV prevention in participants at substantial risk Intervention: PrEP Comparison: no PrEP  
Outcomes Anticipated absolute effects* 
(95% CI)  
Relative effect 
(95% CI)  
Person-
years of 
follow up  
(studies)  
Certainty of 
the evidence 
(GRADE)  
Comments 
Risk with no 
PrEP 
Risk with PrEP 
HIV infection: MSM 
(all clinical trials) 40 per 1,000  
10 per 1,000 
(4 to 24)  
RR 0.25 
(0.10 to 0.61)  
5,103 
(6 RCTs)  
⨁⨁⨁⨁ 
HIGH  
PrEP is effective in preventing HIV 
acquisition in MSM with a risk reduction of 
75%  
HIV infection: MSM, 
trials with high 
(>80%) adherence  
66 per 1,000  
9 per 1,000 
(4 to 23)  
RR 0.14 
(0.06 to 0.35)  
960 
(3 RCTs)  
⨁⨁⨁⨁ 
HIGH  
PrEP is highly effective in preventing HIV 
acquisition in MSM in trials with high 
adherence (over 80%) with a risk 
reduction of 86%  
HIV infection: 
Serodifferent couples  20 per 1,000  
5 per 1,000 
(3 to 9)  
RR 0.25 
(0.14 to 0.46)  
5,237 
(2 RCTs)  
⨁⨁⨁⨁ 
HIGH  
PrEP is effective in preventing HIV 
acquisition in serodifferent couples with a 
risk reduction of 75%  
Heterosexual 
transmission (all 
clinical trials) 
41 per 1,000  
32 per 1,000 
(19 to 53)  
RR 0.77 
(0.46 to 1.29)  
6,821 
(4 RCTs)  
⨁⨁⨁⨁ 
HIGH  
PrEP is not effective in preventing 
heterosexual HIV transmission (all trials) 
Heterosexual 
transmission: trials 
with high (>80%) 
adherence  
31 per 1,000  
12 per 1,000 
(6 to 26)  
RR 0.39 
(0.18 to 0.83)  
1,524 
(1 RCT)  
⨁⨁⨁⨁ 
HIGH  
PrEP is effective in preventing heterosexual 
HIV transmission in trials with high 
adherence (over 80%) with a risk 
reduction of 61%  
People who inject 
drugs  7 per 1,000  
3 per 1,000 
(2 to 6)  
RR 0.51 
(0.29 to 0.92)  
9,666 
(1 RCT)  
⨁⨁⨁⨁ 
HIGH  
PrEP is effective in preventing HIV 
transmission in people who inject drugs 
with a risk reduction of 49%  
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Summary of findings table: Efficacy of PrEP 
Patient or population: HIV prevention in participants at substantial risk Intervention: PrEP Comparison: no PrEP  
Outcomes Anticipated absolute effects* 
(95% CI)  
Relative effect 
(95% CI)  
Person-
years of 
follow up  
(studies)  
Certainty of 
the evidence 
(GRADE)  
Comments 
Risk with no 
PrEP 
Risk with PrEP 
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).  
CI: Confidence interval; RR: Risk ratio  
GRADE Working Group grades of evidence 
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different 
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect  
 
Summary of findings table: Safety of PrEP 
Patient or population: HIV prevention in participants at substantial risk Intervention: PrEP Comparison: no PrEP  
Outcomes Anticipated absolute effects* (95% CI)  Relative effect 
(95% CI)  
Person-years of 
follow up  
(studies)  
Certainty of the 
evidence 
(GRADE)  
Comments 
Risk with no PrEP Risk with PrEP 
Safety outcome:  
Any adverse event  776 per 1,000  
784 per 1,000 
(768 to 799)  
RR 1.01 
(0.99 to 1.03)  
17,358 
(10 RCTs)  
⨁⨁⨁⨁ 
HIGH  
Adverse events do not occur more commonly in 
patients taking PrEP compared with placebo. 
Adverse events were common in trials (78% of 
patients reporting 'any' event).  
Safety outcome:  
Serious adverse events  81 per 1,000  
73 per 1,000 
(60 to 91)  
RR 0.91 
(0.74 to 1.13)  
17,778 
(12 RCTs)  
⨁⨁⨁⨁ 
HIGH  
Serious adverse events do not occur more 
commonly in patients taking PrEP compared with 
placebo. Serious adverse events occurred in 7% of 
patients in trials but most were not drug related.  
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Summary of findings table: Safety of PrEP 
Patient or population: HIV prevention in participants at substantial risk Intervention: PrEP Comparison: no PrEP  
Outcomes Anticipated absolute effects* (95% CI)  Relative effect 
(95% CI)  
Person-years of 
follow up  
(studies)  
Certainty of the 
evidence 
(GRADE)  
Comments 
Risk with no PrEP Risk with PrEP 
Safety outcome: Deaths  
13 per 1,000  
10 per 1,000 
(8 to 15)  
RR 0.83 
(0.60 to 1.15)  
12,720 
(11 RCTs)  
⨁⨁⨁◯ 
MODERATE a 
Deaths did not occur more commonly in people 
taking PrEP compared with placebo in trials. No 
deaths were related to PrEP.  
Safety outcome: Drug 
resistance mutations in 
patients with acute HIV at 
enrolment  
53 per 1,000  
174 per 1,000 
(62 to 435)  
RR 3.30 
(1.17 to 8.27)  
44 
(5 RCTs)  
⨁⨁⨁◯ 
MODERATE b 
Patients randomised to receive PrEP who had acute 
HIV at enrolment were at increased risk of 
developing resistance mutations to the study drug. 
Most conferred resistance to emtricitabine.  
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).  
CI: Confidence interval; RR: Risk ratio  
GRADE Working Group grades of evidence 
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different 
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect  
Explanations 
a. Imprecision was detected due to few observations. b. Imprecision was detected due to few observations. Additionally, only a minority of studies tested for resistance mutations. 
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4.1  Objective 
The objective of this chapter is to assess the clinical effectiveness and safety of oral 
antiretroviral pre-exposure prophylaxis (PrEP) therapy to prevent HIV acquisition. A 
systematic review of randomised trials that assessed the efficacy and or safety of 
PrEP was undertaken to achieve this goal. 
4.2.  Methods 
A systematic review of randomised controlled trials (RCTs) was performed.  
4.2.1  Criteria for considering studies for this review 
Table 1 outlines the population, intervention, comparison, outcomes, study design 
(PICOS) criteria for inclusion of studies. It was decided a priori that subgroups would 
be defined by population at risk of acquiring HIV (men who have sex with men 
[MSM], serodifferent couples, people who inject drugs [PWIDs] and heterosexuals).  
 
Table 4.1. PICOS criteria 
PICOS criteria: study selection 
Population Anyone at elevated risk of HIV acquisition. Populations include: 
1. men who have sex with men 
2. serodifferent couples 
3. people who inject drugs (PWIDs) 
4. heterosexuals.  
Intervention Pre-exposure prophylaxis (any oral antiretroviral formulation): 
• tenofovir only versus placebo or no treatment 
• tenofovir + emtricitabine versus placebo or no treatment 
• tenofovir only versus tenofovir + emtricitabine.  
Comparator Placebo, no treatment or alternative oral PrEP medication 
(including alternative dosing schedule) 
Outcomes Primary outcome: HIV incidence 
Secondary outcomes: 
1. adherence to PrEP (as measured by the primary studies, 
plasma drug concentration favoured over self-report) 
2. adverse events associated with PrEP (frequency and type 
of adverse effects or complications, including ‘any’ adverse 
event, serious adverse events and deaths, as reported in 
primary studies) 
3. incidence of other sexually transmitted infections (STIs) 
and behaviour change associated with PrEP administration 
(such as episodes of condomless anal intercourse, number 
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of new sexual partners and recreational drug use). 
4. viral drug mutations that confer resistance to tenofovir and 
or emtricitabine 
Studies Randomised clinical trials 
 
Note: for the remainder of this assessment ‘tenofovir/emtricitabine’ refers to 
tenofovir and emtricitabine fixed dose combination. 
4.2.2  Search methods for identification of studies 
Electronic searches were conducted in Medline (PubMed), Embase, the Cochrane 
Register of Controlled Trials, CRD DARE Database, Morbidity and Mortality Weekly 
Report (CDC), and Eurosurveillance reports. Furthermore, hand-searching of journals 
was also performed. Databases were searched on 31 July 2018. 
The WHO International Clinical Trials Registry Platform and ClinicalTrials.gov were 
searched for ongoing or prospective trials. 
No restrictions were placed based on location of the intervention. No language 
restrictions were used. Articles in languages other than English were translated 
where necessary. 
The detailed search strategies for each of the databases MEDLINE via PubMed, 
EMBASE and the Cochrane Central Register of Controlled Trials are provided in 
Appendix 3.1. 
4.2.3  Data collection  
Two reviewers independently read the titles, abstracts and descriptor terms of the 
search output from the different databases to identify potentially eligible studies. Full 
text articles were obtained for all citations identified as potentially relevant for 
inclusion. Both reviewers independently inspected these to establish the relevance of 
the articles according to the pre-specified criteria. Studies were reviewed for 
relevance based on study design, types of participants, interventions and outcome 
measures (see Table 4.1).  
4.2.4  Data extraction and management 
Data were independently extracted using an agreed data extraction proforma. Both 
reviewers verified the extracted data. Extracted information included the following: 
 Study details: citation, study design and setting, time period and source of 
funding. 
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 Participant details: study population demographics, eligibility criteria for trial 
enrolment, risk characteristics, population size and attrition rate. 
 Intervention details: type of drug, comparator, dosing schedule, duration and 
route of administration. 
 Outcome details: incidence of HIV infection (including type of laboratory tests 
used to confirm HIV diagnosis before and after administering PrEP), degree of 
adherence to PrEP, adverse events (‘any’ events, serious adverse events and 
deaths), behavioural change (condom use, number of sexual partners and other 
STI infections) and study drug mutations that confer resistance to tenofovir and 
or emtricitabine. 
Review Manager 5.3 software was used to record extracted data.(60) Data were 
independently extracted and entered into RevMan by both reviewers; all 
disagreements were resolved by discussion. Where appropriate, results were pooled 
using a random effects model to estimate Mantel–Haenszel risk ratios.  
Appendix 3.2 provides additional details on the data collection, management and 
analysis plan as presented in the study protocol. 
4.2.5  Assessment of risk of bias in included studies 
Two reviewers independently examined the components of each included trial for 
risk of bias using a standard form. The Cochrane Risk of Bias tool was employed.(40) 
This included information on the sequence generation, allocation concealment, 
blinding (participants, personnel and outcome assessor), incomplete outcome data, 
selective outcome reporting and other sources of bias. The methodological 
components of the studies were assessed and classified as adequate, inadequate or 
unclear as per the Cochrane Handbook of Systematic Reviews of Interventions. 
Where differences arise, they were resolved by discussions with a third reviewer.  
An overall assessment of the quality of the evidence was assessed using the Grading 
of Recommendations Assessment, Development and Evaluation (GRADE) 
approach.(37) 
4.2.6  Measures of treatment effect 
Outcome measures for dichotomous data were calculated as risk ratios (RRs) with 
95% confidence intervals (CIs). The risk of HIV infection represents the number of 
HIV infections that occurred per person-years of follow up data. The RR represents 
the risk of HIV infection in the intervention (PrEP) group compared with the control 
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group. The modified intention-to-treat was used in all analyses — the denominator 
in this case represents the total post-randomisation number less the number of 
participants found to be HIV positive at enrolment.   
A meta-analysis was performed to provide a pooled risk if there was sufficient 
homogeneity across studies (all statistical analysis was performed in Review 
Manager 5.3 or STATA SE).  
4.2.7  Dealing with missing data 
As per the study protocol, authors would be contacted to provide further information 
on study results if data were missing (this was not necessary). 
4.2.8  Assessment of heterogeneity 
Clinical heterogeneity was assessed by the reviewers based on the description of the 
interventions and comparators in the RCTs. Statistical heterogeneity was examined 
using the I2 statistic. An I2 statistic above 50–70% implied significant heterogeneity. 
4.2.9  Subgroup analysis 
It was decided a priori that all analyses would be stratified by the population group 
investigated. The four populations were MSM, serodifferent couples, heterosexuals 
and people who inject drugs (PWIDs). Typically, trials reported that the presence of 
any of the following in the prior 12 month period resulted in an elevated risk of 
infection: condomless intercourse with a HIV positive or a partner of unknown status 
from a population with high HIV prevalence, the use of illicit drugs during sex 
(chemsex), anal STI diagnoses or prior treatment with post-exposure prophylaxis. In 
the case of serodifferent couples, the higher the viral load in the HIV-infected 
partner, the higher the risk to the HIV-uninfected partner. PrEP is not indicated in 
serodifferent partnerships where the HIV positive individual is on antiretroviral 
treatment and virally suppressed (less than 200 copies/mL). In the case of people 
who inject drugs, risk relates to the mode of potential HIV transmission (through 
sharing of needles or sexual transmission) and background prevalence of HIV in this 
group. 
Subgroup analysis was subsequently performed across the different population 
groups. First, studies were assessed by dosing schedule and by comparator. While 
the only licensed indication for PrEP is daily oral administration, alternative schedules 
have been examined in RCTs, such as ’on-demand’ PrEP during high-risk periods.(29) 
Studies that compared PrEP with placebo, PrEP with no treatment and PrEP with 
another PrEP medication or dosing schedule were all analysed separately. 
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Studies were then stratified by high (>80%) and low (<80%) trial-level adherence. 
Adherence was typically measured by self-report, pill count or plasma drug 
concentration monitoring. Plasma drug monitoring was favoured over self-report/pill 
count for the purpose of assessing adherence as it is the most objective method and 
minimises recall bias. 
In the assessment of the safety of PrEP, adverse events were analysed separately in 
three subgroups. These subgroups consisted of ‘any’ adverse events, serious 
adverse events and deaths. The definitions for adverse events and serious adverse 
events followed the definitions used in the primary studies. 
In the assessment of behaviour change, the effect of PrEP on condom use, number 
of sexual partners and change in STI diagnoses were assessed. If there was a lack 
of data or agreed definitions for these outcomes, a narrative review was performed. 
Finally, drug resistance to study medications was assessed among seroconverters. 
Subgroups included mutations in patients who were enrolled with acute HIV 
infection at the time of enrolment (unknown to investigators) and those who 
seroconverted during the course of the trial. Resistance mutations to tenofovir and 
or emtricitabine were documented among seroconverters who were prescribed study 
drug and compared with mutations documented among seroconverters who were 
prescribed placebo or not on treatment. 
4.2.10 Reporting guidelines 
Reporting adhered to the PRISMA reporting guidelines for systematic reviews.(61) 
4.3  Results 
4.3.1  Description of included studies 
In total, 15 RCTs were retrieved (see Figure 4.1 for flow diagram of study selection). 
Seven RCTs were placebo-controlled trials that evaluated daily oral PrEP.(62-68) Two 
studies randomised participants to receive either immediate or delayed PrEP.(69, 70) 
Three placebo-controlled trials investigated non-daily PrEP, including intermittent 
and ‘on-demand’ (also known as event-based) PrEP.(10, 71, 72) Two RCTs did not 
contain a control arm: one compared two different PrEP formulations (tenofovir and 
tenofovir/emtricitabine)(73) and one compared three different PrEP dosing 
schedules.(74) One study contained three arms: PrEP, placebo and ‘no pill’.(75)  
Four distinct patient populations were assessed. Six RCTs enrolled MSM,(10, 66, 69-71, 75) 
five enrolled heterosexual participants,(63-65, 68, 74) three enrolled serodifferent 
couples(67, 72, 73) and one enrolled PWIDs.(62) Of the MSM trials, one also enrolled 
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female sex workers and one also enrolled transgender women. Of the heterosexual 
trials, three enrolled women only, one enrolled women and men, and one enrolled 
women and transgender males. 
Included studies involved 25,051 participants encompassing 38,289 person-years of 
follow-up data. Of the 15,062 participants that received active drug in the 
intervention arms of trials, 8,239 (55%) received combination tenofovir/emtricitabine 
and 6,823 (45%) received single agent tenofovir. Follow-up periods ranged from 17 
weeks to 6.9 years. Four trials were conducted in high-income countries (USA, 
England, France and Canada), eleven were conducted in low- or middle-income 
countries (including nine trials in sub-Saharan Africa) and one was a multicenter trial 
conducted across four continents. The characteristics of included studies are 
provided in Tables 4.4 to 4.7.   
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Figure 4.1. Flow diagram of study selection 
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Table 4.4. Study characteristics: MSM population 
Study Location Population Interventionɣ Comparison Background 
country HIV 
prevalence 
Number of 
participants 
Follow-up 
period 
Hosek 2013 
(Project 
PrEPare) 
United States 
 
 
Young MSM. 
Median age: 19.97 
years (range: 18–
22) 
Sex: 100% men 
Tenofovir/ 
emtricitabine  
Daily PrEP with 
placebo and to ‘no 
pill’ 
MSM HIV 
prevalence = 
14.5% in 
2014* 
58 24 weeks; 27 
person-years 
 
Grohskopf 
2013 (CDC 
Safety 
Study) 
United States 
 
 
MSM. Age range: 
18–60 years 
Tenofovir Immediate/delayed 
PrEP with 
immediate/delayed 
placebo. 1:1:1:1 
trial design: 
tenofovir,  placebo, 
delayed tenofovir 
and delayed 
placebo groups 
MSM HIV 
prevalence = 
14.5% in 
2014* 
400 2 years; 800 
person-years 
iPrEx  
(Grant 
2010) 
Peru, 
Ecuador, 
South Africa, 
Brazil, 
Thailand, and 
United States 
MSM and 
transgender 
women. Age range: 
18–67 years. Sex: 
100% male at 
birth; 1% female 
gender identity 
Tenofovir/ 
emtricitabine 
Daily PrEP with 
placebo 
Varies by 
country 
2499 3324 person-
years (median, 
1.2 years; 
maximum, 2.8 
years) 
McCormack 
2015 
(PROUD) 
England 
 
 
MSM. Median age: 
35 years 
Sex: 100% men 
Tenofovir/ 
emtricitabine 
Immediate PrEP 
with delayed PrEP 
MSM HIV 
prevalence = 
7.7% in 2016* 
545 504 person-
years. 
Maximum: 48 
weeks 
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Molina 
2015 
(IPERGAY) 
France and 
Canada 
 
 
MSM. Median age 
35 PrEP group, 34 
placebo group; 
Sex: 100% men 
Tenofovir/ 
emtricitabine 
Intermittent (‘on 
demand’) PrEP with 
placebo. 
Participants were 
instructed to take a 
loading dose of two 
pills of tenofovir-
emtricitabine or 
placebo 2 to 24 
hours before sex, 
followed by a third 
pill 24 hours after 
the first drug 
intake and a fourth 
pill 24 hours 
later.** 
France MSM 
HIV prevalence 
= 17.7% in 
2011; Canada 
MSM HIV 
prevalence = 
14.9% in 
2011* 
400 431.3 person-
years. 
Maximum: 24 
months. 
Median 9.3 
months 
Mutua 
2012 (IAVI 
Kenya 
Study)  
Kenya 
 
 
Female sex 
workers and MSM. 
Mean age: 26 
years (range: 18–
49); Sex: 67 men; 
5 women 
Tenofovir/ 
emtricitabine 
Daily/intermittent 
PrEP to daily 
/intermittent 
placebo 
MSM HIV 
prevalence = 
18.2% in 
2010* 
72 4 months; 24 
person-years 
Tenofovir = Tenofovir Disoproxil Fumarate 
ɣ In all cases, tenofovir dose was 300mg and emtricitabine dose was 200mg  
*UNAIDS 2018 (www.epidem.org)  
**In case of multiple consecutive episodes of sexual intercourse, participants were instructed to take one pill per day until the last sexual intercourse and then to take the two postexposure pills.   
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Table 4.5. Study characteristics: Serodifferent couples 
Study Location Population Interventionɣ Comparison Background 
country HIV 
prevalence 
Number of 
participants 
Follow-up  
Kibengo 2013 
(IAVI Uganda 
Study) 
Uganda 
 
 
Sero-discordant 
couples. Mean age: 
33 years (range: 
20–48); Sex: 50% 
women; 50% men 
Tenofovir/ 
emtricitabine 
Daily/intermitte
nt PrEP with 
daily/intermitte
nt placebo 
6.6% in 2013, 
adults 15 to 49 
years* 
72 couples  4 months; 24 person-
years 
Baeten 2012 
(Partners 
PrEP Study) 
Kenya 
and 
Uganda 
 
 
Sero-discordant 
couples. Age range: 
18–45 years; Sex: 
seronegative partner 
was male in 61–
64% of couples 
(depending on 
group assignment) 
Tenofovir/ 
emtricitabine 
and tenofovir 
(three arms: 
two active 
arms and one 
placebo arm) 
Daily PrEP with 
placebo 
5.5 to 6.7% in 
2012, adults 
15 to 49 
years* 
4,747 couples 7,830 total person-
years. Median: 23 
months, IQR 16–28, 
range 1–36 months 
Baeten 2014 
(Partners 
PrEP Study 
Continuation) 
Kenya 
and 
Uganda 
Sero-discordant 
couples. Age range: 
28–40 years; Sex: 
62–64% men 
(depending on 
group assignment)  
Tenofovir/ 
emtricitabine 
and tenofovir 
(Two Active 
Arms) 
Tenofovir/emtri
citabine 
combination 
versus 
tenofovir 
5.5 to 6.7% in 
2012, adults 
15 to 49 
years* 
4,410 couples 8,791 person-years. For 
those assigned active 
PrEP at the initial 
randomisation: median 
35.9 months; IQR 30–
36 months. For those 
re-randomised from 
placebo: median 12 
months; IQR 12–12 
months 
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Tenofovir = Tenofovir Disoproxil Fumarate, SD = standard deviation, IQR = interquartile range. 
ɣ In all cases, tenofovir dose was 300mg and emtricitabine dose was 200mg  
**Source=UNAIDS 2018 (www.epidem.org)  
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Table 4.6. Study characteristics: Heterosexual population 
Study Location Population Interventionɣ Comparison Background 
country HIV 
prevalence 
Number of 
participants 
Follow-up 
Bekker 2018 
(ADAPT Cape 
Town) 
South 
Africa 
 
Women and 
transgender males. 
Median age of 
women was 26 years 
(IQR 21–37; range 
18–52) 
Tenofovir 
/emtricitabine 
Daily, time and 
event-driven 
PrEP≠ 
18.8% among 
adults 15–49 in 
2017* 
191 29 weeks, 99 
person-years 
follow-up 
Marrazzo 2015 
(VOICE) 
South 
Africa, 
Uganda, 
and 
Zimbabwe  
Women. Median age: 
24 years (range: 18–
40); Sex: 100% 
women 
5 arms: tenofovir/ 
emtricitabine, 
tenofovir and 1% 
tenofovir vaginal 
gel (compared 
with placebo oral 
PrEP and placebo 
vaginal gel) 
Daily PrEP with 
placebo 
6.3 to 18.8% in 
2015, adults 15-
49 years* 
4,969 5,509 
person-years 
of follow-up. 
Maximum: 36 
months 
Peterson 2007 
(West African 
Safety Study) 
Nigeria, 
Cameroon, 
and Ghana 
 
 
Women. Age range: 
18–34 years; Sex: 
100% women 
(mostly sex workers) 
Tenofovir Daily PrEP with 
placebo 
Prevalence 
among sex 
workers 
unknown 
936 428 person-
years. 
Maximum: 12 
months 
Thigpen 2012 
(TENOFOVIR2) 
Botswana 
 
 
Heterosexual men 
and women. Age 
range: 18–39 years; 
Sex: 54.2% men; 
45.8% women 
Tenofovir/ 
emtricitabine 
Daily PrEP with 
placebo 
23.1% in 2012* 1219 1,563 person-
years 
(median: 1.1 
years; 
maximum: 3.7 
years) 
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VanDamme 
2012 (FEM-
PrEP) 
Tanzania, 
South 
Africa, and 
Kenya 
 
  
Women. Median age: 
24.2 years (range: 18–
35); Sex: 100% women 
Tenofovir/ 
emtricitabine 
Daily PrEP with 
placebo 
Range: 3.4 to 
18.4% in adults 
15–49, 2012* 
2,120 1407.4 
person-
years. 
Maximum: 
52 weeks 
Tenofovir = Tenofovir Disoproxil Fumarate.   SD = standard deviation. 
ɣ In all cases, tenofovir dose was 300mg and emtricitabine dose was 200mg  
*Source: UNAIDS 2018. Available at www.epidem.org   
≠; time-driven = twice a week plus a post-sex dose; event-driven = one tablet both before and after sex 
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Table 4.7 Study characteristics: People who inject drugs 
Study Location Population Interventionɣ Comparison Background 
country HIV 
prevalence 
Number of 
participants 
Follow-up 
Choopanya 2013 
(Bangkok Tenofovir 
Study) 
Thailand 
(Bangkok) 
 
 
People who 
inject drugs. 
Median age: 31 
years (range: 
20–59) 
80% male 
Tenofovir Daily PrEP with 
placebo 
Prevalence of 
HIV in PWID in 
Thailand: 19% 
in 2014* 
2,413 9,665 person-
years 
(mean 4.0 
years, SD 
2.1; 
maximum 6.9 
years) 
Tenofovir = Tenofovir Disoproxil Fumarate. SD = standard deviation. PrEP – pre-exposure prophylaxis 
ɣ In all cases, tenofovir dose was 300mg and emtricitabine dose was 200mg  
*Source: UNAIDS 2018. Available at www.epidem.org  
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4.3.2  Risk of bias 
All included RCTs were judged to have low risk of bias (Figures 4.2 and 4.3). Two 
studies were open-label trials and, as such, blinding of participants or investigators 
was not possible; these were, therefore, deemed at high risk of bias. A further three 
studies were placebo-controlled trials that additionally investigated alternate dosing 
schedules; while participants and investigators were blinded to drug assignment, 
they could not be blinded to regimen assignment. One study contained a ‘no pill’ 
arm that could not be blinded in addition to a placebo arm. Two studies had unclear 
risk for reporting bias due to the fact that study protocols were not available.  
Figure 4.2. Risk of bias summary 
 
This graph represents the review authors' judgements about each risk of bias item for each included study 
 
 
 
Draft: Health technology assessment of a PrEP programme for populations at substantial risk of 
sexual acquisition of HIV 
Health Information and Quality Authority 
Page 77 of 244   
Figure 4.3. Risk of bias graph  
  
This graph represents the review authors' judgements about each risk of bias item presented as percentages across all 
included studies 
4.3.3  Adherence 
Adherence was measured in a number of ways across trials. Commonly used 
measures included self-report, pill counts, a medication event monitoring system 
(MEMS), structured interviews and plasma drug detection methods. Adherence 
varied greatly across studies. Plasma drug monitoring is considered the gold 
standard for adherence assessment. The highest rates of adherence by drug 
monitoring were obtained in the MSM-only studies by Molina et al. (86% had 
tenofovir detectable)(29) and McCormack et al. (88% were prescribed sufficient study 
drug, and drug plasma concentration was 100% in a sample of participants who 
reported that they took the drug).(70) In contrast, adherence by plasma drug 
detection was exceptionally low in two studies (<30%).(63, 68)  
In general, estimates of adherence using self-report and pill counts were far higher 
than those estimated using plasma drug monitoring. In the study by Marrazzo et al., 
stark differences existed between self-report and plasma drug measurements.(68) 
Participants’ adherence reached 90% by self-report, 86% by returned products, and 
88% as assessed with audio computer-assisted self-interviewing (ACASI). However, 
in a random sample, tenofovir was detected in 30%, 29% and 25% of available 
plasma samples from participants randomly assigned to receive tenofovir, 
tenofovir/emtricitabine fixed dose regimen, and tenofovir gel, respectively. 
In the study by Van Damme et al., 95% of participants reported that they had 
usually or always taken the assigned drug.(63) Drug-level testing, however, revealed 
much lower levels of adherence. Among women with seroconversion in the 
tenofovir/emtricitabine group, the target plasma level of tenofovir was identified in 7 
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of 27 women (26%) at the beginning of the infection window (excluding six women 
for whom the window started at enrolment), in 7 of 33 (21%) at the end of the 
window, and in 4 of 27 (15%) at both visits. Among the uninfected control 
participants, the numbers of women with target-level tenofovir were somewhat 
higher: 27 of 78 women (35%) at the beginning of the infection window, 35 of 95 
(37%) at the end of the window, and 19 of 78 (24%) at both visits. 
For the purpose of analysis in the following sections, adherence greater than 80% 
was deemed high and anything lower suboptimal. Table 4.8 provides a summary of 
adherence across studies. 
Table 4.8. Adherence, as measured in primary studies 
Study Intervention Adherence 
Bekker 2018 
(ADAPT 
Cape Town) 
Tenofovir/emtricitabine 
(daily, time and event-
driven PrEP) 
• 75% (7,283 of 9,652 doses taken) for daily regimen; 
65% (2,367 of 3,616 doses taken) for time-driven 
regimen and 53% (1,161 of 2,203 doses taken) for 
those event-driven regimen by electronic drug 
monitoring. 
Baeten 
2012 
(Partners 
PrEP)  
Tenofovir/emtricitabine 
and tenofovir (three 
arms: two active arms 
and one placebo arm) 
• Factoring in missed visits, other reasons for non-
dispensation of study medication and non-adherence 
to dispensed study pills, 92.1% of follow-up time was 
covered by study medication. 
• Among 29 subjects on the tenofovir and 
emtricitabine/tenofovir arms who acquired HIV-1, 
31% had tenofovir detected in a plasma sample at the 
seroconversion visit compared with 82% of 902 
samples from a randomly-selected subset of 198 
subjects who did not acquire HIV-1. 
Baeten 
2014 
(Partners 
PrEP) 
Tenofovir/emtricitabine 
and tenofovir (two 
active arms) 
• Study medication was taken by participants on 90.0% 
of days during follow-up time (factoring in protocol-
defined study medication interruptions, missed visits, 
and non-adherence to dispensed study pills, as 
measured by monthly pill counts of returned study 
tablets). 
• Among subjects who acquired HIV-1, the minority 
(14/51, 27.5%) had tenofovir detected in a plasma 
sample at the visit at which HIV-1 seroconversion was 
detected, compared with the majority (1,047/1,334, 
78.5%) of samples from a randomly selected subset 
of subjects who did not acquire HIV-1. 
Choopanya 
2013 
(Bangkok 
Tenofovir 
Study) 
Tenofovir (daily) • Adherence was assessed daily at directly observed 
therapy (DOT) visits and monthly at non-DOT visits 
using a study drug diary. On the basis of participants’ 
study drug diaries, participants took the study drug an 
average (mean) of 83.8% of days. 
• Plasma samples were obtained from 46 participants 
with incident HIV infections the day infection was 
detected, and from 282 HIV-negative participants to 
test for the presence of tenofovir. Tenofovir was 
detected in one (1%) of 177 participants in the 
Draft: Health technology assessment of a PrEP programme for populations at substantial risk of 
sexual acquisition of HIV 
Health Information and Quality Authority 
Page 79 of 244   
placebo group and 100 (66%) of 151 participants in 
the tenofovir group. 
• In the case-control analysis in participants assigned to 
tenofovir, tenofovir was detected in the plasma of 5 
(39%) of 13 HIV-positive participants and 93 (67%) 
of 138 HIV-negative participants. 
Grant 2010 
(iPrEx) 
Tenofovir/emtricitabine 
(daily) 
• The rate of self-reported pill use was lower in the 
emtricitabine–tenofovir group than in the placebo 
group at week 4 (mean, 89% vs. 92%) and at week 8 
(mean, 93% vs. 94%) but was similar thereafter 
(mean, 95% in the two groups). 
• The percentage of pill bottles returned was 66% by 
30 days and 86% by 60 days. 
• Among subjects in the emtricitabine–tenofovir group, 
at least one of the study-drug components was 
detected in 3 of 34 subjects with HIV infection (9%) 
and in 22 of 43 seronegative control subjects (51%). 
Grohskopf 
2013 (CDC 
Safety 
Study) 
Tenofovir (daily) • Adherence was measured by pill count, medication 
event monitoring system (MEMS) and self-report; 
adherence ranged from 77% (pill count) to 92% 
(MEMS). 
Kibengo 
2013 (IAVI 
Uganda 
Study) 
Tenofovir/emtricitabine 
(daily or intermittent) 
• Median MEMS adherence rates were 98% (IQR: 93–
100) for daily PrEP regimen, 91% (IQR: 73–97) for 
fixed intermittent dosing and 45% (IQR: 20–63) for 
post-coital dosing. 
• There was no difference in adherence rates between 
active and placebo groups, thus these two groups 
were combined for the adherence analyses. 
Hosek 
2013 
(Project 
PrEPare) 
Tenofovir/emtricitabine 
(daily) 
• Self-reported medication adherence averaged 62% 
(range 43–83%) while rates of detectable tenofovir in 
plasma of participants in the emtricitabine/tenofovir 
arm ranged from 63.2% (week 4) to 20% (week 24). 
Mazzarro 
2015 
(VOICE) 
Tenofovir (oral), 
tenofovir/emtricitabine 
(oral) and vaginal 
tenofovir gel (all daily) 
• 90% by self-report, 86% by returned products and 
88% as assessed with audio computer-assisted self-
interviewing (ACASI). 
• In a random sample, tenofovir was detected in 30%, 
29% and 25% of available plasma samples from 
participants randomly assigned to receive tenofovir, 
tenofovir/emtricitabine and tenofovir gel, respectively. 
McCormac
k 2015 
(PROUD) 
Tenofovir/emtricitabine 
(daily) 
• Overall, sufficient study drug was prescribed for 88% 
of the total follow-up time. 
• Tenofovir was detected in plasma of all 52 sampled 
participants (range 38–549 ng/mL) who reported that 
they were taking PrEP. 
Molina 
2015 
(Ipergay)*  
Tenofovir/emtricitabine 
(intermittent) 
• Median pills per month: 15 pills. 
• In the tenofovir–emtricitabine group, the rates of 
detection were 86% for tenofovir and 82% for 
emtricitabine, respectively, a finding that was 
consistent with receipt of each drug within the 
previous week. Tenofovir and emtricitabine were also 
detected in eight participants in the placebo group, 
three of whom were receiving postexposure 
prophylaxis. 
• Computer-assisted structured interviews also 
performed to assess most recent sexual episode. 
Draft: Health technology assessment of a PrEP programme for populations at substantial risk of 
sexual acquisition of HIV 
Health Information and Quality Authority 
Page 80 of 244   
Overall, 28% of participants did not take tenofovir-
emtricitabine or placebo, 29% took the assigned drug 
at a suboptimal dose and 43% took the assigned drug 
correctly. 
Mutua 
2012 (IAVI 
Kenya 
Study) 
Tenofovir/emtricitabine 
(daily or intermittent) 
• There was no difference in adherence rates between 
treatment and placebo groups, thus these groups 
were combined for the adherence analyses. Median 
MEMS adherence rates were 83% (IQR: 63–92) for 
daily dosing and 55% (IQR:28–78) for fixed 
intermittent dosing (p=0.003). 
Peterson 
2007 
(West 
Africa 
Study) 
Tenofovir (daily) • The amount of product used was estimated by 
subtracting the number of pills returned from the 
number dispensed, and dividing this number by the 
total number of days in the effectiveness analysis.  
• Drug was used no more than 69% of study days. 
Excluding time off product due to pregnancy, drug 
was used for no more than 74% of study days. 
Thigpen 
2012 
(TENOFOVI
R2) 
Tenofovir/emtricitabine 
(daily) 
• The two groups had similar rates of adherence to the 
study medication as estimated by means of pill counts 
(84.1% in the tenofovir–emtricitabine group and 
83.7% in the placebo group, P = 0.79) and self-
reported adherence for the preceding 3 days (94.4% 
and 94.1%, respectively; P = 0.32). 
• Among the four participants in the tenofovir–
emtricitabine group who became infected with HIV 
during the study, two (50%) had detectable levels of 
tenofovir and emtricitabine in plasma obtained at the 
visit before and closest to their estimated 
seroconversion dates. among the 69 participants, 
matched by sample date, who did not undergo 
seroconversion, 55 (80%) and 56 (81%) had 
detectable levels of tenofovir and emtricitabine, 
respectively. 
VanDamme 
2012 
(FEM-  
PrEP) 
Tenofovir/emtricitabine 
(daily) 
• At the time of study-drug discontinuation, 95% of 
participants reported that they had usually or always 
taken the assigned drug. Pill-count data were 
consistent with ingestion of the study drug on 88% of 
the days on which it was available to the participants.  
• In contrast, drug-level testing revealed much lower 
levels of adherence. Among women with 
seroconversion in the tenofovir–emtricitabine group, 
the target plasma level of tenofovir was identified in 7 
of 27 women (26%) at the beginning of the infection 
window (excluding six women for whom the window 
started at enrolment), in 7 of 33 (21%) at the end of 
the window, and in 4 of 27 (15%) at both visits. 
Among the uninfected control participants, the 
numbers of women with target-level tenofovir were 
somewhat higher: 27 of 78 women (35%) at the 
beginning of the infection window, 35 of 95 (37%) at 
the end of the window, and 19 of 78 (24%) at both 
visits. 
 Tenofovir = Tenofovir Disoproxil Fumarate 
* non-daily regimen  
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4.3.4  HIV acquisition 
HIV infection was measured in 11 trials comparing PrEP with placebo and three RCTs 
comparing PrEP with no PrEP. Three trials enrolled very few participants (≤ 72 
participants) and followed patients for a very short duration (≤24 weeks); these 
trials, therefore, detected very few seroconversions, with two trials detecting no HIV 
infections in either treatment or placebo arms.  
The following sections present the HIV acquisition rate by each distinct population 
group investigated. Additionally, analyses are stratified by comparator (placebo or no 
treatment) and by trial-level adherence (high >80% or low <80% adherence). In all 
analyses, the risk of HIV infection is by modified intention-to-treat — participants 
found to be HIV positive at enrollment (but after randomisation) were excluded. The 
RR represents the ratio of risk (number of events per person-year) in the 
intervention group compared with control. 
4.3.4.1 MSM population 
Six studies investigated the effects of PrEP in the MSM population. A meta-analysis 
of all studies demonstrated a risk ratio of 0.25 (95% CI: 0.1 to 0.61; 5,103 person-
years of data), indicating a 75% reduction in the risk of HIV acquisition. Point 
estimates all favoured treatment, although not all were statistically significant. Five 
studies compared PrEP with placebo (Figure 4.5) and one compared PrEP with no 
treatment (Figure 4.6). 
Figure 4.4. Forest plot: PrEP in MSM (all studies) 
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Figure 4.5. Forest plot: PrEP versus placebo  
 
Figure 4.6. Forest plot: PrEP versus no treatment  
 
When stratified by adherence, heterogeneity was greatly reduced (I2 reduced from 
52% to 0%). PrEP was most effective in studies with high adherence, as expected, 
where risk of HIV acquisition was reduced by 86% (RR 0.14; 95% CI 0.06 to 0.35; 
n=3 studies, 960 person-years of data). When adherence was under 80%, PrEP risk 
of acquisition was reduced by 45% (RR 0.55, 95% CI 0.37 to 0.81; n=3 studies, 
4,143 person-years of data). Figures 4.7 and 4.8 provide forest plots of these meta-
analyses. 
Figure 4.7. Forest plot: High adherence (>80%) 
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Figure 4.8. Forest plot: Low adherence (<80%) 
 
Two open-label extensions were conducted following the conclusion of these trials. 
First, the iPrEx Open-label Extension(36) enrolled 1,603 HIV-negative men who were 
previously part of three PrEP trials.(66, 69, 75) Participants were offered daily 
tenofovir/emtricitabine and were followed up for 72 weeks after enrolment. HIV 
incidence was 1.8 infections per 100 person-years compared with 2.6 infections per 
100 person-years in those who concurrently did not choose PrEP (hazard ratio [HR]: 
0.51, 95% CI: 0.26 to 1.01, adjusted for sexual behaviours). Drug levels were also 
examined by dried blood spot testing, and these levels were extrapolated to pill 
taking and compared to HIV incidence. No seroconversions were seen when drug 
levels were compatible with taking four or more pills per week.  
 
Second, the IPERGAY Open-label Extension enrolled 362 individuals to take on-
demand tenofovir–emtricitabine and followed them for a median of 11.7 months, of 
whom 299 (83%) completed follow-up.(33) One HIV infection occurred (0.19 per 100 
person-years, 95%: CI 0.01 to 1.08). 
4.3.4.2 Serodifferent couples 
Three studies investigated the impact of PrEP on HIV transmission in serodifferent 
couples. In all three studies, the HIV-infected partner was not on antiretroviral 
therapy (studies were conducted in Kenya and Uganda; HIV-infected participants did 
not meet criteria for ART initiation at the time of enrolment). Details on the CD4 
count (a type of cell that HIV infects) or viral load of the HIV-infected partners was 
not reported. 
Two studies investigated the effect of PrEP compared to placebo. A total of 4,849 
couples were enrolled, and the seronegative individual was male in the majority 
(>60%) of cases. One trial enrolled few participants (n=24), and the duration of the 
trial was very short (4 months). Therefore, the results did not contribute to the 
effect estimates as no seroconversions were reported.  
The trial by Baeten et al., 2012, consisted of three arms: tenofovir/emtricitabine 
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(n=1,568 participants), tenofovir alone (n=1,572 participants) and placebo (n=1,568 
participants). Tenofovir/emtricitabine resulted in a 75% risk reduction (RR 0.25, 
95% CI: 0.14 to 0.46) and tenofovir alone resulted in a 67% risk reduction (RR 0.33, 
95% CI: 0.19 to 0.56). Adherence was high in this trial: sufficient drug was 
redeemed to cover 92.1% of follow-up and 82% of 902 samples from a randomly-
selected subset of 198 subjects (who did not acquire HIV) tested positive for study 
drug. 
Figure 4.9. Forest plot: PrEP in serodifferent couples,    
  tenofovir/emtricitabine versus placebo 
 
One study investigated the effect of tenofovir/emtricitabine combination therapy 
compared with single-agent tenofovir in the prevention of HIV in serodifferent 
couples. This study was a continuation of the 2012 study by Baeten et al.; once 
efficacy was confirmed in PrEP versus placebo analysis, serodifferent couples in the 
placebo group were re-randomised to receive PrEP containing tenofovir/emtricitabine 
or tenofovir. Of the original sample, 4,410 couples were re-randomised and 
contributed 8,741 person-years of data to the study. There was no statistically 
significant difference between the groups; however, the point estimate favoured 
tenofovir/emtricitabine (RR 0.68, 95% CI: 0.39 to 1.18). HIV transmission was rare, 
at a rate of 6 cases per 1,000 person-years. 
Figure 4.10. Forest plot: tenofovir+emtricitabine versus tenofovir 
 
4.3.4.3 Heterosexual transmission 
Five studies enrolled heterosexual participants, four were placebo-controlled and one 
compared different drug schedules. Four enrolled only women, and one enrolled 
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both men (54.2%) and women (45.8%).  
Placebo-controlled trials encompassed 7,252 participants in total. A meta-analysis of 
studies did not demonstrate a statistically significant reduction in HIV acquisition 
(Figure 4.11); however, three of the four studies reported low adherence (Figure 
4.13). Thigpen et al., 2012, achieved adherence >80% and reported a risk reduction 
of 61% (RR 0.39, 95% CI 0.18 to 0.83; 1,524 person-years of data) (Figure 4.12).  
Figure 4.11. Forest plot: PrEP in heterosexual participants (all studies) 
 
Figure 4.12. Forest plot: high adherence (>80%) 
 
Figure 4.13. Forest plot: low adherence (<80%) 
 
In a separate analysis, the efficacy results from Thigpen et al. were assessed by 
participant sex. Efficacy was only achieved in males, with a risk reduction of 80% 
(RR 0.2, 95% CI 0.04 to 0.91). Females achieved a reduction of 51%; however,this 
failed to reach statistical significance. Appendix 3.5 provides details of these 
separate analyses.  
The study by Marrazzo et al. included four arms in total: tenofovir, 
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tenofovir+emtricitabine, 1% tenofovir vaginal gel and placebo. In the above meta-
analyses, both active arms were combined. Comparing each arm compared with 
placebo showed that none of the interventions reduced the risk of HIV acquisition. 
Adherence was extremely low (<30%) in all arms. 
Finally, Bekker et al., 2018, compared different PrEP regimens in 191 women in 
South Africa. Intervention arms included daily PrEP, time-driven PrEP and event-
driven PrEP. Time-driven indicated PrEP taken twice a week plus a post-sex dose 
and event-driven PrEP indicated one tablet taken both before and after sex. Fewer 
infections occurred in the daily PrEP arm; however, there were no statistically 
significant differences in HIV acquisition comparing either event or time-driven PrEP 
with daily PrEP. 
4.3.4.4 People who inject drugs 
Only one study was identified that investigated PrEP use among people who inject 
drugs. Daily oral tenofovir (300mg) was compared to placebo in this trial. PrEP was 
found to be effective, with a 49% reduction in HIV acquisition (RR 0.51, 95% CI: 
0.29 to 0.92; 9,666 person-years of data). Adherence was 67% in a sample of HIV-
uninfected individuals in this trial.  
In this study, HIV transmission may have occurred sexually or parenterally. 
Methamphetamine was the most common drug injected by participants. 
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Figure 4.14. Forest plot: PrEP in people who inject drugs 
 
4.3.4.5 Relationship between efficacy and adherence 
Efficacy was closely related to participants’ adherence to PrEP across trials. Figure 
4.15 shows a scatterplot comparing efficacy and adherence (measured by plasma 
drug concentration; n=7 trials). A regression model yielded a R2 of 0.92; adherence 
therefore, explains 92% of the variation in efficacy across trials (Figure 4.15). This 
result was significant (p<0.001). 
Figure 4.15. Efficacy as a function of adherence 
 
Only trials that reported plasma drug concentrations contributed to anlaysis: (Baeten 2012 (Partners PrEP), Choopanya 2013 
(Bangkok Tenofovir Study), Grant 2010 (iPrEx), Mazzarro 2015 (VOICE), McCormack 2015 (PROUD), Molina 2015 (Ipergay), 
Thigpen 2012 (TDF2 study), VanDamme 2012 (FEM-PrEP) 
A meta-regression was performed to account for trial size. Figure 4.16 gives the 
meta-regression line. Efficacy (as RRs) and adherence (by proportion with plasma 
drug detectable) were strongly associated (p<0.001). As the proportion adherent 
increases from 0.5 to 0.6, the RR decreases by 0.13. Therefore, on average, a 10% 
increase in adherence increases efficacy by 13%.  
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Figure 4.16. Fitted meta-regression line of the relationship between trial-
   level PrEP adherence and efficacy 
  
Only trials that reported plasma drug concentrations contributed to anlaysis: (Baeten 2012 (Partners PrEP), Choopanya 2013 
(Bangkok Tenofovir Study), Grant 2010 (iPrEx), Mazzarro 2015 (VOICE), McCormack 2015 (PROUD), Molina 2015 (Ipergay), 
Thigpen 2012 (TDF2 study), VanDamme 2012 (FEM-PrEP) 
 
4.3.5  Safety 
It was decided a priori to stratify adverse events into three groups: ‘any’ adverse 
event, serious adverse events and deaths. The definition of what constituted a 
serious adverse event was not described in most primary studies. Whether serious 
adverse events or deaths were considered drug-related was also recorded. Expected 
adverse events were recorded, including reversible renal insufficiency and changes in 
bone mineral density. 
4.3.5.1 Any adverse event 
Overall, 12 studies reported data on ‘any’ adverse events; ten compared PrEP with 
placebo and two compared tenofovir alone to tenofovir/emtricitabine. A meta-
analysis of participants reporting ‘any’ adverse events comparing PrEP with placebo 
demonstrated no significant difference between groups (RR 1.01; 95% CI 0.99 to 
1.03; 17,358 participants). Comparing tenofovir with tenofovir/emtricitabine, one 
study noted a small increase in adverse events in the tenofovir/emtricitabine group 
(RR 1.23; 95% CI 1.03 to 1.33) and another failed to show any difference. Figures 
4.15 and 4.16 provide forest plots of these findings.  
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Figure 4.15. Forest plot: PrEP versus placebo 
 
Figure 4.16. Forest plot: tenofovir/emtricitabine versus tenofovir 
 
Several studies reported mild decreases in renal function among PrEP users that 
returned to normal following discontinuation of PrEP use,(29, 63) while a reduction in 
creatinine clearance (a measure of renal function) was not observed in others.(62, 67)  
4.3.5.2 Serious adverse events 
All 15 studies reported data in relation to the risk of serious adverse events: 12 were 
placebo-controlled, one compared PrEP with no PrEP and two compared 
tenofovir/emtricitabine with tenofovir.  
 
In the placebo-controlled trials, none showed an increased risk of serious adverse 
events associated with PrEP use and one study actually demonstrated a statistically 
significant reduced risk (RR 0.44; 95% CI 0.31 to 0.61). In three studies, the risk 
was not estimable as there were no serious adverse events recorded. The meta-
analysis demonstrated a pooled RR of 0.91 (95% CI: 0.74 to 1.13; 17,778 
participants). The overall rate of serious adverse events was 6.9% across treatment 
arms. 
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Figure 4.17. Forest plot: PrEP versus placebo — serious adverse events 
 
Only one trial compared PrEP with no treatment. An increased rate of serious 
adverse events was noted in the treatment arm (RR 3.42; 95% CI 1.4 to 8.35; see 
Figure 4.18). It is noteworthy, however, that study authors did not consider any of 
the 27 serious adverse events to be study drug-related. 
Figure 4.18. Forest plot: PrEP versus no treatment — serious adverse  
events 
 
Two studies compared tenofovir and tenofovir/emtricitabine. One study found no 
significant difference between groups and another found a statistically significant 
increased rate of serious adverse events in the tenofovir/emtricitabine group (RR 
2.48; 95% CI: 1.42 to 4.33). Overall, 7 per 1,000 additional serious adverse events 
occurred in the tenofovir/emtricitabine group. 
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Figure 4.19. Forest plot: Tenofovir/emtricitabine versus tenofovir 
 
4.3.5.3 Deaths 
Fourteen studies provided data on deaths. There were no deaths recorded in any 
arm of five trials. Across subgroups (PrEP versus placebo, prep versus no treatment 
and tenofovir/emtricitabine versus tenofovir), there was no statistically significant 
increase in the number of deaths in the PrEP group. Of the deaths that occurred, 
none were considered to be drug-related in any trial. Figures 4.20 to 4.22 present 
forest plots of these meta-analyses. 
Figure 4.20. Forest plot: PrEP versus placebo 
 
Figure 4.21. Forest plot: PrEP versus no treatment 
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Figure 4.22. Forest plot: Tenofovir/emtricitabine versus tenofovir 
 
4.3.6  Change in behaviour and STI rates 
Eleven trials measured changes in behaviour while taking PrEP. The most common 
methods for assessing sexual behaviour were condom use (measured in eight 
studies) and number of sexual partners (measured in 10 studies). One trial assessed 
changes in recreational drug use. Five trials assessed the change in STI rates. Table 
4.9 provides details in the changes in behaviour and STI diagnoses across studies.  
Due to the differences in how sexual behaviour was reported, including differing 
definitions and at different time points, a meta-analysis of behavioural change was 
not possible. Studies consistently showed no difference in condom use between 
intervention and control arms. Studies showed either no change in condom use 
throughout the duration of the study (n=4 studies) or increases in condom (n=4 
studies). This observation was similarly found in studies comparing PrEP with no 
treatment, which possibly better reflects real-world situations.  
Similarly, no studies that assessed the number of sexual partners showed differences 
between the intervention and control arms. Most studies showed no change in the 
number of sexual partners throughout the duration of the study (n=6 studies); four 
studies showed a slight reduction in number of sexual partners and one showed an 
increase. In the study that showed an increase, investigators noted the possibility of 
partner underreporting at baseline.(71) For this reason, authors also compared the 
median number of sexual partners at month two and month four, which was the 
same at both time points. 
Five studies recorded changes in the incidence of STIs. No study reported an 
increase in STIs or a between-group difference in STI diagnoses. The study by 
McCormack et al.,(70) an open-label study comparing PrEP with no treatment in MSM, 
measured the incidence of rectal chlamydia/gonorrhea as a proxy for condomless 
anal intercourse. This study benefitted from the fact that it better represents ‘real-
world’ situations by virtue of its open-label design. No difference in the occurrence of 
rectal gonorrhoea or chlamydia was observed between groups, despite a suggestion 
of risk compensation among some PrEP recipients (an increase in risky sexual 
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behaviour when on PrEP). Van Damme et al.(63) also assessed STI incidence in 
women by pelvic examination and similarly did not note a difference between 
treatment and control groups. 
Choopanya et al., 2013, the only study to enroll intravenous drug users, noted a 
reduction in intravenous drug use and needle sharing over the course of the 
study.(62) Study authors also noted a reduction in the number of sexual partners. 
Table 4.9. Change in sexual behaviour/STI rates 
Study Measure Outcome 
Baeten 2012 
(Partners PrEP)  
• Having sex 
without a 
condom with 
HIV-positive 
partners in 
prior month  
• STI diagnoses 
from sex acts 
outside 
partnership 
• At enrolment, 27% of HIV-1 seronegative 
partners reported sex without condoms with 
their HIV-1 seropositive partner during the 
prior month. This percentage decreased during 
follow-up (to 13% and 9% at 12 and 24 
months) and was similar across the study 
arms.  
• The proportion reporting outside partnerships 
and who acquired sexually transmitted 
infections during follow up did not differ across 
the study arms. 
Baeten 2014 
(Partners PrEP) 
Unreported  
Bekker 2018 
(ADAPT Cape 
Town) 
Unreported  
Choopanya 
2013 (Bangkok 
Tenofovir 
Study) 
• Drug use 
behaviour 
• Number of 
sexual partners 
• Tenofovir and placebo recipients reported 
similar rates of injecting and sharing needles 
and similar numbers of sexual partners during 
follow up with no interactions between time 
and treatment group. 
• Overall, number of participants reporting 
injecting drugs or sharing needles reduced 
over time.  
• Sex with more than one partner decreased 
from 522 (22%) at enrolment to 43 (6%) at 
month 72. 
Grant 2010 
(iPrEx) 
• Number of anal 
sex acts 
• Proportion of 
anal sex acts 
with a condom 
• STI diagnoses 
• Sexual practices were similar in the two groups 
at all time points.  
• The total numbers of sexual partners with 
whom the respondent had receptive anal 
intercourse decreased, and the percentage of 
those partners who used a condom increased 
after subjects enrolled in the study. 
• There were no significant between-group 
differences in the numbers of subjects with 
syphilis, gonorrhea, chlamydia, genital warts 
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or genital ulcers during follow-up. 
Grohskopf 
2013 (CDC 
Safety Study) 
Unreported 
Hosek 2013 
(Project 
PrEPare) 
Male-to-male 
unprotected 
anal sex acts 
• No significant differences among the three 
treatment groups across visits. 
• Insignificant trend from baseline to week 24 of 
decreasing unprotected anal sex acts across all 
treatment arms. 
Kibengo 2013 
(IAVI Uganda 
Study) 
HIV behaviour 
change 
• The median number of sexual partners in the 
past month remained at 1 (IQR: 1–1) during the 
trial.  
• No other HIV risk behaviours reported at baseline 
changed during the trial 
Mazzarro 2015 
(VOICE) 
Unreported  
McCormack 
2015 (PROUD) 
• Number of 
sexual 
partners 
• Incident 
STIs  
• Total number of different anal sex partners varied 
widely between baseline and year 1. No 
significant difference between groups at one year 
was detected. 
• Proportion with confirmed rectal 
chlamydia/gonorrhea was similar in immediate 
and delayed arms (proxy for condomless anal 
intercourse).  
• Adjusted odds ratio for rectal chlamydia or 
gonorrhea: 1.00 (0.72–1.38) (adjusted for 
number of sexual health screens) 
Molina 2015 
(Ipergay)  
• Total 
number of 
sexual 
intercourse 
events 
• Proportion of 
events 
without a 
condom 
• Number of 
sexual 
partners 
• Incident 
STIs 
• Sexual practices did not change overall among 
the participants during the study period as 
compared with baseline: there were no significant 
between group differences in the total number of 
episodes of sexual intercourse in the four weeks 
before, in the proportion of episodes of receptive 
anal intercourse without condoms, or in the 
proportion of episodes of anal sex without 
condoms during the most recent sexual 
intercourse.  
• There was a slight but significant decrease in the 
number of sexual partners within the past two 
months in the placebo group as compared with 
the tenofovir—emtricitabine group (7.5 and 8, 
respectively; p = 0.001).  
• The proportions of participants with a new 
sexually transmitted infection (of the throat, 
anus, and urinary tract combined) during follow-
up were similar, with 41% in the tenofovir—
emtricitabine group and 33% in the placebo 
group (P = 0.10).  
Mutua 2012 HIV behaviour • The median number of sexual partners in the 
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(IAVI Kenya 
Study) 
change past month increased from three (IQR 2–4) at 
baseline to four (IQR 2–8) at month 4 during the 
trial.  
• Because there may have been underreporting of 
sex partners at baseline, authors also compared 
the median number of sexual partners month 2 
(4) and at month 4 (4). 
Peterson 2007 
(West Africa 
Study) 
• Condom use 
at last sex 
• Number of 
sex acts 
• Number of 
partners 
• During screening, participants reported an 
average of 12 coital acts per week with an 
average of 21 sexual partners in the previous 30 
days (including 11 new partners). During follow-
up, participants reported an average of 15 coital 
acts per week, with an average of 14 sexual 
partners in the previous 30 days (six new 
partners). Of note, most participants in this study 
were sex workers. 
• Self-reported condom use increased from 52% at 
screening (average across all sites during the last 
coital act prior to screening) to approximately 
92% at the enrolment, month 3, month 6, and 
month 9 visits, to 95% at the month 12 visit (for 
acts occurring during the last seven days). The 
average condom use during the follow-up period 
was 92%. 
Thigpen 2012 
(TENOFOVIR2) 
• Protected 
sex episodes 
with main/ 
most recent 
casual 
partner 
• Number of 
sexual 
partners 
• The percentage of sexual episodes in which 
condoms were used with the main or most recent 
casual sexual partner was similar in the two study 
groups at enrolment (81.4% [range, 76.6 to 
86.4] in the tenofovir–emtricitabine group and 
79.2% [range, 71.6 to 87.6] in the placebo 
group, P = 0.66) and remained stable over time.  
• The reported number of sexual partners declined 
in both groups during the course of the study. 
VanDamme 
2012 (FEM-
PrEP) 
• Number of 
partners 
• Sex acts 
without a 
condom 
• Pelvic STIs 
• There was no evidence of increased HIV risk 
behaviour during the trial, with modest but 
significant reductions in the numbers of partners 
(mean reduction, 0.14; P<0.001 by paired-data t-
test), vaginal sex acts (mean reduction, 0.58; 
P<0.001), and sex acts without a condom (mean 
reduction, 0.46; P<0.001) reported by women at 
the last follow-up visit, as compared with seven 
days before enrolment.  
• Fewer than half the study participants agreed to 
undergo a pelvic examination. There were no 
significant between-group differences in the 
prevalence of pelvic STIs. 
4.3.7  Drug mutations 
Seven placebo-controlled trials provided data on HIV mutations (to tenofovir and or 
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emtricitabine) among seroconverters. Seroconverters were subgrouped into those 
who had acute HIV infection at enrolment (unknown to study investigators) and 
seroconverters post-randomisation (during the follow-up period). 
4.3.7.1 Acute HIV at enrolment 
In total, there were 44 seroconversions at enrolment, 25 who received study drug 
and 19 who received placebo. There were nine mutations detected in total, eight 
among those receiving a study drug and one in a patient receiving placebo. The RR 
for any drug mutation was 3.53 (95% CI: 1.18 to 10.56) (Figure 4.23). 
Figure 4.23. Forest plot: any drug mutation (PrEP versus placebo) 
 
Of the nine drug resistance mutations, seven were for emtricitabine (one in a 
placebo arm and six in tenofovir/emtricitabine arms). In placebo-controlled trials, the 
RR of emtricitabine mutation was 3.72 (95% CI: 1.23 to 11.23) in those receiving 
tenofovir plus emtricitabine.  
 
Figure 4.24. Forest plot: emtricitabine mutation 
(tenofovir/emtricitabine versus placebo) 
 
Tenofovir mutations were rare. Two occurred overall: one in a tenofovir-only arm 
and one in a tenofovir/emtricitabine arm. Due to the rarity of events, no meta-
analyses yielded significant results (Figure 4.24). 
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4.3.7.2 HIV post-randomisation 
Among participants who seroconverted postrandomisation, the development of 
resistant mutations was uncommon, which makes assessing relative risk difficult. Of 
551 seroconverters, only seven resistance mutations were detected. One tenofovir 
mutation was noted in a tenofovir-only arm (k65n, a rare tenofovir resistance 
mutation) and six emtricitabine mutations were noted (five in tenofovir/emtricitabine 
arms and one in placebo). 
4.4  Discussion 
This systematic review and meta-analysis of 25,051 individuals encompassing 38,289 
person-years of follow-up data confirms that oral PrEP to prevent HIV acquisition in 
populations at substantial risk is both effective and safe.  
Fifteen high-quality RCTs, which were conducted in high-, middle- and low-income 
countries, were retrieved. Follow up ranged from 17 weeks to 6.9 years. Due to 
differences in mode of transmission, all analyses were stratified by risk group. Six 
trials enrolled men who have sex with men (MSM), two trials enrolled serodifferent 
couples, five trials enrolled heterosexuals and one trial enrolled people who inject 
drugs (PWID).  
PrEP was found to be highly effective in preventing HIV acquisition in MSM with a risk 
reduction of 75% across all trials, rising to 86% in trials with high adherence. Two 
open-label extensions(33, 36) that followed the conclusion of four of these RCTs 
confirmed this high efficacy; one open-label extension(36) found no seroconversions in 
participants that took a minimum of four pills per week (of a daily dosing regimen). 
Of the six trials in MSM, the PROUD Phase 3 trial,(70) conducted at 13 sexual health 
clinics in England, would appear highly applicable to MSM in Ireland. This is due to 
the similarities in background HIV prevalence (7.8% among MSM in Ireland versus 
7.7% in the UK, see Chapter 3, Section 3), PrEP delivery model (provision through 
sexual health clinics) and by virtue of its open-label design (which may better reflect 
real-world situations). In this trial, a total of 23 participants became infected with 
HIV over the course of the study: three in the daily tenofovir/emtricitabine group 
and 20 in the deferred (no-PrEP) group, representing a relative risk reduction of 
86% (95% CI: 53 to 96%). The number needed to treat over one year to prevent 
one HIV infection was 13.  
PrEP was effective in preventing HIV acquisition in HIV-uninfected partners of 
serodifferent couples, with a risk reduction of 75%.(67, 72) Another study compared 
combination tenofovir/emtricitabine to tenofovir alone; no significant difference in 
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PrEP efficacy was noted.(73) All studies were conducted in sub-Saharan Africa. It is 
assumed that the biological efficacy of PrEP is likely to be identical across populations. 
It is unclear if PrEP is effective in heterosexual individuals at substantial risk due to 
poor trial-level adherence. A meta-analysis of four identified studies showing non-
significant results (RR 0.77, 95% CI: 0.46 to 1.29). PrEP was effective in preventing 
heterosexual HIV transmission in one trial where adherence was high (61% 
reduction).(64) Efficacy in this trial (by modified intention to treat) was only 
demonstrated in male participants; the reduction in seroconversions among females 
failed to reach statistical significance. Efficacy was not demonstrated in the 
remaining three trials, all enrolling females.(63, 65, 68) Adherence was noted to be low 
and all studies were conducted in sub-Saharan Africa. It is unclear if the results of 
these studies are transferable to Ireland where background HIV prevalence and 
demographic characteristics are significantly different. 
PrEP was effective in preventing HIV transmission in PWID in the only high-quality 
trial retrieved that enrolled drug users. Risk was reduced by 49%.(62) However, this 
trial may not be directly applicable to the Irish context. Participants were intravenous 
drug users from Thailand, and stimulant drugs (such as methamphetamine) were 
the most commonly injected drugs. It is difficult to separate the impact of PrEP on 
parenteral HIV transmission from sexual transmission in PWID. The authors of the 
study acknowledge that, although the study was designed to measure the impact on 
parenteral transmission, participants may have become infected sexually.  
Chemsex and slamming (the act of injecting the drugs used in chemsex) should be 
distinguished from injecting drug use involving heroin as the demographics of users 
and risk factors for HIV acquisition are different. Chemsex is frequently reported in 
MSM at high risk of HIV acquisition and involves drugs such as methamphetamine, 
methedrone and gamma hydroxybutyrate (GHB), and it significantly increases the 
risk of sexual HIV acquisition. In 2015, it was estimated that 7% of MSM engaged in 
chemsex in Ireland.(76) Opiate drug users who do not have a sexual risk factor for 
HIV and are at risk of HIV infection from sharing needles should ideally be offered 
needle exchange and opiate substitution in the first instance to minimise their risk of 
acquiring HIV and other blood-borne infections. 
Adherence varied greatly across studies. Adherence was either recorded by self-
report, pill count, structured interviews or by plasma drug monitoring. Plasma drug 
monitoring was considered the most objective measurement for adherence 
assessment; adherence by this measurement ranged from 25% to 88% across trials. 
Efficacy was found to be strongly associated with adherence (p<0.01), and 
adherence explained 92% of the variation in efficacy across trials. Highest efficacy 
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was noted in trials with highest adherence (as measured by plasma drug 
monitoring). In general, an interesting observation was that efficacy (in %) was 
consistently similar to the proportion who adhered to the PrEP regimen. 
Caution should be used when generalising results from low-income to high-income 
countries when large sociodemographic differences exist, including background HIV 
prevalence. All studies that enrolled heterosexuals in this systematic review were 
conducted in sub-Saharan Africa, where HIV prevalence was as high as 23.1% 
(Botswana). By contrast, HIV prevalence in Ireland is approximately 0.2% in the 
general population (see Chapter 3). The only study that enrolled PWID was 
conducted in Thailand; drug users in Thailand have an estimated HIV prevalence of 
almost 20%. With the exception of one study that enrolled MSM in England, 
prevalence estimates among MSM were also somewhat higher (14.5% in the US, 
14.9% in Canada and 14% in France compared with 7.8% in Ireland).(35) 
Changes in sexual behaviour patterns were measured in a number of ways, including 
condom use, number of sexual partners and new STI diagnoses. The most clinically 
relevant outcome is STI diagnoses due to the fact that the other two indicators are 
self-reported and are subject to reporting bias. Unfortunately, placebo-controlled 
trials are not very helpful in assessing risk compensation (altering sexual behaviour 
due to the knowledge that PrEP is protective). One purpose of the placebo is to 
control for behaviour, and it is not possible to reach conclusions on the impact of 
PrEP on behaviour as participants do not know if they are on active drug. However, 
it is possible to evaluate the impact of the support provided to all participants over 
time (counselling on safer sex practices and provision of condoms). 
Studies showed either no change in condom use over time (n=4 studies) or an 
increase in condom use (n=4 studies). Most studies showed no change in the 
number of sexual partners throughout the duration of the study (n=6 studies), four 
studies showed a slight reduction in number of sexual partners and one showed an 
increase. In the study that showed an increase, investigators noted the possibility of 
partner underreporting at baseline.(71) In the open-label PROUD study, in which 
participants knew they were taking PrEP, there was no difference between the 
immediate and deferred (no-PrEP) groups in the total number of sexual partners 
(p=0.57) in the three months prior to the one-year questionnaire, but a greater 
proportion of the immediate group reported receptive anal sex without a condom 
with 10 or more partners compared with the deferred group (21% versus 12%, p-
=0.03). There was no difference in the frequency of bacterial STIs during the 
randomised phase (p=0.74). 
PrEP was found to be safe in RCTs. However, the maximum follow-up period was 
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6.9 years and, therefore, long-term safety was not assessed. Not all studies defined 
what constituted adverse events (including serious adverse events). A high rate of 
adverse events was noted in some control arms, including a higher rate of serious 
adverse events in the placebo arm of one trial (compared with active drug). 
Therefore, occurrence is not evidence of causality. A meta-analysis of placebo-
controlled trials demonstrated that adverse events (overall) and serious adverse 
events do not occur more commonly with PrEP compared with placebo, and no drug-
related deaths were reported. There was no difference in adverse event rates 
comparing single agent tenofovir with tenofovir/emtricitabine in combination.  
A transient elevation of creatinine was noted in some studies with resolution upon 
discontinuation of study drug. Where renal function has been affected, PrEP was 
associated with mild, non-progressive and reversible reductions in creatinine 
clearance.(10, 62, 66, 67, 70) Some trials found slight decreases in bone mineral 
density.(64, 68) There are no long-term data on bone health or evidence of increased 
fracture risk, however. Following the CDC MSM safety study, in multivariate analysis, 
back pain was associated with use of tenofovir and also a small decrease in bone 
mineral density among a subset of 184 men in the San Francisco site. However, 
tenofovir use was not associated with bone fractures.(32)  
One risk associated with the administration of PrEP is the development of drug 
resistance. This could occur due to PrEP failure (considered a rare event when 
adherence is adequate) or due to an unrecognised acute HIV infection at enrolment. 
Seven placebo-controlled trials evaluated drug resistance. In total, there were 44 
seroconversions at enrolment, 25 who received study drug and 19 who received 
placebo. There were nine mutations detected, eight among those receiving PrEP and 
one in a patient receiving placebo. The RR for any drug mutation was 3.53 (95% CI: 
1.18 to 10.56). Of the nine resistant mutations, seven conferred resistance to 
emtricitabine. Development of resistance post-randomisation was uncommon. The 
potential for development of resistance emphasises the need for careful participant 
screening, including ascertaining if the patient could be in the ‘window period’ (the 
time between exposure to HIV and the point when HIV testing will give an accurate 
result) at enrolment, to ensure the patient is HIV negative prior to commencing 
PrEP. This highlights the need for PrEP delivery as part of a holistic programme that 
incorporates HIV testing and patient counselling regarding the risk and long-term 
consequences of resistance if poorly adherent to PrEP. 
In conclusion, high-quality evidence exists that PrEP is safe and highly efficacious in 
preventing HIV acquisition in populations at substantial risk, including MSM and 
serodifferent couples. Efficacy is strongly associated with adherence. The 
generalisability of trials that enrolled heterosexual participants (conducted in sub-
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Saharan African countries) and PWID (conducted in Thailand) to the Irish setting is 
unclear, however, due to substantial demographic differences. Adverse events, 
including serious adverse events, did not occur more commonly in PrEP users 
compared with placebo in trials. Placebo-controlled trials are not sufficient to 
measure behaviour change associated with PrEP. However, an increase in high-risk 
behaviour over time was not noted and in many cases decreased, which is probably 
due to the risk reduction support offered to trial participants. 
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5 Systematic review of economic evaluations 
Key points 
 
 A systematic review of economic evaluations identified 18 studies from ten 
different countries, published between 2009 and 2018. The majority of 
studies (n=17) investigated PrEP use in gay, bisexual and other men who 
have sex with men (MSM) with one study focussing on people who inject 
drugs (PWID). Fifteen studies evaluated PrEP taken daily and three studies 
assessed PrEP taken ‘on demand’. 
 The annual cost of daily PrEP ART in MSM and PWID studies ranged from 
€232 to €14,659 per person (mean €6,543). Costs were lower in European 
compared with North American studies (mean annual PrEP cost of €6,419 
versus €7,702). The mean annual cost of on-demand PrEP ART was €4,313. 
 Parameter estimates for the efficacy of PrEP in reducing the risk of HIV 
transmission in MSM ranged from 44%-99%. In nine of the seventeen MSM 
studies, the efficacy was equal to or above 86%. The efficacy of PrEP was 
49% in the PWID study. 
 Seven studies were at risk of bias due to industry support. Four studies were 
at risk of bias due to conflicting or competing interests and financial 
disclosures were not stated in three studies. 
 PrEP was considered cost saving in two studies. A further six studies reported 
an ICER below €45,000, the willingness-to-pay threshold commonly used in 
Ireland. Three studies estimated an ICER above €45,000. This is not 
necessarily an indication of cost-effectiveness, as countries have different 
willingness-to-pay thresholds. 
 Risk compensation was included in the base case scenario of one study and 
as part of a scenario analysis in five studies. The maximum impact of risk 
compensation was a 30% increase in STIs. 
 None of the studies could be considered directly applicable to Ireland. 
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5.1 Introduction 
The aim of this chapter is to summarise the available evidence on the cost-
effectiveness of PrEP to prevent the sexual acquisition of HIV. The applicability of 
studies to the Irish setting is assessed and the context and populations for which 
PrEP is most likely to be cost-effective are determined. 
Mathematical models provide a framework to combine all the information available 
on PrEP (uptake, efficacy, adherence, changes in sexual behaviour and cost) to 
provide insights into the potential epidemiological impact, cost-effectiveness and 
budget impact of PrEP at a population level. A cost-effectiveness analysis compares 
the cost and outcomes of two or more different options and usually involves 
calculation of the cost of obtaining a gain in health, such as infections averted, 
deaths averted, additional years of life (‘life years gained’ [LYGs]), quality-adjusted 
life years (QALYs) gained or disability-adjusted life-years (DALYs) averted. The 
advantage of using a standardised measure such as QALYs gained is that outcomes 
can be compared across interventions in any disease area.  
5.2 Methods 
A systematic review was undertaken to summarise the cost-effectiveness literature 
for oral PrEP when used to prevent HIV infection. The applicability of the evidence 
was assessed to inform cost-effectiveness in an Irish health and social care setting. 
5.2.1  Search Strategy 
5.2.1.1 Search terms and database search 
A search string was developed to identify relevant studies. This comprised key words 
pertaining to the epidemiology of HIV, PrEP treatment and economic evaluation. The 
search of electronic databases was conducted from 2000 until 02 October 2018. The 
electronic search included the following databases: PubMed, Embase, EBSCOhost 
(CINAHL + EconLit), University of York’s CRD DARE and HTA databases and the 
Cochrane Library. A grey literature search was also conducted which included hand-
searching of journals and disease-specific conference proceedings (for example, 
AIDS Research and Human Retroviruses, Journal of the International AIDS Society 
(JIAS), HIV Medicine). The review followed national guidelines for the retrieval and 
interpretation of economic literature.(77) 
5.2.1.2 Criteria for inclusion of studies 
Table 5.1 outlines the Population, Intervention, Comparator, Outcome, Study 
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(PICOS) criteria for the selection of studies.  
Table 5.1 Inclusion criteria for the review of cost-effectiveness 
studies 
Population  HIV-negative patients at high risk of contracting HIV. Subgroups include 
gay, bisexual and other men who have sex with men (MSM), persons 
who inject drugs (PWID), serodifferent couples (SDC) and heterosexual 
individuals at high risk. 
Intervention  Oral tenofovir-containing PrEP.  
Comparator  Usual care (current suite of HIV prevention strategies, such as provision of 
condoms, HIV testing and Treatment as Prevention [TasP]). 
Outcomes  Incremental cost-effectiveness ratios (ICERs), cost per HIV infection 
averted, LYG, QALYs, DALYs, any measure of cost and benefits. 
Study Designs  Economic evaluations (cost-utility, cost-effectiveness, partial economic 
evaluation studies (cost-analysis, cost-of illness) . 
Key: DALY – disability-adjusted life year; HIV – human immunodeficiency virus; PrEP – pre-exposure 
prophylaxis; QALY – quality-adjusted life year. 
Studies for which the intervention was not relevant were excluded. These included 
non-oral PrEP, oral PrEP that did not contain tenofovir, and PrEP that was employed 
as part of a wider HIV prevention strategy (such as changes to the frequency of HIV 
testing or the provision of anti-retroviral therapy [ART] to HIV-infected individuals in 
countries where ART is not universally available). Studies were also excluded in 
cases where the comparator was not relevant, published only as abstracts or were 
not in English. These included studies that compared PrEP administration with 
increased coverage of ART in HIV-infected individuals. These studies were 
considered irrelevant as early and effective ART is the standard of care for HIV 
positive individuals in Ireland. Finally, studies were excluded due to the study design 
(that is, the cost or cost-effectiveness of PrEP was not evaluated).  
5.2.2 Identification of studies 
Titles and abstracts retrieved were downloaded and stored in EndNote reference 
manager. Citations were independently screened by two reviewers per the inclusion 
and exclusion criteria. References obtained by hand-searching were added to the 
database and duplicates were removed.  
5.2.3 Data extraction and management 
Data were extracted using standardised data extraction templates by two 
independent reviewers. These data included identification information (author, year 
and country), key epidemiological parameters (incidence and prevalence of HIV, 
efficacy of PrEP and target population demographics), costing data (cost of PrEP 
medication, cost of PrEP delivery [laboratory investigations, follow-up appointments 
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etc], cost of ART in HIV-infected individuals, cost of non-ART HIV-related care and 
the discount rate applied), clinical outcomes (number of seroconversions, number of 
LYG, QALYs, DALYs) and cost-effectiveness outcomes (ICERs).Details of model 
design, assumptions and limitations were also extracted. All costs were inflated using 
the consumer price index (CPI) for health and converted to 2017 Irish Euro using 
purchasing power parity (PPP). 
5.2.4 Applicability of included studies 
The quality, relevance and credibility of the modelling studies were assessed using 
the Consensus on Health Economic Criteria (CHEC) list.(78) The methodological 
relevance and transferability of studies to the healthcare system in Ireland were 
appraised by employing the International Society for Pharmacoeconomics Outcomes 
and Research (ISPOR) questionnaire.(79) Relevance was assessed on the grounds of 
the study population, characteristics of the intervention, outcomes measured and the 
overall study context. The credibility of the results was considered using criteria 
related to the design, validation and analysis methods, the quality of the data used, 
as well as how the results were reported and interpreted, and whether the authors 
had any conflicts of interest. Two reviewers independently applied the questions and 
any disagreements were be resolved by discussion, or if necessary, a third reviewer. 
5.3 Results 
5.3.1 Search results 
Details of the search process are presented in Figure 5.1. In total, 1,582 records 
were retrieved from electronic searches (after 192 duplicate records were removed). 
The title and abstract were screened and 1,517 irrelevant records were removed 
leaving 65 studies for full text review. Sixteen relevant economic studies (80-95) met 
the inclusion criteria and were included. The reference lists of eight systematic 
reviews (96-103) identified in the full text review were screened and one additional 
study was identified for inclusion.(104) One additional study was identified as part of 
the grey literature search,(105) this brought the total to eighteen studies. Appendix 
4.1 provides a full list of excluded studies (including reasons for their exclusion). 
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Figure 5.1. Flow diagram of studies identified and included in the review 
of cost-effectiveness studies  
 
5.3.2 Quality and applicability of evidence 
The population, comparator, perspective, costs and outcomes were appropriate in all 
studies, and the study design in all but one study.(85) The generalisability of results 
was low with many of the results only applicable within the context of the study. The 
results of four studies were considered transferable outside of the scope of the 
research.(89, 90, 94, 105) 
A potential conflict of interest pertaining to either direct payments or funding of 
research was reported in four studies.(81, 87, 89, 92) This related to personal fees, direct 
payments and research grants to authors. Gilead provided financial support in three 
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cases.(87, 89, 92) In one study, no financial disclosures were made.(85) There were no 
conflicts of interests disclosed in one study(84) and no funding reported in one 
study.(93)  
In regard to transferability, the target population (MSM and PWID) of included 
studies was relevant to this HTA. However, significant demographic differences 
existed between identified studies and the Irish population. 
The intervention and comparator were applicable in all studies. The primary clinical 
outcome of HIV infections averted was reported in all studies and utility outcomes 
were quantified in QALYs in all but four studies. Two studies reported DALYs which 
is more relevant to developing countries. The other studies were cost-effectiveness 
analyses which reported life years saved and the cost per infection prevented. 
None of the papers explicitly stated that the model used was internally or externally 
validated. The validity and design of 17 of the models was suitable; however, two 
cost prevention models appeared overly simplified to apply to other settings. The 
data used in the model were suitable for all studies and the analysis was adequate. 
Uncertainty was considered in 17 economic evaluations apart from the 
aforementioned cost prevention studies which only altered the discount rate as part 
of a sensitivity analysis. The reporting of results was consistently accurate and 
balanced in all studies.  
The costs were presented appropriately, however the cost year was not explicitly 
stated in six studies. Although the costs could be identified from references it was 
unclear if they had been inflated or converted to a particular year or a present value 
when the study was published.  
5.3.3  Overview of study characteristics  
Of the 18 studies included in this review, six were set in the United States, five in 
Europe (France, Netherlands, Spain, and the UK), two in South America (Brazil and 
Peru), two in Canada, two in Australia and one in Thailand (see Table 5.2).  
Sixteen of the eighteen economic evaluations carried out a cost-utility analysis (CUA) 
and two studies conducted cost-effectiveness analysis (CEA). A mathematical model 
was used to evaluate PrEP in 15 studies, the most common model being a dynamic 
transmission model (n=10), followed by a decision analytic model (n=2), state-
transition Monte Carlo stimulation model (n=2) and a Bernoulli Process model (n=1). 
Three studies did not use a model, instead calculating the cost per infection averted 
(using the number needed to treat [NNT]).   
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Ten studies adopted the perspective of a public payer, six a societal perspective and 
one the perspective of a third party payer. The perspective was not stated in one 
study.  
Discounting reflects a societal preference for benefits to be realised in the present 
and costs to be experienced in the future. Discounting facilitates comparison 
between costs and benefits that occur at different times. Costs and benefits were 
discounted at rates of 3% (n=11 studies)(80, 83, 84, 86-89, 92, 94, 95, 104), 3.5% (n=2)(81, 90) 
or 5% (n=1).(105) Two studies did not state a base case scenario, but reported three 
scenarios where discount rates of 0%, 3% and 5% were applied to costs and 
benefits.(91, 93) These studies reference CADTH guidelines (3rd edition) which state a 
discount rate of 5% should be applied.(106) This scenario was therefore considered 
the base case and reported in tables and figures. No discounting was applied to 
costs or outcomes in two studies. The studies were based on a single year of PrEP 
provided in the first year, so this was not discounted.(82, 85)  
Sixteen studies modeled patients taking daily PrEP as the base case scenario while 
two studies considered ‘on-demand’ PrEP dosing regimens. The target population for 
the intervention was exclusively MSM in 17 studies and PWID in one study. No study 
investigated the cost-effectiveness of PrEP in heterosexuals at high risk of HIV 
acquisition or serodifferent couples. 
All studies compared the intervention of providing PrEP free of charge against the 
comparator of the status quo (‘No PrEP’). The infrastructure and costs for providing 
PrEP differed between studies due to different standards pertaining to screening, 
monitoring and counseling. A detailed description of each study is provided in 
Appendix 4.5. 
Table 5.2. Study characteristics, subgroup population, perspective and 
discount rate 
Study Country Type of 
analysis 
Population Perspective Discount 
Rate 
Bernard (2017)(80) USA CUA PWID Societal 3% 
Cambiano (2018)(81) UK CUA MSM Public payer 3.5% 
Desai (2008)(104) USA CUA MSM Public payer 3% 
Durand-Zaleski 
(2016)(82) 
France CEA MSM Public payer N/R 
Gomez (2012)(83) Peru CUA 
(DALYs) 
MSM Public payer 3% 
Gray (2017)(105)  Australia CUA MSM Public payer 5% 
Juusola (2012)(84) USA CUA MSM Societal 3% 
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Lin (2016)(85) USA CUA MSM Societal N/R 
Luz (2018)(86) Brazil CEA MSM Public payer 3% 
MacFadden 
(2018)(87) 
Canada CUA MSM Public payer 3% 
McKenney 
(2017)(88) 
USA CUA MSM Societal 3% 
Nichols (2016)(89) Netherlands CUA MSM Third Party 
Payer 
3% 
Ong (2017)(90) UK CUA MSM Public payer 3.5% 
Ouellet (2015)(91) Canada CUA MSM Societal 5%* 
Paltiel (2009)(92) USA CUA MSM Societal 3% 
Reyes-Uruena 
(2018)(93) 
Spain CUA MSM N/R 5%* 
Schneider (2014)(94) Australia CUA MSM Public payer 3% 
Suraratdecha 
(2017)(95) 
Thailand CUA 
(DALYs) 
MSM Public payer 3% 
Key: CUA = cost-utility analysis; DALY = disability-adjusted life year; MSM = men who have sex with men; PWID = people who 
inject drugs; SDC = serodiscordant couples; N/R = not reported 
* Three scenarios presented whereby discount rates of 0%, 3% and 5% for costs and benefits were adopted. These studies 
reference CADTH guidelines of 5%. This was taken as the base case scenario. 
 
The following sections report outcomes by the population identified: MSM (5.3.3) 
and PWID (5.3.4). 
5.3.4 MSM population 
Seventeen studies were identified that assessed cost or cost-effectiveness in the 
MSM population (81-88, 90-95, 104, 107). Studies were conducted in the USA (n=5), Canada 
(n=2), UK (n=2), Australia (n=2), and one each in Brazil, France, Netherlands, Peru, 
Spain and Thailand.  
There was no universal definition of what constituted ‘high risk’ across studies.. 
Furthermore, there were differences in the method used to calculate this ‘high risk’ 
group.. UK and Australian studies employed data-driven methods using information 
collected at STI clinics to obtain a more precise estimate of the population eligible. 
(81, 90, 105) Other studies assigned an arbitrary figure for the proportion at high risk 
(for example, a third of all MSM).(95) In some studies, the cost effectiveness of PrEP 
for MSM at low and medium risk, as well as the whole MSM population, was 
considered in scenario analyses.  
Six of the nine studies that used dynamic transition models to calculate the cost 
effectiveness of PrEP either adapted a previously developed HIV transmission model 
or adopted a model used in a previous cost-effectiveness study. The models adapted 
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were the HIV synthesis model,(108) OPTIMA model (109) and a precursor to the 
OPTIMA, the Prevtool model.(110) The remaining three studies developed novel 
dynamic transmission models for their analysis. Of the two studies using decision 
analytic models, one was based on a novel model while the other was adapted from 
a previous model. The state-transition Monte Carlo models were adaptions of the 
cost-effectiveness of preventing AIDS complications (CEPAC) model.(111) The 
Bernoulli process model was a novel approach to evaluating the cost-effectiveness of 
PrEP. This model stated the incremental cost per prevented case of HIV was defined 
as the additional unit cost of the intervention per person divided by the intervention 
effect. 
A non-mathematical method was used in three studies (Table 5.3). These studies 
(Durant-Zaleski et al.(82)[CEA], Ouellet et al.(91)[CUA] and Reyes-Uruena et 
al.(93)[CUA]) employed a simplified approach of multiplying the cost by the NNT (that 
is, the cost to avert one infection), and to estimate cost-effectiveness, dividing this 
by the health benefit (such as QALY gained). As these models are static, the impact 
of PrEP on the HIV epidemic and the onward transmission of HIV are not captured. 
The NNT was stated as 17.2, 51.78 and 58.1 for Durant-Zaleski et al., Ouellet et al. 
and Reye-Uruena et al., respectively. The substantial difference in NNT is explained 
by the fact that Ouellet et al. and Reye-Uruena et al. used local incidence data 
(Canada and Spain, respectively) as opposed to the trial data (IPERGAY) used by 
Durant-Zaleski et al. The use of IPERGAY trial data is considered appropriate in this 
study, however, as it enrolled participants from the same population as the target 
population for the cost-effectiveness analysis. 
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Table 5.3. Economic model type and PrEP efficacy estimate used in 
MSM studies 
Mathematical modelling 
studies 
Description of economic model PrEP efficacy 
Cambiano (2018)(81) Dynamic individual based stochastic model 
(HIV synthesis model) 
86% 
Desai (2008)(104) Stochastic compartmental mathematical 
model 
50% 
Gomez (2012)(83) Deterministic compartmental mathematical 
model 
92% 
Gray (2017)(105)  Dynamic transmission model (Prevtool) 99% 
Juusola (2012)(84) Deterministic dynamic compartmental 
model 
44% 
Lin (2016)(85) Bernoulli process model 44% 
Luz (2018)(112) State-transition Monte Carlo stimulation 
model (CEPAC) 
95%  
(43.2%)* 
MacFadden (2018)(87) Dynamic stochastic compartmental model 44% 
McKenney (2017)(88)  Decision analytic model 56% 
Nichols (2016)(89) Deterministic mathematical transmission 
model 
86% 
Ong (2017)(90) A static decision analytic model 86% 
Paltiel (2009)(92) State-transition Monte Carlo stimulation 
model (CEPAC) 
50% 
Schneider (2014)(94) Stochastic agent-based model 95% (75%)* 
Suraratdecha (2017)(95) Dynamic transmission model (OPTIMA) 75% 
Non-mathematical 
modelling studies 
Description of economic model PrEP efficacy 
Durand-Zaleski (2017)(82) Non-mathematical cost effectiveness 
analysis 
86% 
Ouellet (2015)(91) Non-mathematical cost utility analysis 44% 
Reyes-Uruena (2017)(93) Non-mathematical cost utility analysis 86% 
* Combined efficacy and adherence. Overall effectiveness in parenthesis.  
Parameter estimates for the efficacy of PrEP in reducing the risk of HIV transmission 
used in the studies ranged from 44%-96%. (Table 5.2). As detailed in Chapter 4, the 
iPrEx trial (2010) reported an efficacy of 44% and the trial by Peterson et al. (2007) 
reported an efficacy of 50%. The efficacy from iPrEx was employed in four models(84, 
85, 87, 91) and that of Petersen et al. in two models.(92, 104) A relative risk reduction of 
75% from a 2012 study by Baetens et al. was used in the base case in two 
studies.(94, 95) The most recently published PrEP RCT trials, PROUD (2016) and 
IPERGAY (2015), reported an effectiveness of 86% for both daily and on-demand 
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dosing schedules in the MSM group. This estimate was used in five studies.(81, 88-90, 
93) The remaining two studies used a combination of adherence and efficacy 
resulting in efficacies of 96%(86) and 52%.(83)  
Thirteen studies used pooled utility values derived from a 2002 meta-analysis 
published by Tengs and Lin.(113) Time-trade-off was used to elicit utilities from 
patients which were estimated as a utility of 0.94 for asymptomatic HIV infection, 
0.82 for symptomatic HIV and 0.7 for AIDS. Two UK studies used utility values from 
a study by Miners et al. that merged two UK cross-sectional surveys, the ASTRA 
study (2012) and the Health Survey for England (2011), to generate comparisons 
between HIV-infected and HIV-uninfected individuals using multivariable models.(114) 
The disutility values associated with HIV infection were: HIV-positive diagnosed with 
CD4>200 cells/mm3 -0.1 (95% CI: -0.08; -0.12); HIV-positive diagnosed with 
CD4≤200 cells/mm3 -0.15 (95% CI: -0.11; -0.19). Values for HIV-positive diagnosed 
stage 4 (WHO) -0.55 (95% CI: -0.38; -0.71) and HIV-positive diagnosed stage 3 
(WHO) -0.22 (95% CI -0.15; -0.31) were sourced from a study on the global burden 
of disease study.(115) The two remaining CUA papers, Gomez et al. (2012) and 
Suraratdecha et al. (2018), conducted in low/middle income countries, used DALYs 
rather than QALYs (as recommended by the WHO).(116)   
Table 5.4 provides the annual cost of PrEP medication used in each study. All costs 
were inflated using the consumer price index (CPI) for health and converted to 2017 
Irish Euro using purchasing power parity (PPP). A daily dosing regimen was the base 
case scenario in most studies although two studies used event-based (also known as 
‘on demand’) dosing.(81, 82) One study calculated the average cost of PrEP for 
patients taking five pills per week and the other study based the cost of PrEP on 
patients taking a mean of 15.6 pills per month (SD: 7.2).  
Table 5.4.  Estimated annual cost of PrEP used in economic evaluations  
converted to 2017 Ireland (€) 
Study 
(Year) 
Annual 
Cost of 
PrEP 
ART 
Annual Cost of 
PrEP ART 
(2017 Irish €) 
Annual 
Monitoring and 
Screening Costs 
Annual 
Cost of 
PrEP 
Program
me 
Annual 
Cost 
PrEP 
Program
me  
(2017 
Irish €) 
Cambiano 
(2018)(81) 
£3,248* €3,553 £649** £3,897 €4,263* 
Desai(2008)(104) $11,315 €6,738 Year 1: €1,300 
Subsequent 
years: $1,020 
$12,615 €7,512 
Durand-Zaleski 
(2016)(82) 
€3,117* €3,115 Year 1: €738 
Subsequent 
€4,271 €4,268* 
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* PrEP On-Demand Dosing ** Incremental cost of £176 used model. This is the estimated cost of PrEP monitoring (£649) minus the usual care 
cost for high risk MSM (£473). 
 
The annual price of daily PrEP ART ranged from €232 to €11,659 and the mean cost 
was €6,397. The annual cost of PrEP was lowest in South American counties (Brazil 
[€232] and Peru [€554]) and highest in Thailand (€14,222). The annual cost of on-
demand PrEP ART was €3,115, €4,738 and €6,271 (mean €4,708) in the studies that 
used this dose regimen as the base case.  
 
In European studies the cost of daily PrEP ART ranged from €4,738 to €7,282; the 
mean cost was €6,419 (n=3). In North American studies the cost of daily PrEP ART 
ranged from €7,058 to €10,301 (n=6) and the mean cost was €7,702. A lower cost 
of PrEP, up to 80% less than the original price, was routinely varied in sensitivity 
analysis. 
A discount rate was applied in the base case analysis to future costs and outcomes 
in thirteen of the seventeen papers. Only one study used a discount rate of 5%, all 
others studies used 3% or 3.5%. The impact of discount rate has a significant 
impact on cost-effectiveness as models follow patient over lifetime. The cost of PrEP 
is upfront, while the benefits of avoiding HIV infection are spread over the lifetime, it 
years: €690 
Gomez (2012)(83)  $600 €554 $230 $830 €767 
Gray (2017)(105) $10,249 €5,610 $645 $10,894 €5,963 
Juusola (2012)(84)  $9,312 €9,188 $771 $10,083 €9,188 
Lin (2016)(85) $8,969 €6,318 Year 1:$1,534 
Subsequent 
years: $1,204 
$10,338 €7,282 
Luz (2018)(86)  $270 €232 $22 $292 €250 
MacFadden 
(2016)(87) 
$10,012 €6,606 Initial visit: $305 
Subsequent Visit: 
$100 
$10,617 €7,005 
McKenney 
(2017)(88)  
$10,711 €7,058 $1,173 $11,884 €7,830 
Nichols (2016)(89) €7,400 €7,282 €2,335 €12,987 €12,780 
Ong (2017)(90) £4,331 €4,738 £649** £4,507 €4,931 
Ouellet (2015)(91) $9,505* €6,271 $2,496 $12,001 €7,918* 
Paltiel (2009)(92) $9,036 €10,301 $336 $9,372 €10,684 
Reyes-Uruena 
(2018)(93) 
€5,874 €7,238 €1,303 €7,177 €8,843 
Schneider 
(2014)(94) 
$9,597  €6,041 $765 $10,362 €6,523 
Suraratdecha 
(2018)(95)  
$14,106 €11,659 $2,985 $17,091 €14,126 
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is likely that a high discount rate will result in the intervention being less cost-
effective. Two non-mathematical models illustrate this with a one-year PrEP 
intervention estimated as cost saving when undiscounted but increased to €39,734 
and €192,019 at 5% discount rate.(91, 93) 
As identified in Chapter 4, there is a concern that use of PrEP may be associated 
with an increase in risky sexual behaviour, also referred to as ‘risk compensation’ 
and ‘sexual disinhibition’. Six studies included changes in condom use and the 
number of sexual partners to capture behaviour changes.(84, 88, 90, 94, 95, 105) No study 
incorporated sexual behaviour change into the base case scenario. One study 
included costs of STI treatment and QALY losses associated with STI diagnosis and 
treatment.(88) Table 5.5 outlines parameters relating to risk compensation used in 
the MSM studies. 
Table 5.5. Sexual risk behaviour parameter values, costs and outcomes 
Study Parameter values for sexual & behavioural 
change 
Cost & outcomes of 
STI & STI Testing 
Gray 
(2018)(105) 
Not modelled in base-case. 
Condom use decreased by: 10%, 30% and 50% 
N/R 
Juusola (2012)(84) Not modelled in base-case.  
Appendix results: 20% increase in partners and  
20% reduction in condom use 
N/R 
McKenney 
(2017)(88) 
Not modelled in base-case.  
Scenario analysis: 25% increase in sexual 
encounters, STI, sexual risk & 25% decrease in 
condom use.   
STI treatment: $180 
($99-295) 
STI test:  
$67 ($27-80) 
STI QALY loss: 0.02 
(0.01-0.03) 
Ong  
(2017)(90) 
Not modelled in base-case.  
Sensitivity analysis: Risk compensation of 10%, 
20% and 30% included.  
N/R 
Schneider (2014)(94) Not modelled in base-case.  
Sensitivity analysis: 25%-75% reduction in 
condom use. 
N/R 
Suraratdecha 
(2017)(95) 
Not modelled in base-case.  
Sensitivity analysis: Condom use reduced by 
10% (0-20%)  
N/R 
N/R = not reported 
The lifetime cost of HIV infection was an important parameter that varied widely 
across studies. To facilitate comparison, all costs were converted to 2017 Irish Euro. 
The annual cost of HIV infection ranged from €3,517 to €25,468 (mean €13,450), 
see Table 5.6. The lowest cost was used in the study conducted in Brazil, where far 
lower costs for ART and healthcare were observed compared with high-income 
countries. There were two studies for which the cost of HIV exceeded €20,000 per 
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year; this was attributed to high costs of ART. Three studies reported an annual cost 
between €10,000 and €20,000. Of the three studies reporting annual costs under 
€10,000, one was the aforementioned Brazilian study and the remaining two studies 
stated costs of €8,412 (USA) and €8,917 (USA). 
Table 5.6.  Estimates of annual cost of HIV used in economic  
evaluations  
Study Annual Cost 
of HIV 
Adjusted Cost 
(2017 Euros) 
Source 
Desai (2008)(104)* $14,179 €10,472 Schackman (2006)(117) 
Durant (2016) $20,000 €20,238 Sloan et al (2012)(118) 
Juusola (2012)(84)** $25,831  €25,468 Schackman (2006)(117) 
Lin (2016)(85)*** $11,943 €8,412 Farnham (2012)(119) 
Luz (2018)(86) $4,100  €3,517 n/a 
MacFadden (2018)(87)* $17,059 €11,255 Krentz (2008)(120) 
McKenney (2017)(88)* $13,533 €8,917 Schackman (2006)(117) 
Reyes-Uruena 
(2018)(93) 
€13,482 €16,613 2016 GESIDA/Spanish 
AIDS National Plan(121) 
* Lifetime cost divided by 24.2 as stated in Schackman et al (2006).  
**Juusola (2012): $6181 – Symptomatic HIV treated, $15,589 – ART, $4,061 – Non-medical costs. 
***Lin (2016): $418,000 lifetime cost of HIV per Appendix, divided by 35 years. 
 
5.3.5 PWID 
One US study estimated the cost-effectiveness of using PrEP to reduce HIV 
transmission in PWID.(80) A dynamic transmission model was adapted from a 
previously developed model by the same lead author.(122) All costs were presented in 
2015 US dollars. When adjusted to 2017 Irish euro, the annual drug cost of PrEP 
was €8,579 with screening costing €686 a year. The prevalence of HIV was 9.8%. 
The effectiveness of PrEP in averting HIV infection for PWID was stated as 48.9%. 
This was based on the Bangkok tenofovir study, in which participants did not have 
access to needle exchange, which determined PrEP efficacy in PWID.(123) A societal 
perspective was taken. The utility values associated with HIV were derived from 
Tengs and Lin.(113) The dosing regimen was daily, the time horizon 20 years and 
discount rate 3%. The base case ICER for 36% coverage of PrEP was €269,366 with 
a budget impact of €59 billion.  
5.3.6 Summary of Cost-Effectiveness Results 
5.3.6.1 MSM 
Cost-effectiveness results from the 17 studies focusing on the MSM population were 
not uniformly reported. Results are usually interpreted in the context of a 
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willingness-to-pay threshold; this differed by jurisdiction. In Ireland, willingness-to-
pay thresholds of €20,000/QALY and €45,000/QALY are used to interpret the cost-
effectiveness for medicines in Ireland. 
In eight of the eleven mathematical cost-utility studies which reported QALYs, the 
baseline ICER was below €45,000 (see Table 5.7). Five of the studies which reported 
PrEP to be cost-effective used estimates of PrEP efficacy significantly lower (43%-
56%) than the efficacy estimate (86%) from the more recent PROUD or IPERGAY 
trials. This indicates that PrEP is likely more cost-effective than stated in these 
studies. 
Table 5.7. Baseline ICER in mathematical modelling studies reporting 
QALYS  
One Australian study did not report ICERs, but instead presented uptake scenarios 
and calculated the annual cost of PrEP for which PrEP would be cost-effective at 
different willingness-to-pay (WTP) thresholds. The current estimated PrEP unit cost 
(of $10,249) would need to fall by 26-47% for the scenarios in which PrEP is used 
only by high-risk MSM to be considered cost-effective. At a WTP of $30,000 
(€32,708), the authors concluded that PrEP would be cost-effective in a scenario 
where 30% of high risk MSM take PrEP and the annual cost was less than €4,132. 
The two UK-based mathematical modeling studies which found PrEP to be a cost 
saving intervention employed an efficacy value of 86%.(81, 90) One employed a 
dynamic transmission model with an 80 year time horizon and the other a decision 
analysis that assessed the lifelong costs and benefits following one year of PrEP 
Study 
(Year) 
Country Baseline Outcomes: 
ICER  
 (€ per QALY/DALY) 
Adjusted cost of 
Outcomes 
(€ Ireland 2017) 
Cambiano (2018)(81) UK Cost saving Cost saving 
Desai(2008)(104) USA $31,972 €23,613/QALY gained 
Gray (2017)(105) Australia N/R N/R 
Juusola (2012)(84)  USA $44,556 €43,961/QALY gained 
Lin (2016)(85) USA $58,849 €41,452/QALY saved 
MacFadden 
(2016)(87) 
Canada $34,999 €41,367/QALY 
McKenney (2017)(88)  USA $64,000 €42,170/QALY gained 
Nichols (2016)(89) Netherlands €7,800 <€20,000/QALY gained 
Ong (2017)(90) UK Cost saving Cost saving 
Paltiel (2009)(92) USA $298,000 €339,791/QALY gained 
Schneider (2014)(94) Australia $180,146 €113,339 Cost/QALY 
(10 partners, 15% 
coverage) 
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administration. Decision analytic models underestimate cost-effectiveness as, unlike 
dynamic transmission models, they fail to capture the prevention of onward HIV 
transmission (‘snowball effect’). 
Finally, two mathematical studies reported an ICER greater than €45,000 and stated 
that PrEP was not cost-effective.(92-94) The highest reported costs per QALY were 
€339,791 (US study) and €113,339 (Australian study). The US study (2009) pre-
dated the iPrEx, PROUD and IPERGAY trials and as such, employed an efficacy of 
50%. Additionally, the annual cost of PrEP (€9,891) was higher than average. In a 
sensitivity analysis the efficacy of PrEP was increased to 90%, resulting in a cost per 
QALY of €121,980. The Australian study was more applicable to Ireland, using an 
efficacy of 95% (provided adherence was at least 75%) and the cost of ART was 
lower than the median €6,041.  
Two of the non-mathematical studies presented least expensive (on-demand PrEP) 
and most expensive (daily PrEP) scenarios and used discount rates of 0%, 3% and 
6% (Table 5.8). The Canadian study found PrEP to be cost-saving when 
undiscounted or at a discount rate of 3%. PrEP was cost-effective when a 5% 
discount rate was used (ICER €31,233 to €39,734). The Spanish study concluded 
that, when undiscounted, on-demand PrEP was cost saving and daily PrEP was cost-
effective (ICER €7,740). When the discount rate was increased to 3%, on-demand 
PrEP was estimated to be cost-effective (ICER €20,587), but daily PrEP exceeded the 
Irish threshold for cost-effectiveness (ICER €70,761). When a 5% discount rate 
(CADTH guidelines) was applied both on-demand (ICER €53,392) and daily PrEP 
(ICER €192,019) far exceeded the Irish cost-effectiveness threshold. 
Table 5.8. Baseline ICER in non-mathematical modelling studies 
 
The other non-mathematical study did not incorporate QALYs. The cost of averting 
one HIV infection was calculated at three prices for PrEP. The international market 
price (€60/30 tablets), French generic price (€180/30 tablets) and the French drug 
Study 
(Year) 
Country Baseline Outcomes: 
ICER  
 (€/$ per 
QALY/DALY) 
Adjusted cost of Outcomes 
(€ Ireland 2017) 
Durand-Zaleski 
(2016)(82) 
France €75,258 €75,214 per infection averted 
Ouellet 
(2015)(91) 
Canada $60,233 ICER €39,734 
(Most expensive HIV cost, 5% 
discount) 
Reyes-Uruena 
(2018)(93) 
Spain €156,830 ICER €192,019 
(Daily PrEP, 5% discount) 
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list price (€501/ 30 tablets). These different costs of PrEP resulted in a cost per HIV 
infection averted of €26,771, €37,948 and €75,214. 
Two studies reported cost per DALY averted, and one study cost per life year saved 
(LYS). LYS and DALYs are not applicable to a developed country such as Ireland for 
which the QALY is the gold standard used to quantify health outcomes. Furthermore, 
three of these studies were at the extreme ends in terms of the cost of PrEP. The 
annual cost of PrEP in two of the South American studies (€223-€554) was 
significantly below the median (€7,170) whilst the cost in the Asian study was 
significantly higher (€14,222). These studies are summarised in Table 5.9. 
Table 5.9. Baseline ICER in mathematical studies not reporting QALYs 
Sensitivity Analysis 
Fifteen studies conducted a sensitivity analysis. The key parameters influencing cost 
effectiveness were the drug cost, the effectiveness of PrEP in averting HIV infections 
and the incidence of HIV. The US study which reported the highest cost per QALY 
noted that if efficacy increased from 50% to 90%, the ICER decreased from 
€339,791 to €129,960. A similar reduction was observed when the annual cost of 
drug was reduced from €10,300 to €5,150: the ICER decreased to €121,980. A 
combination of a lower annual drug cost and increased efficacy would therefore 
potentially have made PrEP cost-effective, however, multivariate analysis was not 
conducted. Another US-based study found that PrEP offered to high risk MSM at an 
efficacy of 44% had an ICER of €43,961. When the annual cost of PrEP was reduced 
from €9,188 to €4,594, the ICER reduced to €24,829. The impact of increased 
efficacy was observed in a Canadian study when the base case scenario reported an 
ICER of €23,092 at 44% efficacy which was reduced to €15,021 (76% efficacy) or 
€10,483 (96% efficacy). A Dutch deterministic mathematical modelling study 
estimated that the cost per QALY gained would be less than €20,000. At 80% 
effectiveness, daily PrEP could be considered cost-saving if the price of PrEP is 
reduced by 70%, and on-demand PrEP could be considered cost-saving if the price is 
reduced by 30-40%. 
The incidence of HIV had a marked impact on results when studied in sensitivity 
analysis. The UK study by Ong et al found PrEP to be cost saving in most scenarios 
Study 
(Year) 
Country Baseline Outcomes: 
  ICER  
 (€ per QALY/DALY) 
Adjusted cost of Outcomes 
(€ Ireland 2017) 
Gomez (2012)(83)  Peru €1,780 €1,644/DALY averted 
Luz (2018)(86)  Brazil $2,530 €2,170/LYS 
Suraratdecha 
(2018)(95)  
Thailand $4,957 
 
€4,097 Cost per DALY averted 
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when considering different values for efficacy, cost of PrEP and future costs of ART 
for HIV. When incidence was varied, PrEP remained cost-effective in most scenarios; 
however it was no longer cost saving when the incidence of HIV decreased below 
2.0 per 100 person-years. Sensitivity analyses in other studies also noted improved 
cost-effectiveness with higher PrEP efficacy estimates. Sensitivity analyses in other 
studies also noted improved cost-effectiveness with higher PrEP efficacy 
estimates.(81, 88) 
5.3.6.2 PWID 
The cost-effectiveness of PrEP in PWID was reported in one study. Using an uptake 
rate of 36%, PrEP was not found to be cost-effective (ICER of €269,366) compared 
with standard care. 
5.4 Discussion 
The systematic review identified eighteen economic evaluations of PrEP to prevent 
HIV infection. Evidence of cost-effectiveness was inconsistent due to differences in 
the study input parameters and design, with incremental cost-effectiveness ratios 
(ICERs) ranging from cost saving to €339,791 per Quality-Adjusted Life Year (QALY) 
gained. Evidence from sensitivity analyses suggests that the annual cost of PrEP and 
the estimate of effectiveness used are important drivers within individual studies. 
The discount rate applied is also influential, with PrEP becoming less cost-effective in 
studies where a higher discount rate was applied. There were insufficient details 
available on some key parameters, for example five studies did not report the 
incidence of HIV. This could explain the difference in results as it is an important 
determinant of cost-effectiveness (PrEP is more likely to be cost-effective when 
background incidence is high). 
Three studies, two from the UK and one from Australia, were most applicable to 
Ireland regarding the perspective, efficacy of PrEP (based on Chapter 4 results) and 
the incidence of HIV. The two UK studies (which used a discount rate of 3.5%) 
estimated that PrEP would be cost-saving.(5, 14) The Australian study (105) used a 
range of willingness-to-pay thresholds, of which $60,000 (Australian Dollars) is most 
closely aligned to the €45,000 used in Ireland. In this study, PrEP would only be 
considered cost-effective if the annual cost of PrEP (€5,587) fell by 26-47%. 
However, PrEP would be considered cost-effective or cost saving if generic PrEP is 
used, which is the case in Ireland. This study employed a 5% discount rate, which is 
the discount rate used for HTA in Ireland.  
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Of note, the perspective used in health economic evaluations has important 
implications for the interpretation of the results. For example, an intervention may 
not appear to be cost-effective when the public payer perspective is considered, but 
if that same intervention has benefits other than those born by the health sector, it 
may be cost-effective. In Ireland the perspective taken is that of the public payer, 
hence studies adopting a societal perspective may be less relevant to this HTA. 
The systematic review identified four types of mathematical model: dynamic 
transmission, decision analytic, state-transition Markov, and Bernoulli process model. 
Three economic evaluations were also identified that did not use a mathematical 
model. Economic models have different properties that both affect the result and the 
interpretation of the results. In deterministic models, the output of the model is fully 
determined by the parameter values and the initial conditions whereas stochastic 
models possess some inherent randomness. Dynamic models, on the other hand, 
track the transmission of infection in the population. The model can therefore 
incorporate future costs and benefits such as onward transmission. This accounts for 
all individuals for which PrEP averts HIV infection, including those who do not 
directly take part in the programme. These future benefits and costs require a 
significant amount of detailed information on prevalence, incidence and even 
migration patterns. Furthermore, assumptions have to be made not only about the 
HIV epidemic and whether it will remain stable or fluctuate, but also the future costs 
of both PrEP and HIV treatment. This increasing number of assumptions is 
associated with a greater level of uncertainty compared with static models. The key 
limitation of decision analytic models is that they do not incorporate the non-linear 
dynamics of HIV and therefore do not quantify the impact of PrEP on the wider HIV 
epidemic. This limits the impact of PrEP as onward transmission is not included and 
as such decision analytic models are considered more conservative when assessing 
the impact of PrEP. 
Although clinical data presented in Chapter 4 has not suggested significant increases 
in risky sexual behaviour in PrEP users (‘risk compensation’ or behavioural 
disinhibition), it is a factor that could influence the cost-effectiveness of PrEP. Sexual 
disinhibition is the concept whereby those taking PrEP may engage in more risky 
sexual behaviour with an increase in sexual partners and decrease in condom use. 
This could therefore lead to an increase in STIs in this population, causing increased 
costs and a decrease in utilities. This factor was incorporated into the sensitivity 
analysis of four studies with arbitrary increases of 10-30% modeled; however, 
inclusion of risk compensation had a negligible effect on the estimate of cost-
effectiveness.  
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The three economic evaluations most applicable to the Irish healthcare system found 
the use of PrEP in MSM to prevent the sexual acquisition was cost-effective and cost 
saving at generic drug pricing. However, due to differences in the discount rates, 
lifetime cost of HIV and annual cost of PrEP medication used, a de novo economic 
evaluation using Irish data to estimate the cost-effectiveness and budget impact in 
the Irish health care setting was required to inform decision-making. 
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6 Economic evaluation 
Key points 
 An original discrete-time transition Markov model was developed to 
compare the costs and benefits of providing a national PrEP 
programme in Ireland.  
 This cross-sectional population model tracks all HIV-negative Irish 
gay, bisexual and other men who have sex with men (MSM) at the 
outset of the simulation (2018) and follows these men over their 
lifetime. While a prospective PrEP programme would enrol all eligible 
participants and not exclusively MSM at substantial risk, only MSM are 
considered for the purposes of cost-effectiveness modelling due to 
the fact that more than 95% of participants are expected to be MSM 
and very limited data were retrieved on other groups. 
 In the base case analysis, PrEP is cost saving, with an incremental 
cost-effectiveness ratio (ICER) of -€2,735 over the cohort’s lifetime 
(95% CI: -€16,486 to €21,585). This means that providing PrEP is 
less costly, and more effective (in terms of quality-adjusted life years 
[QALYs] gained), than not providing PrEP. 
 Univariate deterministic sensitivity analysis was carried out to identify 
how sensitive these results are to changes in the input parameters. 
The results are robust to considerable variations in the main 
assumptions and plausible parameter values.  
 PrEP effectiveness was the main driver of cost-effectiveness in the 
model. PrEP was found to be cost saving when adherence-related 
effectiveness is 60% or more. At an effectiveness of 44% (reported 
in iPrEX, the lowest effectiveness recorded among MSM), the ICER is 
€4,711/QALY (highly cost-effective). 
 The ICERs were also sensitive to key cost parameters, including the 
cost of HIV care and the cost of PrEP. However, PrEP was still 
considered cost saving over a range of plausible costs. 
 Two-way sensitivity analysis was carried out on the proportion of 
MSM at high risk and the PrEP uptake rate. PrEP becomes more cost 
saving as either parameter increases. 
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 Although PrEP is currently only licensed for daily dosing, in the scenario 
where 50% of PrEP recipients follow event-based dosing, the ICER 
decreases to -€4,594 (95% CI: -€20,158 to €14,150). 
 The mean number of people estimated to join a potential PrEP 
programme in Year 1 is 1,705 people (95% CI: 617 to 3,452). 
 The incremental budget impact of the PrEP programme is €1.5m in the 
first year (95% CI: €0.5m to €3m) and €5.4m over 5 years (95% CI: 
€1.8m to €11.5m). 
 In the base case analysis, an average of 173 HIV infections are 
estimated to be averted in the first five years. 
 Extending the budget impact assessment beyond five years, the yearly 
incremental budget impact becomes negative after eight years and the 
aggregate budget impact (‘break even’ point) is reached after 14 years 
(all programme and medication costs will have been recouped). 
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6.1 Methods 
6.1.1 Overview of economic evaluation 
Chapter 5 (systematic review of prior cost-effectiveness studies) highlighted the 
significant variability in the cost-effectiveness of PrEP. The estimated cost-
effectiveness is influenced by a number of parameters that tend to be country 
specific, including sociodemographic differences and differences in the cost of 
antiretroviral therapy (ART) used as PrEP and in the treatment of HIV. As such, a de 
novo economic model tailored to the Irish context is required to estimate the cost-
effectiveness and budget impact of a PrEP programme in Ireland.  
This chapter describes the economic model constructed and the estimated cost-
effectiveness and budget impact of providing a PrEP programme in Ireland. The 
objective of the economic evaluation is to aid decision-making by estimating the 
incremental costs and benefits of funding a PrEP programme for those at substantial 
risk of sexual HIV acquisition. 
The target population is gay, bisexual and other men who have sex with men (MSM) 
who are eligible for PrEP, and the setting is the Irish publicly-funded health and 
social care system, namely, the Health Service Executive (HSE). While a prospective 
PrEP programme would enrol all eligible participants and not exclusively MSM at 
substantial risk, only MSM are considered for the purposes of cost-effectiveness 
modelling due to the fact that more than 95% of participants are expected to be 
MSM and very limited data were retrieved on other groups. For comparison, 99% of 
participants in the first year of Scotland’s national PrEP programme were male 
(n=1,855), and 99% of these were MSM (n=1,846). 
6.1.2 Perspective, time horizon and discount rate 
Consistent with national guidelines for the economic evaluation of health 
technologies, the perspective adopted was that of the HSE in Ireland. Only direct 
costs to the HSE were considered. The time horizon of the analysis was the cohort’s 
lifetime. A discount rate of 5.0% was applied to both costs and benefits.  
6.1.3 Choice of comparator 
The comparator chosen was that of the current suite of HIV prevention strategies in 
Ireland (barrier protection, treatment-as-prevention [TaSP], post-exposure 
prophylaxis [PEP]) without access to PrEP. While there currently is no organised 
PrEP progrmme in Ireland, it is acknowledged that components of the proposed 
programme are being provided on an ad hoc basis. As illustrated in Chapter 7 
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Section 7.4, a number of publicly funded STI clinics have designated some of their 
STI clinics as PrEP clinics, where screening and monitoring of PrEP eligible patients 
takes place. Medications are not provided by the publicly funded system, rather 
patients pay for PrEP out of pocket. There is also evidence that patients are 
accessing PrEP through online sites. As the numbers of patients accessing PrEP, their 
persistence with treatment and the treatment effectiveness are unknown, for 
simplicity the comparator adopted in the base case analysis assumed no current 
access to PrEP. Additionally, as individuals currently pay for PrEP out of pocket, 
using the current ad hoc arrangement as a comparator would bias the analysis 
against adopting a HSE-funded PrEP programme due to the fact that direct costs 
only are considered (PrEP medications are currently obtained at no additional cost to 
the HSE). Table 6.1 outlines the base case for the economic evaluation. 
Table 6.1. Base case 
Element of technology 
assessment 
Base case 
Evaluation type  Cost-utility analysis 
Perspective on costs The publicly-funded health and social care system 
in Ireland (HSE) 
Perspective on outcomes All health benefits accruing to individuals 
Choice of comparator The current suite of HIV prevention strategies in 
Ireland (barrier protection, treatment-as-
prevention [TaSP], post-exposure prophylaxis 
[PEP]) without access to an organised PrEP 
programme 
Synthesis of effectiveness Based on systematic review and meta-analysis 
(Chapter 4: Efficacy) 
Outcome measurement Quality-adjusted life year (QALY) gained 
Discount rate Apply an annual rate of 5.0% on costs and 
outcomes occurring after the first year 
Sensitivity analysis Deterministic and probabilistic sensitivity analysis 
6.1.4 Model structure 
An original state transition Markov model was developed to compare the costs and 
consequences of providing a PrEP programme in Ireland. The model is a closed 
cross-sectional population model that tracks the entire population of Irish HIV-
uninfected MSM at the outset of the simulation (2018) and follows these men until 
they die.  
The basic model structure is shown in Figure 6.1. In the model, the risk status of 
MSM is either categorised as ‘high’ or ‘medium/low’ risk. ‘High risk’ is defined by the 
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eligibility criteria for PrEP, as outlined in Chapter 2. All other MSM are considered 
‘medium/low risk’. Additionally, ‘high risk’ individuals may be taking PrEP (‘PrEP high 
risk’) or not (‘No PrEP high risk’). It is assumed that individuals in the ‘medium/low 
risk’ group will not take PrEP as they do not meet the eligibility criteria. Individuals 
may move between these health states, until they acquire HIV or die.  
Figure 6.1. Model structure 
 
Key: HIV — human immunodeficiency virus; PrEP — pre-exposure prophylaxis. 
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6.1.5 Sensitivity analysis 
Monte Carlo simulation was carried out, with each parameter being defined as a 
distribution based on the plausible range of values, which were then sampled over 
the course of 10,000 replications to take account of the uncertainty associated with 
the model outputs. Deterministic univariate sensitivity analysis was carried out to 
estimate the effect of uncertainty pertaining to individual parameter estimates. 
6.2 Clinical and epidemiological parameter estimates 
6.2.1 Target population 
6.2.1.1 Numbers and proportions of MSM by risk group 
Due to the fact that 95% or more of eligible individuals are likely to be MSM, and in 
the absence of data specific to other groups in Ireland, the modelled cohort 
comprises only MSM for the purposes of cost-effectiveness modelling. The overall 
number of MSM in Ireland was estimated using CSO population estimates and 
information from Healthy Ireland surveys.  
The estimated total male population aged 16 to 80 was 1,802,395 in 2018.(42) The 
2017 Healthy Ireland Survey, which is a nationally representative probability based 
survey, found that 4% of men had reported that their last sex was with a man.(23) 
This is the most recent Healthy Ireland survey that reports sexual behaviour data. A 
previous Healthy Ireland survey reported a higher rate of 6%.(41) To ascertain sexual 
orientation, the Healthy Ireland survey asked respondents what gender the last 
person they had sex with was. The survey, therefore, does not capture bisexual men 
whose last sexual encounter was with a woman.  
Another survey (My World Survey National Study of Youth Mental Health, 2012) of 
young male and female adults and adolescents (n=14,306) noted that 4% identified 
as gay and 4% as bisexual.(13) An earlier study, the Irish Study of Sexual Health and 
Relationships (2006), reported lower rates: 1.6% of 3,188 male respondents 
classified themselves as homosexual and 1.1% as bisexual.(30) The range of 
prevalences of MSM are presented in Table 6.2. 
Table 6.2. MSM prevalence 
Survey Proportion MSM 
Healthy Ireland 2017 4% 
Healthy Ireland 2015 6% 
My World Survey National Study of 8% (male and female, young 
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Youth Mental Health 2012 adult and adolescent sample) 
The Irish Study of Sexual Health 
and Relationships 2006 
2.7% 
Key: MSM — men who have sex with men. 
As the Healthy Ireland surveys are the most recent surveys identified and consist of 
a nationally representative sample, older surveys were not used to estimate the MSM 
population. Table 6.3 outlines these estimates. 
Table 6.3. MSM population 
Population  Number 
Population of Ireland*  4,857,015 
Male population aged 16 to 80* 1,802,395 
Population Mean Range 
Proportion MSM** 5% 4 to 6% 
MSM population 84,713  68,491 to 101,737 
*Source: CSO 2018 estimates 
**Pooled analysis of Healthy Ireland surveys 2015 and 2017 
As this reflects all MSM, the number of MSM that are HIV positive (7.8% of those 
tested, or 5% of total [see Chapter 3: Epidemiology]) is subtracted to obtain the 
HIV-negative MSM population. Additionally, an arbitrary increase of 5% was applied 
to account for the non-MSM group in the budget impact analysis. In the absence of 
Irish data, a 5% increase was thought to fully capture this group, keeping in mind 
that less than 1% of Scotland’s PrEP programme consisted of non-MSM individuals. 
6.2.1.2 Proportion sexually active 
The question posed by the Healthy Ireland ascertained the sex of respondents’ last 
sexual encounter and provides information on the proportion that may be MSM. 
However, the sexual health component of Healthy Ireland surveys excludes those 
who are not yet sexually active. Additionally, as it refers to prior sexual exposure, 
one cannot assume that the respondents are currently sexually active.  
For this reason, the proportion of MSM who are currently sexually active was 
estimated. Information on the sexually active heterosexual population were 
identified in the The Irish Study of Sexual Health and Relationships (ISSHR)(124) and 
The Irish Longitudinal Study on Ageing (TILDA)(125) datasets and, for the MSM 
population, from ISSHR.(124) Data were pooled from older age groups (TILDA) and 
younger age groups (ISSHR) to estimate the proportion sexually active in a 
heterosexual population. Data on the proportion of the MSM population that are 
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sexually active was reported in the ISSHR, but due to the small number of survey 
respondents the results were not reported by age band. In the absence of 
information regarding the age distribution of the survey respondents, it was, 
therefore, not possible to calculate an appropriately age-weighted average 
proportion. The reported overall proportion that was sexually active in the MSM 
population was lower than for the heterosexual population. The proportion of MSM 
that are sexually active was conservatively estimated as the average of the figures 
reported for MSM and heterosexual populations and applied to the MSM age 
distribution of MISI 2015.  
Overall, the proportion of MSM aged 16 to 80 that are currently sexually active was 
estimated at 63% (95% CI: 49 to 76%). The wide confidence interval reflects the 
uncertainty associated with these estimates. However, these surveys are relatively 
old (ISSHR was published in 2006) and they may not be reflective of current sexual 
practices.   
6.2.1.3 Proportion at high sexual risk for HIV 
The proportion of MSM in Ireland who are at high sexual risk of HIV is unknown. For 
the purpose of this HTA, ‘high risk’ was defined by the eligibility criteria for PrEP. As 
outlined in Chapter 2, Section 2.4.1, MSM are at sufficient risk to be deemed eligible 
for PrEP if one or more of the following conditions are met: 
 reported condomless anal sex with at least two casual partners over the last 
six months  
 documented or reported episode of an acute STI over the last 12 months 
(excluding anogenital warts and non-primary herpes simplex virus)  
 documented or reported use of HIV post-exposure prophylaxis following 
sexual exposure (PEPSE) over the last 12 months  
 engagement in chemsex over the last six months 
 the individual is a partner of a HIV-positive person who is not stably 
suppressed on antiretroviral therapy. 
In the report HIV Pre-Exposure Prophylaxis (PrEP) in Ireland: PrEP estimates for 
populations at risk of sexual acquisition of HIV,(21) or the ‘PrEP Cascade’, compiled by 
the HSE, the Sexual Health and Crisis Pregnancy Programme (SHCPP) and the 
Health Protection Surveillance Centre (HPSC), the proportion of MSM who are at 
high risk was estimated based on secondary analysis of the Men who have Sex with 
Men Internet Survey Ireland (MISI 2015), a national online sexual behaviour 
study.(27) An estimated 23% (95% CI: 22.7 to 23.3%) of respondents would be 
considered eligible based on French PrEP eligibility criteria, or 706 out of 3,045 
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respondents. Additional information on the MISI dataset is provided in Chapter 3, 
Section 3.4. 
Since then, in 2017, Ireland participated in a pan-European MSM survey, the 
European Men who have sex with men Internet Survey (EMIS 2017), the results of 
which are expected later this year. EMIS 2017 was an online cross-sectional 
behavioural surveillance survey of MSM, conducted across Europe and elsewhere, 
including Ireland. The overall aim of EMIS-2017 was to generate data useful for the 
planning of HIV and STI prevention and care programmes and for the monitoring of 
national progress in this area by describing the level and distribution of HIV 
transmission risk and precautionary behaviours.  
Following discussion at the EMIS Ireland 2017 Steering committee meeting on 25 
March 2019, there was agreement that the EMIS Ireland 2017 dataset should be 
used to provide the most up-to-date percentage of MSM at substantial risk of 
sexually acquired HIV and eligible for PrEP. The following results were provided to 
HIQA by the EMIS Ireland 2017 Steering committee. 
The EMIS Ireland 2017 report included 2,083 qualifying cases of men/trans-men 
aged between 17 and 74 with respondents from each county in Ireland. Fewer than 
1% identified as trans-men. Figure 6.2 shows the distribution of ages across the 
entire sample.  
Figure 6.2. Age distribution of respondents (N=2,083) 
 
0
20
40
60
80
100
120
17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 53 55 57 59 61 63 65 67 69 71 73
N
um
be
r 
of
 r
es
po
nd
en
ts
 
Age (years) 
Draft: Health technology assessment of a PrEP programme for populations at substantial risk of 
sexual acquisition of HIV 
Health Information and Quality Authority 
Page 131 of 244   
Additional demographic information on EMIS Ireland 2017 respondents are 
presented in Chapter 3, Section 3.4.  
For use in this HTA, the EMIS study authors applied Irish PrEP eligibility criteria to 
the Irish portion of responses to identify the proportion at substantial risk for the 
purpose of economic modelling. Table 6.6 shows the number and percentage of 
MSM at substantial risk for sexually acquired HIV and eligible for PrEP using the Irish 
criteria. The number eligible for PrEP based on overlapping survey responses was 
647 (31%). A number of adjustments to the Irish PrEP eligibility criteria had to be 
made based on the EMIS Ireland 2017 dataset.  
Table 6.6. Eligibility for PrEP using the EMIS Ireland 2017 dataset 
Criteria used EMIS 2017 
N (%) 
Aged ≥ 17 years  2,083 (100) 
Man/ transman 2,083 (100) 
Sexually active 2,083 (100) 
Never tested for HIV/last HIV test negative 1,929 (93) 
ONE of the following  
CAI with ≥ 2 non-steady partners last 12 
months* 
457 (24) 
STI diagnosis in last 12 months 252 (13) 
Ever had ≥2 treatments of PEP ** 42 (2) 
Use of stimulant drugs during sex last 6 
months*** 
181 (9) 
Eligible for PrEP† 647/2083 (31) 
* Irish eligibility criteria is CAI with two or more casual partners in the past six months. 
** Irish eligibility criteria is reported use of PEP over last 12 months. 
***The stimulant drugs included in this definition were: ecstasy/MDMA, cocaine, amphetamine 
(speed), crystal methamphetamine (Tina, Pervitin), mephedrone and ketamine. Irish eligibility criteria 
define drugs used during sex as ‘crystal meth, GHB/GBL, mephedrone and ketamine’. 
† Number eligible for PrEP based on overlapping survey responses.  
Note that the results of EMIS and MISI are not directly comparable, as different 
eligibility criteria for PrEP were used to identify the eligible population, in addition to 
other sociodemographic factors. It is, nonetheless, of concern that high-risk 
behaviour has increased in the MSM group in Ireland over a relatively short time 
period. The number who reported ‘CAI [condomless anal intercourse] with two or 
more non-steady partners in past 12 months’ doubled, from 12% in MISI 2015 to 
24% in EMIS 2017. Smaller increases were noted for acute STI diagnoses, and there 
may have been an increase in chemsex use. 
As both MISI and EMIS are online surveys that target sexually active MSM, it is 
unknown how representative respondents are of the general MSM population. One 
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UK study compared sociodemographic and behavioural differences between MSM 
participating in convenience surveys (such as EMIS 2017) and national sample 
surveys.(126) In this study, the national survey consisted of MSM aged 18–64 years 
(n=148) interviewed for Britain's third National Survey of Sexual Attitudes and 
Lifestyles (Natsal-3) undertaken in 2010–2012. Participants in contemporaneous 
convenience surveys were British male residents interviewed in the European MSM 
Internet Survey (EMIS 2010) (n=15,500); the London Gay Men's Sexual Health 
Survey (n=797) and Scotland's Gay Men's Sexual Health Survey (n=1,234). A range 
of high-risk behaviours were compared, such as sexual behaviours (for example, 
condomless anal intercourse), STI diagnoses and drug use.  
Table 6.7 compares the EMIS 2010 data with the national sample (Natsal-3), for 
three outcomes: condomless anal intercourse, diagnosed STI and drug use. A 
comparison of all four studies is provided in the Appendix 5.1. These data indicate 
convenience samples may over-report behaviours that are considered high risk. 
Table 6.7. Comparison of self-reported high risk behaviour findings 
from EMIS with Natsal-3 
Outcome aOR* LCI UCI 
Condomless anal intercourse (with 2+ 
partners), past year 
2.30 1.18 4.59 
Diagnosed with STI, past year 1.91 0.85 4.30 
Drug use, past year 3.62 2.33 5.61 
Key: aOR — adjusted odds ratio; LCI — lower confidence interval; UCI — upper confidence 
interval. 
*Adjusted for age, academic qualification and London residency (EMIS); age, employment and 
ethnicity (London-GMSHS); age and academic qualification (Scotland-GMSHS) 
Source: Prah et al. 2016 
Not only is it possible that respondents over-report certain behaviours in 
convenience surveys, it is possible that sexually active MSM are more likely to self-
select to participate in sexual behaviour surveys than non-sexually active MSM, 
leading to a biased sample of participants. It is, therefore, reasonable to assume 
that datasets such as EMIS and MISI are not nationally representative samples. Also, 
as evidenced by Figure 6.2, it is noted that the age distribution of respondents in 
EMIS differs significantly from that of the general MSM population (a relatively young 
sample was obtained). 
Due to the difficulty in ascertaining the true proportion of MSM who are at 
substantial sexual risk of HIV in Ireland, it was decided pragmatically to arbitrarily 
assign a starting mean proportion of 20% to sexually active MSM with a wide 
variation (95% confidence interval [CI]: 3% to 48%) and to calibrate this with 
observed data (see Section 6.3). This calibration exercise obviates the need for a 
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nationally representative survey sample to inform parameter values and ensures the 
model outputs are plausible with respect to the Irish HIV epidemic. A scenario 
analysis was also performed, using the proportion at high risk (31%) identified in the 
EMIS Ireland 2017 report without model calibration (see Section 6.4.2.1). 
6.2.1.4 PrEP uptake 
The most applicable international data to date on the actual numbers of MSM likely 
to avail of PrEP emanate from Scotland’s experience of their first year of a national 
PrEP programme. Overall, 1,872 individuals were prescribed PrEP at least once in the 
first year of the Scottish NHS PrEP programme (Scotland’s population is 5.4 million 
compared with 4.8 million in Ireland).(127) Very little other data were available to 
guide the uptake rate of PrEP in Ireland.  
One online survey from 2016 of PrEP awareness and acceptability among MSM in 
four celtic nations (Scotland, Wales, Northern Ireland and the Republic of Ireland) 
found that 58.5% of respondents would be willing to take PrEP.(128) The study 
consisted of an online self-complete survey of HIV-negative/status unknown MSM 
who reported condomless anal intercourse with two or more men in the last year, 
recruited from gay sociosexual media. Over half of respondents (58.5%, 226/356) 
reported that they would be willing to use PrEP if available to them. However, only a 
third of men responded that they were aware of PrEP (34.5%, 132/386). The 
inconsistency between knowledge of PrEP and willingness to use it means that 
58.5% may be an over-estimate. Additionally, as participants were recruited through 
sociosexual media, it is unclear if respondents are representative of the MSM group 
as a whole. 
Separate from issues of uptake rate, the number of HIV negative MSM engaged in 
services (that is, attend STI clinics) in Ireland is also unknown. In the previously 
mentioned ‘PrEP Cascade’, three scenarios were examined: 15, 30 or 45% 
engagement in services. While engagement in services may guide the estimation of 
the target population, it is noteworthy that in the Scottish programme, 28% of PrEP 
users in the first year had not attended any public Scottish NHS sexual health clinic 
in the two years prior to PrEP programme implementation and almost 20% had not 
visited a publicly funded Scottish STI clinic in over 10 years (and possibly never). 
Therefore, prospective PrEP users will likely be a combination of those currently 
engaged and those not engaged with STI services. 
Taking an approximation of engagement in services (30%), increasing this 
approximation by 19% to account for new STI clinic attendees (36%), and 
incorporating the uptake rate previously outlined (58.5%), roughly 21% of eligible 
MSM may avail of PrEP. Similar to the method used to estimate the proportion of 
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MSM who are high risk (Section 6.2.1.3), a calibration exercise was undertaken to 
produce plausible estimates for the uptake rate (see Section 6.3). In the calibration 
process, this 21% uptake was varied widely (95% CI: 14 to 30%). Uptake estimates 
that corresponded with a plausible number of PrEP users (based on Scottish data) 
and a plausible incidence of HIV were selected. 
Of note, for the purposes of cost-effectiveness modelling, a cohort of MSM (with a 
mean age of 36.7, based on the age distribution of attendees at the Gay Men’s 
Health Service) was followed for their lifetime. Due to the fact that the cohort is 
closed (new members do not join the group), the proportions in each group do not 
remain static over time. In contrast to the closed cohort modelled as part of the 
cost-effectiveness analysis, the budget impact model is an open model in the sense 
that new entrants (migrants and 16 year olds coming of age) can enter the model 
after Year 1. The number of new entrants was calculated using CSO population 
estimates.(129)  
6.2.1.5 Movement between risk groups 
It was also necessary to estimate the movement of individuals between risk groups 
over time (those eligible for PrEP [‘high risk’ in model] and those not eligible for PrEP 
[‘Medium/Low risk’ in model]). No Irish data were identified that follow MSM over 
time to ascertain the duration an individual remains at ‘high risk’ and the proportion 
of ‘high risk’ individuals that become ‘medium/low risk’ after a defined period. 
The change in high risk behaviour over time in high risk MSM was estimated in a 
2017 UK study.(130) Study authors analysed change in high risk behaviour via a 
longitudinal five year follow-up of high risk MSM (the proxy for ‘high risk’ was a 
diagnosis of a recent bacterial STI infection) from 2009. Data were extracted from 
GUMCAD, the mandatory surveillance system for STIs that collects data on all STI 
tests and diagnoses from all commissioned sexual health services in England. It 
allows pseudo-anonymised digital download of patient-level data on all diagnoses at 
GUM clinics. Each pseudo-anonymised record contains a clinic identifier as well as a 
local patient number, so data from the same individual attending the same clinic can 
be linked longitudinally.  
Overall, the proportion of MSM identified in the initial (2009) high risk group 
(n=11,742) who continued to be at high risk in each of the subsequent four years 
(2010 to 2013) decreased rapidly over the first two years (2010 and 2011). Of the 
initial 2009 high risk cohort, 65.64% were never characterised as high risk over the 
subsequent four years (see Table 6.8). Following the initial high risk year, the 
average length of time someone was categorised as being at high risk was less than 
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two years. These findings, however, only apply to MSM in GUM clinics in the UK who 
are entered into the GUMCAD system. Therefore, generalising to high risk MSM who 
are not engaged in services, and generalising to MSM in jurisdictions outside 
England, should be done with caution. Additionally, it is not known if the proxy used 
for a change in high risk behaviour, that is a diagnosis of a recent bacterial STI 
infection, can be generalised to other high risk behaviours. Furthermore it is noted 
that while visits can be linked longitudinally, this is limited to attendances at the 
same clinic, so these data may underestimate the proportion that is subsequently 
categorised as high risk. 
Table 6.8. Proportion of high risk MSM in 2009 subsequently 
categorised as high risk 
High risk MSM in 2009: 11,742 
Subsequent years Proportion high risk 
Never 65.64% 
1 additional year 24.14% 
2 additional years 6.99% 
3 additional years 2.50% 
4 additional years 0.72% 
1. To interpret this table, of the high risk MSM in 2009, 65.64% were not high risk in the subsequent four years; 
24.13% were high risk the following year, 6.99% were high risk for the following 2 years, 2.5% for 3 years and 0.72% for 4 
years. 
These data suggest that roughly one third of MSM who are classified as ‘high risk’ 
are still classified as ‘high risk’ following the first year in English GUM clinics. 
Approximately 7%, 2.5% and less than 1% of those at high risk in year one were 
classified as high risk in years 2, 3 and 4, respectively. 
These proportions were applied to MSM at substantial risk in the model. Two-thirds 
of the ‘high risk’ group move into the ‘medium/low risk’ group after one year. Due to 
the fact that the overall proportion of MSM at ‘high risk’ is unlikely to change 
substantially over time, to balance this movement of individuals the model allows 
movement of MSM from ‘medium/low risk’ to ‘high risk’ in the model. 
6.2.1.6 PrEP discontinuation 
It was assumed that individuals at high risk on PrEP whose risk status changes to 
medium/low risk would discontinue PrEP from their next three-monthly clinic visit 
onwards (as they no longer meet the eligibility criteria). Limited data were identified 
on the proportion of high risk individuals who voluntarily discontinue PrEP despite 
still meeting eligibility criteria. Similarly, limited data were identified on the 
proportion who re-start PrEP following an interruption. Some economic modelling 
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studies (such as a 2018 UK study(131)) applied a probability of 0.5 with a wide 
variation (95% CI: 0.27; 0.73) for the purpose of analyses.  
In the first year of the PrEP clinic operating at the Gay Men’s Health Service, there 
were 950 attendees; 431 were first visits and the remainder follow-up visits. It is not 
possible to ascertain the drop-out rate as individuals joined the programme on a 
rolling basis. It is also not known if those attending for first visits were new to PrEP 
or if they had previously access PrEP elsewhere. Additionally, it is not known 
whether those who discontinued did so because they no longer met the eligibility 
criteria (no longer considered at substantial risk) or if they discontinued for other 
reasons (for example, due to affordability issues or moved to another clinic). 
Short-term retention rates have been published by the Welsh PrEP programme.(53) 
Data for all participants enrolled between 1 July 2017 and 1 December 2017 were 
analysed on 2 January 2018. Of 261 patients who started PrEP, 182 (70%) were still 
taking PrEP at the end of the five-month study period, eight stopped taking PrEP and 
44 were lost to follow-up or their status was unknown. Ninety six percent of 
participants were MSM, with a median age of 33 years.  
One-year retention rates were reported in Australia.(132) The EPIC-NSW study was an 
implementation cohort study which recruited high risk MSM taking PrEP in New 
South Wales. By the end of the 12-month follow-up period (until 31 October 2017), 
7,621 participants were enrolled. The persistence of participants taking PrEP was 
inferred by reviewing follow-up visit attendance. After three months, 90% (n=3,259) 
attended the follow-up visit. This dropped to 76% (n=2,804) by the end of the 
twelve month follow-up visit. In total, 97% (n=3,577) participants were dispensed 
study drugs more than once in the year after the first date of dispensing.  
In this model a 12-month retention of 76% (95% CI: 75 to 77%) based on data 
from the EPIC-NSW cohort in Australia has been used, as it is the cohort with 
complete data whose programme is most similar to that envisaged in Ireland. 
In Scotland, a total of 45 individuals were coded as having stopped PrEP during the 
first year of their national programme (this represents 2% of the 1,872 patients who 
were prescribed PrEP during this time). Additional analysis, based on sequential 
prescription data in addition to PrEP coding, is planned to more accurately assess 
the numbers of individuals who may have stopped PrEP during the year. 
The only other data identified relating to retention and discontinuation rates were 
from programmes in North America (all information presented at the Conference on 
Retroviruses and Opportunistic Infections [CROI], March 2018). While interpretation 
is complicated by a lack of detail in the study reports regarding how data were 
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collected and the fact that a high discontinuation was attributed to lack of health 
care insurance at some sites, these reports provide the longest follow-up data on 
PrEP use due to the fact that to PrEP was licensed by the FDA in 2012, many years 
before the EU/EEA (2016). 
 Montreal(19): The Actuel PrEP cohort was assessed for discontinuation and 
interruptions between 1 January 2011 and 1 September 2017. The cohort 
measured 450 consistent PrEP users (36%), 114 PrEP users (9%) who 
temporarily stopped and re-initiated PrEP at least once, 214 individuals who 
permanently discontinued PrEP (17%) and 480 individuals who were lost to 
follow-up (38%). 
 Detroit(133): Between July 2016 and March 2017, thirty-four (76%) 
interviewed patients had initiated PrEP, of whom 17 (50%) had subsequently 
discontinued their medication a mean of 92 days (95% CI ± 23.8) following 
receipt of a prescription. 
 Los Angeles(134): A longitudinal analysis of patients who initiated PrEP at the 
Los Angeles LGBT Center between March 2014 and February 2017 was 
undertaken. At the end of the analysis period, 47% (n = 809) of patients who 
started PrEP were active, 37% had discontinued, and 16% were lost to 
follow-up. By three months, 32% (n=572) discontinued, and 45% (n=802) 
discontinued by six months.  
 San Francisco(135): Patients receiving PrEP within the San Francisco 
Department of Public Health Primary Care (SFPC) clinics are included in a 
centralised PrEP registry to monitor metrics such as uptake and persistence. 
Patients receiving PrEP at any time from January 2015 to February 2016 were 
analysed, regardless of initiation date. The median time enrolled was 217 
days, with 67% persistence at 1 year. 
 Atlanta(19): PrEP users were followed between October 2015 and March 2017. 
As of March 2017, only 78/201 (39%) participants remained persistent in 
PrEP care. 
Another US study published in 2019 examined persistence with PrEP via pharmacy 
fill records from a national chain pharmacy to describe persistence on PrEP 
medication over a two‐year period.(136) De‐identified pharmacy fill records of 7,148 
eligible individuals who initiated PrEP were followed for 24 months. Persistence was 
56% in year 1, 63% in year 2 and 41% from initiation to year 2. A key limitation to 
this study was that data were from a single pharmacy chain and therefore 
individuals changing pharmacies could be persistent on PrEP, but classified as non‐
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persistent. Additionally its applicability may be low to the Irish context as many users 
had to pay a copay. 
6.2.2  HIV epidemiological parameters  
6.2.2.1 HIV incidence in each risk stratum 
To model the effects of PrEP, the incidence of HIV in MSM at substantial risk must 
be ascertained, as well as the incidence in medium/low risk MSM. In Chapter 3, the 
notification rate of HIV, reported in Ireland by the HPSC, is described in detail. This, 
however, is not the same as the incidence of HIV, as diagnoses are dependent on 
testing. 
A 2017 study estimated the incidence of HIV in ‘high risk’ MSM in the UK using 
GUMCAD, a comprehensive, pseudo-anonymised digital download of patient-level 
data on all sexually transmitted infection (STI) services and diagnoses provided in 
GUM clinics in England.(130) To assess risk group, GUMCAD data on HIV negative 
clinic-attending MSM for 2009 to 2013 were extracted, and the diagnosis or not of 
any bacterial STI in the previous year was used as a proxy to indicate recent 
condomless anal intercourse and to stratify the future risk of being diagnosed with 
HIV. Those with a bacterial STI in the previous year were labelled ‘high risk’ and 
eligible for PrEP, and those without as having ‘medium risk’ for HIV acquisition. A 
limitation of this method is that the proxy used for high risk (recent bacterial STI) 
only applies to a subset of MSM at high risk.  
HIV incidence estimation methodology followed that used in Desai et al.(137) HIV 
incidence for high and medium risk MSM in England was estimated using data from 
2012, the most recent year whereby complete one-year follow-up data (up to year 
2013) was available. To calculate HIV incidence in 2012, MSM were followed from 
their first negative HIV test of the calendar year until seroconversion or their last 
attendance occurring within 12 months of the first test. In 2012, of the 17,429 high 
risk HIV negative MSM attending GUM clinics, a total of 6,239 were repeat tested for 
HIV, with 130 seroconversions, and an estimated HIV incidence of 3.3 per 100 
person-years (95% CI: 2.8 to 4.9 per 100 person-years). Of the 68,076 medium risk 
HIV negative MSM attending, 19,953 repeat tested, with 194 seroconversions, and 
an estimated HIV incidence of 1.5 per 100 person-years (95% CI 1.3 to 1.8 per 100 
person-years). HIV incidence was 2 per 100 person-years (95% CI 1.8 to 2.2 per 
100 person-years) in the overall HIV negative MSM GUM attendees. From the above 
data, the incidence in medium/low risk combined can be calculated (0.43 per 100 
person years). 
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Similar HIV incidence rates were estimated by Desai et al., analysing GUMCAD data 
for the year 2012.(138) Study authors estimated the overall incidence of HIV as 2.0 
per 100 person-years in MSM and 3.2 per 100 person-years in the high risk stratum. 
These annual rates were converted to yearly probabilities in the model, according to 
the following conversion: 
 
 
From the systematic review of efficacy (Chapter 4), the pooled efficacy of PrEP to 
prevent sexual acquisition of HIV in MSM was estimated at 75% (meta-analysis of 
six trials). More recent MSM trials (open-label PROUD and IPERGAY) reported a 
higher efficacy (86%). The PROUD and IPERGAY trials noted higher adherence than 
previous studies, and may be more applicable to Ireland due to the fact PrEP was 
administered through STI clinics in resource-rich countries. The sensitivity analysis 
varied the efficacy of PrEP between the lowest efficacy reported (the iPrEX trial; 
relative risk [RR]: 0.56 [95% CI: 0.37 to 0.84]) and the highest (pooled analysis of 
PROUD/IPERGAY; RR: 0.14 [95% CI: 0.06 to 0.35]). These RRs are multiplied by the 
rate of HIV acquisition in MSM at high risk to estimate the incidence of HIV in PrEP 
users. 
Of note, an older cohort study in Australia recorded relatively lower incidence rates 
(the Health in Men study [HIM]).(139) The study recruited participants from June 
2001 to December 2004. Interviews were conducted from June 2001 to June 
2007. The incidence in the cohort overall was 0.78 per 100 person-years, and nine 
risk variables were associated with an HIV incidence of 2 per 100 PY or greater. 
Stepwise inclusion of these variables revealed a ‘high‐incidence’ subgroup of men 
representing 24% of the total follow‐up time with a combined HIV incidence of 2.71 
per 100 person-years (the variables that contributed to this figure were condomless 
anal sex with HIV-positive partner, condomless anal sex with a casual partner and 
chemsex use). 
6.2.2.2 All-cause mortality 
Age-specific all-cause mortality rates for males in Ireland were retrieved from the 
Central Statistics Office (CSO).(140) 
All-cause mortality for HIV positive males is not reported by the CSO in Ireland. 
Estimates for all-cause mortality in HIV positive individuals are available in the UK. A 
2017 UK study linked cohort data collected by Public Health England (PHE) for 
Probability = (1-e-rate)) 
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individuals aged 15 years and older, diagnosed with HIV in England and Wales from 
1997 to 2012, to the Office for National Statistics (ONS) national mortality 
register.(141) In total, 88,994 people were diagnosed with HIV, contributing 448,839 
person-years of follow up. 
Cohort mortality was significantly higher than the general population for all causes 
(standardised mortality ratio [SMR] 5.7, 95% CI: 5.5–5.8), particularly non-AIDS 
infections (SMR 10.8, 95% CI: 9.8–12.0) and liver disease (SMR 3.7, 95% CI: 3.3–
4.2). All-cause mortality was highest in the year after diagnosis (SMR 24.3, 95% CI: 
23.4–25.2). All-cause mortality in males was 130 per 10,000 person years, with a 
SMR of 4.9 (95% CI 4.8 to 5.1). An adjustment was made for the fact that later 
years in their analyses recorded lower mortality than earlier years. Table 6.9 gives 
the hazard ratios from the Cox proportion hazards model for three time periods. 
Table 6.9. Hazard ratios for all-cause mortality in HIV positive 
individuals 
Diagnosis year Unadjusted hazard ratio Adjusted hazard ratio 
1997–2002 1.0 [reference period] 1.0 [reference period] 
2003–07 0.66 (95%CI: 0.62–0.70) 0.78 (95%CI: 0.70–0.87) 
2008–12 0·65 (95%CI: 0.60–0.71) 0.55 (95%CI: 0.48–0.63) 
Source: Croxford et al. Mortality and causes of death in people diagnosed with HIV in the era of highly active antiretroviral 
therapy compared with the general population: an analysis of a national observational cohort, 2017. 
While mortality rates in the UK and Ireland may differ slightly, it is reasonable to 
assume that the ratio between all-cause mortality in HIV positive individuals and the 
general population would be similar, due to similarities in HIV care between the two 
countries. The adjusted male SMRs have therefore been applied to the all-cause 
mortality rates in Irish men to estimate all-cause mortality in HIV positive MSM in 
Ireland. 
Table 6.10 and Figure 6.3, below, compare these mortality rates. 
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Table 6.10. All-cause mortality in all males and HIV+ males in Ireland 
 All-cause 
mortality: 
all males 
All-cause 
mortality: 
HIV+ males 
Lower CI Upper CI 
35 - 39 years 0.001 0.004 0.004869 0.005173 
40 - 44 years 0.001 0.006 0.006937 0.007371 
45 - 49 years 0.002 0.010 0.011514 0.012233 
50 - 54 years 0.004 0.016 0.018333 0.019478 
55 - 59 years 0.006 0.025 0.028654 0.030445 
60 - 64 years 0.009 0.039 0.045369 0.048205 
65 - 69 years 0.015 0.063 0.072406 0.076931 
70 - 74 years 0.026 0.107 0.123429 0.131143 
75 - 79 years 0.044 0.181 0.209016 0.22208 
80 - 84 years 0.082 0.343 0.394824 0.4195 
85 years and over 0.181 0.755 0.869731 0.924089 
CI – confidence interval  
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Figure 6.3. All-cause mortality in all males and HIV+ males in Ireland, by age 
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6.2.2.3 Utility parameter estimates 
For the cost-utility analysis, where outcomes are expressed as cost per quality-
adjusted life years (QALY) gained, it is necessary to estimate both the baseline 
quality of life of the population as well as the utility weights associated with having a 
diagnosis of HIV.  
In the absence of validated Irish data, baseline quality of life for males by age (for 
those with no current morbidity) was taken from UK estimates for a general 
population based on data from the Health Survey for England (Figure 6.4).(142)  
Figure 6.4. Baseline utility for a general male population 
Formula for curve: General Population EQ-5D utility = 0.9508566 + 0.0212126*male - 0.0002587*age - 0.0000332*age^2 
Utility weights for HIV positive individuals were obtained from a 2014 study.(143) In 
this study, two UK cross-sectional surveys were merged: the ASTRA study, which 
recruited participants with HIV aged 18 years or older from eight outpatient clinics in 
the UK between February 2011 and December 2012; and the Health Survey for 
England 2011, which measures health and health-related behaviours in individuals 
living in a random sample of private households in England. Health-related Quality of 
Life (HRQoL) was assessed with the Euroqol 5D questionnaire three level (EQ-5D-3L) 
instrument that measures health on five domains, each with three levels. Table 6.11, 
below, lists the utility decrements associated with HIV positivity (diagnosed) and by 
CD4 count and ART therapy.  
Note that an assumption was made that an undiagnosed HIV positive individual did 
not have a utility loss. 
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Table 6.11. Disutilities due to HIV positivity, by health state 
Health status Disutilit
y 
95% CI Distributio
n 
Source 
HIV+ -0.11 -0.13 to -0.10 Beta Miners et al. 
HIV+, CD4 count 
>200 cells per μL 
-0.1 -0.12 to -0.08 Beta Miners et al. 
HIV+, CD4 count ≤
200 cells per μL 
-0.15 -0.19 to -0.11  Beta Miners et al. 
HIV+, on ART, VL ≤
50 copies per mL 
-0.11 -0.13 to -0.09 Beta Miners et al. 
HIV+, on ART, VL 
>50 copies per mL 
-0.12  -0.15 to -0.09 Beta Miners et al. 
HIV+, stopped ART -0.14  -0.20 to -0.07 Beta Miners et al. 
HIV+, never started 
ART 
-0.05 -0.08 to -0.02 Beta Miners et al. 
HIV+, undiagnosed 0 Assumption   
Note: 95% range is the same as the confidence interval in the source indicated 
In addition, these utilities were adjusted by age (-0.004 per additional year(143) [in 
addition to the normal aging decrement]). As the imprecision associated with the 
reported reduction in utility due to age was close to zero, a fixed value was used.  
6.2.3 Cost 
6.2.3.1 Cost of PrEP medication 
There are a number of generic formulations of tenofovir/emtricitaine licensed and 
marketed for use in Ireland, for example emtricitabine/tenofovir disoproxil maleate 
(produced by Mylan NV) and emtricitabine/tenofovir disoproxil phosphate (produced 
by Teva Pharmaceutical Industries).  
The wholesale cost was estimated based on reported costs of dispensed PrEP from 
community pharmacies. While a range of costs were identified, it was assumed that 
the HSE could achieve a similar wholesale cost to that obtained by large retail 
chains. The direct cost to the HSE was calculated using the approach outlined in the 
National Centre for Pharmacoeconomics (NCPE) Guidelines for Inclusion of Drug 
Costs in Pharmacoeconomic Evaluations (2018).(144)  
According to these guidelines, the following adjustments should be made: 
i. Apply a wholesale mark-up to the price to wholesaler 
ii. Apply the pharmacy dispensing fee  
iii. Deduct a rebate to PCRS (if applicable).  
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In our calculations, the wholesale mark-up was 8%, the average dispensing fee was 
€5.48 per item and a rebate of 12.5% was applied at the level of price to 
wholesaler. A zero rate of VAT applies to oral medicines.  
6.2.3.2 Cost of PrEP care pathway  
A microcosting or ‘bottom up’ approach was employed to determine costs. Analysis 
was performed from a healthcare perspective; a societal perspective was not 
considered, consistent with national HTA guidelines.(145) Direct health care costs 
were included. Productivity losses as a result of morbidity were not included. 
Retrospective healthcare costs were inflated to 2018 using the Consumer Price Index 
for health (CSO).(10)  
Previously collected cost data from St James’s Hospital GUIDE clinic was used to 
estimate the cost of providing the PrEP care pathway for each patient, as outlined in 
Chapter 2. St James’s Hospital GUIDE clinic has previously estimated staff resource 
use for a typical clinic appointment by HIV positive patients in the ‘Time in Motion 
Study’ (received with permission from Dr Saloni Surah). These times were used as a 
guide to estimate staff resource use for PrEP appointments. Laboratory costs were 
retrieved from St James’s Hospital laboratory and the National Virus Reference 
Laboratory.  
Salary costs were derived from consolidated salary scales available from the Irish 
Department of Health.(146) The midpoint of each scale was selected as the base 
salary. Per Irish guidelines,(11) the base salary was adjusted for non-pay costs: 
employers’ PRSI (@10.75%), superannuation (4% of base salary) and overheads 
(25% of base salary). 
The clinical management pathway for eligible PrEP recipients is described in Chapter 
2. Table 6.12, below, summarises the costs associated with each visit. The cost per 
patient in the first year is €549 and €509 in subsequent years. See Appendix 5.2 for 
full itemised costs. Conservatively, the higher value (€549) is used for all years in the 
model. 
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Table 6.12. Costs associated with each visit in first year 
PrEP Programme: Year 1 (per patient) 
 Unit price Proportion patients 
1st Assessment €187.23 100% 
Starting visit* €16.12 50% 
Subsequent visits in year 1 €118.07 100% 
Total (1st assessment, starting visit*, 3 subsequent visits): €549.50  
*Approximately 50% of participants will require this additional visit 
Cost of ‘usual care’ for high-risk MSM per patient 
Appendix 5.2 provides the cost of ‘usual care’ for high-risk MSM in Ireland. Current 
guidelines in the UK (BASHH) and the US (CDC) recommend three-monthly STI 
screening for MSM at high risk (e.g., multiple anonymous partners).(12) The cost per 
visit is estimated at €127. 
Incremental cost of PrEP programme 
The incremental cost of the PrEP programme is the total cost of the programme, less 
the cost of ‘usual care’ that would theoretically be provided to high-risk MSM without 
a programme in place. 
In the Scottish PrEP programme, based on the NaSH dataset, it was noted that more 
than a quarter (28%) of those prescribed PrEP had not attended a Scottish sexual 
health clinic in the two years before PrEP became available and that 19% had not 
attended a publicly funded Scottish STI clinic in at least 10 years, and possibly 
never. For this reason, it is assumed that approximately a quarter of participants in 
the Irish PrEP programme will be new to services. For the remainder, it was 
assumed that approximately half would attend per BASHH guidelines and half would 
attend at half this rate.  
The estimated average incremental cost of the PrEP programme including screening, 
monitoring and medications is €903 per person per year. It was assumed patients 
would be prescribed a daily PrEP regimen and that four three-monthly prescriptions 
would be redeemed per year. Table 6.13 lists these incremental costs. 
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Table 6.13. Incremental PrEP programme costs per year 
Incremental costs 
 Unit cost 
per visit 
Proportion of cases incurring cost Average yearly 
realised cost 
Usual care  €126.64 25% are not engaged (no visits), 
37.5% attend 4 visits per year and 
37.5% attend 2 visits per year 
€284.94 
PrEP programme (first year) €549.50 
Incremental cost of programme €264.56 
Incremental cost of programme+PrEP medications €903 
Vary by 20% €723 to €1,084 
6.2.3.3 Cost of HIV 
The lifetime and annual costs associated with HIV infection were obtained from a 
2015 UK study.(147) The lifetime costs of MSM infected with HIV in a resource-rich 
setting were estimated using an updated version of the HIV Synthesis progression 
model. This model has been shown to provide a generally close fit to observed data 
relating to the natural progression and treatment outcomes associated with HIV. 
Cost and epidemiological patterns were calibrated to the UK HIV epidemic.  
MSM who were infected with HIV in 2013 aged 30 were modelled over 10,000 
simulations. Based on a median (interquartile range) life expectancy of 71.5 (45.0–
81.5) years for MSM in such a setting, the estimated mean lifetime cost of treating 
one person was £360,800 ($567,000 or €480,000). With 3.5% discounting, it was 
£185,200 ($291,000 or €246,000). The majority, 68% (£245,200), of projected 
lifetime healthcare cost was attributed to ART costs. This translates to an annual 
cost of €11,566 per patient. Table 6.14, below, provides details of the sensitivity 
analysis conducted by study authors. We assumed HIV care costs in Ireland would 
not differ substantially from these estimates. 
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Table 6.14. Mean undiscounted lifetime costs under different model 
assumptions 
Assumption in base-case 
analysis 
New assumption Mean 
lifetime 
costs*  
Base-case analysis - 360,800 
Infected at age 30 years Infected at age 20 years 432,400 
Infected at age 40 years 297,800 
Rate of diagnosis in line with 
that currently observed (median 
CD4 count at diagnosis = 422 
cells/mm3) 
Diagnosed almost immediately after infection 371,000 
Diagnosed only when symptomatic or develop 
AIDS 
294,000 
Never lost from care 5% per year loss to care rate (return to care 
only when symptomatic or develop AIDS) 
353,440 
Initiate ART when CD4 count 
drops below 350 
cells/mm3 (unless symptomatic) 
Initiate ART when CD4 count drops below 500 
cells/mm3 (unless symptomatic) 
361,800 
Initiate ART soon after HIV diagnosis (unless 
symptomatic) 
366,100 
1.5-fold increased risk of non-
AIDS deaths (compared to the 
general population) 
1.1-fold increased risk of non-AIDS deaths 
(compared to the general population) 
387,400 
1.25-fold increased risk of non-AIDS deaths 
(compared to the general population) 
396,400 
1.5-fold increased risk of non-AIDS deaths but 
2-fold in people with unsuppressed viral load 
(compared to the general population) 
358,600 
1.5-fold increased risk of non-AIDS deaths 
(compared to the general population) and 1.5-
fold increased healthcare centre visit costs whilst 
CD4 count <200 cells/mm3 
404,500 
Population distribution of 
adherence  calibrated to data on 
proportion of men with 
suppressed viral load 
Better population distribution of adherence 371,500 
Slightly worse population distribution of 
adherence 
359,400 
Worse population distribution of adherence 241,300 
Patented drugs replaced by 
generic versions (80% 
reduction in price) and 
population distribution of 
adherence  calibrated to data on 
proportion of men with 
suppressed viral load 
Patented drugs replaced by generic versions 
(80% reduction in price) and slightly worse 
population distribution of adherence 
178,400 
Patented drugs replaced by generic versions 
(80% reduction in price) and worse population 
distribution of adherence 
136,900 
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Healthcare centre visit costs 
incurred while undiagnosed are 
the same as those of someone 
who is diagnosed but with CD4 
count >200 cells/mm3 
No healthcare centre visit costs incurred while 
undiagnosed 
348,300 
*All costs in 2013 £ 
Source: Nakagawa et al. 2015 
From the above sensitivity analysis, the range of mean undiscounted lifetime HIV 
costs based on alternative model assumptions is between £136,900 and £432,400. 
The scenario ‘Initiate ART soon after HIV diagnosis’ is most applicable to Ireland as 
that is the standard of care; this cost was used in analyses (£366,100) 
Costs were inflated using the CPI for health to year 2017 (UK) and converted to Irish 
Euro using purchasing power parity (PPP), per Irish guidelines.(28) Table 6.15 gives 
the estimated mean lifetime and annual costs of HIV in Ireland. 
Table 6.15. Estimated mean (undiscounted lifetime and annual costs of 
  HIV 
Model Assumption UK 
(2013 £) 
Ireland 
(2017 €) 
Lifetime   
 Mean 366,100 423,200 
 Least costly alternative 136,900 158,200 
 Most costly alternative 404,500 467,500 
Annual   
 Base case  10,200 
 Least costly alternative  3,800 
 Most costly alternative  11,300 
Note:  All costs rounded to nearest 100. 
 Mean annual cost estimated by dividing the lifetime cost with the number of years infected with HIV.  
Few other studies have estimated the lifetime costs associated with HIV in the era of 
combined ART. Earlier studies typically reported higher lifetime costs, largely due to 
higher ART costs and higher HIV-related morbidity. Schackman et al., 2006, 
estimated that from time of entry into HIV care, an adult starting treatment with 
CD4 count <350 cells/mm3 had a projected life expectancy of 24.2 years and 
projected lifetime cost of $618,900 in 2004 USD (approximately €544,500).(148) A 
study in 2012 by Sloan et al. projected a mean life expectancy of 26.5 years and 
lifetime cost of €535,000 (in 2010 €) for their simulated cohort with mean age 38 
years who started combined ART with CD4 count <350 cells/mm3.(149) These earlier 
studies that report higher HIV care costs and lower life expectancies for HIV positive 
individuals were not deemed reflective of current HIV care in Ireland. 
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Costs used in other economic evaluations varied somewhat. The analysis by 
Cambiano et al., 2018, estimated an annual cost of between €11,200 and €13,900 
(converted to 2017 €) in the UK.(131) Also in the UK, Ong et al. 2017 modelled two 
costs: an annual cost of €10,300 in HIV positive individuals with CD4>200 and 
€13,260 in individuals with CD4<200 (converted to 2017 €). 
The only Irish study identified (Brennan et al. 2015(150)) estimated the cost of 
ambulatory HIV care in an Irish HIV clinic. In 2011/2012, the average monthly cost 
was between €927 and €1,019 (equivalent to €11,124 to €12,228 annually).  
The estimate of €10,200 used in the base case analysis would appear to be a 
conservative estimate (biasing against PrEP) as it is somewhat lower than that used 
by other authors. This cost was varied by 20% in the model (€8,160 to €12,240) 
It was assumed that ART starts immediately after diagnosis. For many, there is a 
delay between infection and diagnosis. A UK study estimated the average time 
between HIV infection and diagnosis date for high-risk MSM, identified from Public 
Health England HIV surveillance data for the years 2011 to 2013.(130, 151) Table 6.16, 
below, demonstrates the time to diagnosis in England. It estimated that 39% are 
diagnosed the year in which they are infected with 82% diagnosed within five years 
of being infected. This lag was incorporated into the budget impact model due to its 
short time frame (5 years), but not the cost-effectiveness model (a lifetime horizon 
was used).  
Table 6.16. Time to HIV diagnosis (UK data) 
Time (Year)  Proportion of HIV Infections 
Occurring in Year-1 that are 
Diagnosed in Year-1 or in 
Subsequent Years  
Cumulative 
Proportion 
Diagnosed 
1  39%  39%  
2  12%  52%  
3 11%  63%  
4  10%  73%  
5  9%  82%  
These data are consistent with the MISI 2015 survey: the proportion of men who 
tested for HIV in the previous 12 months was 39%.(27) Also of note, the HPSC 
reports recent infections in Ireland using the Recent Infection Testing Algorithm 
(RITA) or a p24 antigen positive status.(38) In 2017, it was estimated that 13% of 
HIV diagnoses (of those tested) were likely to be recent infections (within four 
months), using the RITA. By probable routes of transmission, men who have sex 
with men (MSM) had the highest proportion of likely recent cases (16%). 
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6.2.3.4 Cost of Post-Exposure Prophylaxis following Sexual 
Exposure (PEPSE) 
PEP is a HIV prevention intervention in which antiretroviral therapy is administered 
for prophylaxis against infection following exposure to HIV through sexual contact. 
Ideally it should be given as soon as possible following exposure, but may be 
considered for up to 72 hours. It is available following a clinical assessment of risk, 
and is provided to eligible patients free of charge. In Ireland, it is available at 
Emergency Departments, Sexual Assault Treatment Units and at STI clinics.  
The British Association for Sexual Health and HIV (BASHH) have developed UK 
guidelines for the assessment, treatment and monitoring of an individual receiving 
PEPSE.(152) Three clinic visits in total are recommended. Table 6.17 outlines the 
management of a PEPSE patient. The recommended therapy is daily oral 
tenofovir/emtricitabine fixed dose combination with daily oral raltegravir for 28 days. 
Table 6.17. BASHH management of PEPSE patients 
Test Baseline 14 days 8-12 weeks post-
exposure 
HIV Yes  Yes 
Hep B sAg Yes  Only if not immune 
Syphilis, HCV, HBV 
immunity 
Per local clinic policy 
STI testing Yes Yes If further 
unprotected sex 
Creatinine Yes Only if abnormalities 
detected at baseline 
 
Alanine 
transaminase 
(ALT) 
Yes Only if abnormalities 
detected at baseline; 
HBV/HCV co-
infected; or on 
Kaletra® 
 
Urinalysis or uPCR Yes Only if abnormalities 
detected at baseline 
 
Pregnancy test Yes   
Creatine kinase  Only if symptomatic 
or myositis 
 
One course of PEPSE is estimated to cost €964. Appendix 5.2 details these costs. 
Local costing data was applied to BASHH’s management guidelines for PEPSE, 
assuming PEPSE is first administered at a STI clinic as opposed to the Emergency 
Department. As the calculated Emergency Department visit cost was higher, we 
have conservatively chosen the cost of PEPSE at an STI clinic for the purpose of 
analyses. 
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In patients who are taking PrEP as prescribed, PEPSE is not indicated. This is 
therefore a potential cost offset in the economic evaluation. 
Little is known of the frequency of PEPSE prescribing in Ireland. The MISI 2015 
survey reported that of respondents not known to be HIV positive, 4% had ever 
used PEPSE, though this varied by HIV testing history.(153). Those who had 
previously tested negative for HIV were significantly more likely to have used PEPSE 
than those who had never tested (7% versus 0.3%). 
In the study by Ong et al., GUMCAD data was used to investigate PEPSE prescribing 
among high-risk MSM. Of the 17,429 high-risk MSM identified through GUMCAD 
data, 781 courses of PEPSE were prescribed to 663 individuals in the year 2012.(90) 
The total number of PEPSE courses is higher than the total number of individuals as 
some individuals had more than one course of PEPSE. By dividing the absolute 
number of PEPSE prescriptions over the total number of high-risk MSM, the 
proportion of overall PEPSE use was 4.48%.  
We have therefore assumed that approximately 4% of PrEP users will avoid taking 
PEPSE each year. Not only is this a cost offset, it reduces the burden on STI services 
by reducing STI clinic visits. 
6.2.3.5 Cost of STIs due to risk compensation 
The impact of a national PrEP programme on the rates of STIs is unknown. Our 
systematic review and meta-analysis of RCTs (Chapter 4) did not demonstrate a 
significant increase in STIs in those taking PrEP.  
There is, however, some evidence from observational studies that taking PrEP may 
reduce condom use and increase STI rates. One systematic review and meta-
analysis of observational studies noted an increase in rectal chlamydia following the 
introduction of PrEP programmes (odds ratio [OR], 1.59; 95% confidence interval 
[CI], 1.19-2.13).(154) A rise in gonorrhea or syphilis at any site, or chlamydia at non-
rectal sites, was not noted. Table 6.18 outlines their results. 
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Table 6.18. Results from 2018 systematic review and meta-analysis 
Pathogen  Studies OR (95% CI) p-value 
Syphilis  6  1.12 (0.86–1.47)  0.408  
Chlamydia  5  1.23 (1.00–1.51)  0.051  
Rectal  4  1.59 (1.19–2.13)  0.002  
Urethral  3  0.96 (0.61–1.51)  0.857  
Pharyngeal  2  0.93 (0.53–1.62)  0.797  
Gonorrhea 5  1.13 (0.78–1.64)  0.515  
Rectal  4  1.21 (0.78–1.88)  0.397  
Urethral  3  1.61 (0.45–5.78)  0.467  
Pharyngeal  3  1.20 (0.88–1.64)  0.257  
OR – odds ratio 
Subsequent to this meta-analysis, a longitudinal study of 2,981 mostly gay and 
bisexual Australian men who received daily PrEP was published by the same authors 
on 9 April 2019.(155) After adjusting for testing frequency, the increase in incidence 
from one year pre-enrolment to follow-up was significant for any STI (adjusted 
incidence rate ratio, 1.12 [95% CI, 1.02-1.23]) and for chlamydia (adjusted IRR, 
1.17 [95% CI, 1.04-1.33]), but not for gonorrhoea or syphilis. 
Any future rise in STI diagnoses in Ireland following the introduction of a PrEP 
programme may be a result of an actual increase in STI transmission, or may simply 
reflect the frequent testing that is part of the programme, leading to an improved 
detection of STIs. NHS Scotland has released data on its first year of implementing a 
PrEP programme, and has not concluded that there was an actual rise in STIs 
among PrEP users.(127) Among those prescribed PrEP, rates of gonorrhoea (including 
rectal) testing and numbers diagnosed positive increased between the two 12 month 
periods either side of NHS PrEP introduction but rates of actual infection remained 
similar. Such rates were higher among those ever versus never prescribed PrEP; this 
observation indicates that the former are at higher risk of gonorrhea (and therefore 
HIV) infection and that the eligibility criteria for PrEP are likely to be appropriate.  
Similar observations were recorded for chlamydia with an increase in testing and 
diagnoses among MSM ever prescribed PrEP but no overall change in the proportion 
positive pre and during the first year of NHS PrEP. The increases in gonorrhoea and 
chlamydia diagnoses could be attributed to either improved detection, an actual 
increase in the incidence of infection or a combination of both; the explanation is 
likely to be the “combination” one but the ratio of the contributions is uncertain.  
Additionally, there has been a significant rise in the notification rate of both 
gonorrhea and chlamydia in Ireland in recent years (see Figure 6.5). Data specific to 
the MSM population show a steady rise in gonorrhea (Figure 6.6). The impact of 
Draft: Health technology assessment of a PrEP programme for populations at substantial risk of 
sexual acquisition of HIV 
Health Information and Quality Authority 
Page 154 of 244   
PrEP on STI rates would have to take into consideration this secular trend in rising 
notifications over time. 
Figure 6.5. Trend in notification rate per 100,000 population of 
gonorrhoea and chlamydia(156) 
 
Figure 6.6. Notified cases of Gonorrhea in MSM (HPSC)(156) 
 
Taking a conservative approach, a rise in STIs was included in the model. The 
increase in rectal chlamydia reported in the meta-analysis by Traeger et al.(154) was 
applied, whereby PrEP users experience a 33% annual increase in rectal chlamydia 
diagnoses (converting odds ratios to relative risks). The recommended treatment of 
rectal chlamydia, doxycycline 100mg twice daily for 7 days (BASHH 
recommendations),(157) is estimated to cost €3.48 if dispensed in a community 
pharmacy, based on average PCRS list costs adjusted in accordance with cost 
guidelines (although it is noted that most clinics dispense treatment medications 
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directly).(144) The total cost of treating one episode of rectal chlamydia (clinic time, 
investigations and treatment) is estimated to cost approximately €125 (see Appendix 
5.2). A wide variation in cost was applied to account for regional variations in 
management.  
6.3 Process for calibrating model 
A number of model parameters were supported by very limited data or were based 
on international data that may not be directly applicable to Ireland. It is important to 
ensure that the model generates estimates that are reasonable based on observed 
data, such as the incidence and prevalence of HIV and the number of people likely 
to avail of PrEP.  
A calibration exercise was used to explore which parameter values would lead to 
plausible results in the model in terms of the incidence of HIV in the MSM population 
and the number of people who are likely to enrol in the programme. While the 
incidence of HIV is unknown in Ireland, the HPSC reported 151 HIV notifications in 
MSM in 2017 that were new diagnoses (150 was selected as the lower bound due to 
the fact that a certain number of HIV infections are undiagnosed). The range of HIV 
incidence values was set at 150-400. In terms of the number of people likely to 
enrol, the Scottish PrEP programme was the first country to report national figures 
on their experiences in the first year of PrEP implementation. Scotland reported 
1,872 people availed of PrEP in the first year (note that Ireland’s population is 
approximately 10% smaller than Scotland’s, or 4.8 versus 5.4 million). The plausible 
range of PrEP recipients in Ireland was set at between 1,000 and 3,000 individuals. 
6.3.1 Methodology 
Calibration was carried out in relation to six model parameters: 
 Proportion of the male population aged 16-80 who are MSM (prop_MSM) 
 Proportion of the MSM population that are currently sexually active 
(prop_active) 
 Proportion of the MSM population that might be considered at high risk of HIV 
and are therefore eligible for PrEP (prop_HR) 
 Proportion of the PrEP eligible population who are likely to enrol in the 
programme (prop_uptake) 
 Rate of HIV acquisition in the MSM population at high risk of HIV acquisition 
(high_HIV) 
 Rate of HIV acquisition in the MSM population at medium/low risk of HIV 
acquisition (medlow_HIV) 
 
Draft: Health technology assessment of a PrEP programme for populations at substantial risk of 
sexual acquisition of HIV 
Health Information and Quality Authority 
Page 156 of 244   
The mean values for the six parameters were set based on available national and 
international data, but defined as statistical distributions which incorporated 
substantial uncertainty (Table 6.19).  
 
Table 6.19. Initial parameter values used for calibration 
Parameter Distribution Mean LCI UCI 
Proportion of male population aged 
16-80 who are MSM (Prop_MSM) 
beta 0.0500 0.0400 0.0600 
Proportion of MSM currently 
sexually active (Prop_active) 
beta 0.6304 0.4877 0.7623 
Proportion of MSM population 
eligible for PrEP (Prop_HR) 
beta 0.2000 0.0280 0.4827 
Proportion of the PrEP eligible 
population who are likely to enrol 
(Prop_uptake) 
beta 0.2139 0.1396 0.2991 
Rate of HIV acquisition in MSM at 
high risk of HIV acquisition 
(high_HIV) 
gamma 0.0322 0.0143 0.0573 
Rate of HIV acquisition in MSM 
population at medium/low risk of 
HIV acquisition (medlow_HIV) 
gamma 0.0043 0.0015 0.0087 
UCI – upper confidence interval, LCI – lower confidence interval 
Two approaches to parameter value sampling were used: Latin Hypercube and 
Monte Carlo. As Latin Hypercube sampling uses a stratified sampling scheme, it can 
improve coverage of the k-dimensional input space relative to a Monte Carlo 
approach. However, the trade-off is that it is more computationally intensive to 
generate the samples with Latin Hypercube, so there are restrictions on how large a 
sample can be generated. The Latin Hypercube sampling used 10,000 samples and 
the Monte Carlo approach was used with 1,000,000 samples. 
A basic version of the economic model was developed in R version 3.5.2 (2018) that 
calculated the annual incidence of HIV in a ‘no PrEP programme’ scenario, and the 
number of people receiving PrEP in a ‘PrEP programme’ scenario. Both outcomes 
were calculated using the initially sampled random values for the parameters. 
Outcomes were considered plausible if the incidence of HIV in the MSM population 
was between 150 and 400 cases, and the number of people enrolling in the PrEP 
programme was between 1,000 and 3,000. The sampled parameter values from 
simulations which plausible outcome values were then used to fit new univariate 
distributions for the parameters. Correlations between parameters were not 
considered as the software being used for the modelling, TreeAge Pro 2018, only 
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supports correlated normal distributions and not correlated beta or gamma 
distributions. 
Finally, the model was rerun using 10,000 simulations based on the refit parameter 
distributions to determine the extent to which implausible outcome values were 
generated.  
6.3.2 Results 
The proportion of initial simulations that generated plausible outcome values was 
0.171 for Latin Hypercube and 0.175 for Monte Carlo sampling, respectively. As the 
results for both approaches were very similar, only the findings for the Latin 
Hypercube approach are reported here. 
For the 17% of simulations that generated plausible outcome values, there were 
notable correlations between some parameter values (see Table 6.20). For example, 
the proportion high risk and the uptake were negative correlated, suggesting that 
when the proportion at high risk takes on high values the uptake must take on lower 
values to ensure the number of PrEP recipients remains plausible. 
Table 6.20. Correlation between parameters in simulations with 
plausible outcome values based on Latin Hypercube 
sampling method 
 Prop_MSM Prop_active Prop_HR 
Prop_MSM 1 -0.12 -0.15 
Prop_active -0.12 1 -0.33 
Prop_HR -0.15 -0.33 1 
Prop_uptake 0.04 0.04 -0.35 
high_HIV -0.12 -0.04 -0.33 
medlow_HIV -0.21 -0.23 -0.04 
 Prop_uptake high_HIV medlow_HIV 
Prop_MSM 0.04 -0.12 -0.21 
Prop_active 0.04 -0.04 -0.23 
Prop_HR -0.35 -0.33 -0.04 
Prop_uptake 1 0.12 0.05 
high_HIV 0.12 1 -0.22 
medlow_HIV 0.05 -0.22 1 
After refitting, the notable changes in the parameter values were reductions in the 
proportion sexually active, the proportion at high risk of acquiring HIV, and the risk 
of acquiring HIV in the high risk group (see Table 6.21). Appendix 5.3 provides full 
details of all parameters used in probabilistic analysis. 
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Table 6.21. Refit parameter values based on Latin Hypercube sampling 
method 
Parameter Distribution alpha beta Mean LCI UCI 
Proportion of male 
population aged 16-80 
who are MSM 
(Prop_MSM) 
beta 83.3 1735.8 0.0458 0.0368 0.0556 
Proportion of MSM 
currently sexually 
active (Prop_active) 
beta 29.4 18.9 0.6091 0.4660 0.7369 
Proportion of MSM 
population eligible for 
PrEP (Prop_HR) 
beta 6.48 45.9 0.1221 0.049 0.2128 
Proportion of the PrEP 
eligible population who 
are likely to enrol 
(Prop_uptake) 
beta 31.5 83.6 0.2732 0.1984 0.3575 
Rate of HIV acquisition 
in MSM at high risk of 
HIV acquisition 
(high_HIV) 
gamma 100 3333.3 0.0300 0.0244 0.0358 
Rate of HIV acquisition 
in MSM population at 
medium/low risk of 
HIV acquisition 
(medlow_HIV) 
gamma 100 33333.3 0.0030 0.0024 0.0036 
UCI – upper confidence interval, LCI – lower confidence interval 
When the refit parameter distributions were used, 61% of simulations produced 
plausible results for both outcomes. Simulations were more likely to produce 
implausible results for the incidence of HIV (25.6%) than for numbers of PrEP 
recipients (18.3%). A comparison of the confidence bounds for incidence of HIV and 
the plausible range used shows that model simulations will be more likely to over-
estimate the incidence rather than under-estimate it (see Figure 6.7). For the 
outcome of number of PrEP recipients, the model will not be systematically biased in 
over- or under-estimating numbers (see Figure 6.8). Based on the refit distributions, 
the outcomes were estimated as 332 (95% CI: 158 to 590) for HIV incidence and 
1,697 (95% CI: 667 to 3,301) for PrEP recipients. 
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Figure 6.7. Estimated annual incidence of HIV using refit parameter 
values based on Latin Hypercube sampling method 
 
Figure 6.8. Estimated annual number of PrEP recipients using refit 
parameter values based on Latin Hypercube sampling 
method 
 
6.3.3 Discussion 
A calibration process was used to identify what parameter value distributions would 
result in plausible estimates for two outcomes: incidence of HIV in the MSM 
population and the number of likely recipients of PrEP in the first year of a 
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programme being implemented. Both outcomes are themselves subject to 
uncertainty. The estimate of 1,000 to 3,000 PrEP recipients is somewhat arbitrary, 
with the point estimate based on the observed number of PrEP recipients in 
Scotland’s first year of their national programme. It is unclear how similar the MSM 
in population in Ireland is to the Scottish equivalent, and whether there is a similar 
proportion at high risk of HIV.  
The incidence of HIV is also uncertain, as no study to date has estimated the true 
HIV incidence in Ireland. The HPSC report HIV notifications, and it was considered 
reasonable to assume that the lower bound for calibration would reflect HIV 
notifications of new cases among MSM in 2017 in Ireland. This was selected as the 
lower bound due to the fact that a certain number of HIV infections are undiagnosed 
(from Chapter 3, Section 3.3.4.1, more than a third of MISI respondents [36.7%] 
had never tested for HIV and 61.6% had not tested for HIV in the last year). The 
appropriateness of using a HIV notification rate as a proxy for incidence is 
dependent upon the uptake and frequency of HIV testing in a given population, 
however, and it is possible that the true incidence is lower than 150 if testing 
patterns were markedly different in 2017 compared with previous years. Model 
parameters were not calibrated more than what is currently presented due to the 
risk of over-fitting parameters values; as it stands, parameters such as the rate of 
HIV acquisition and the proportion at high risk are considered at their lowest 
plausible values.  
Both sampling methods used for calibration returned similar results with almost no 
difference in the modelled distributions for the two outcomes of interest. 
The analysis suggests that some of the distributions should ideally be correlated in 
the economic model to potentially improve the plausibility of the outcomes. 
However, there are limitations to the economic modelling software in terms of how 
correlated random values are generated. Failure to correlate certain values means 
that there will be additional uncertainty regarding the cost-effectiveness. However, 
the estimated correlations are not based on observed data, but only on what is 
necessary to ensure plausible results from the model. As such, the correlations 
artificially account for uncertainty in what values the parameters should take. 
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6.4 Cost effectiveness analysis results 
6.4.1 Summary of results  
Monte Carlo simulation was performed over the course of 10,000 replications to 
derive estimates of the costs and consequences of implementing a PrEP programme, 
with parameters sampled from their range of plausible values in each replication. All 
analyses were carried out using TreeAge Pro 2018.(158) Figure 6.9 shows that stable 
ICER estimates were achieved after approximately 2,000 replications. This indicates 
that 10,000 replications were sufficient to obtain stable results from the probabilistic 
analysis. 
Figure 6.9. Convergence of ICER estimates  
 
 
In the base case, PrEP is cost saving, with an ICER of -€2,735 over the cohort’s 
lifetime (95% CI: -€16,486 to €21,585). This means that providing PrEP is less 
costly, and more effective (in terms of QALYs gained), than not providing PrEP. The 
cost savings can be explained by the comparatively higher cost of HIV care relative 
to the cost of preventing HIV infection with PrEP, over a range of plausible 
parameter distributions. Table 6.22 provides summary statistics of the base case 
analysis. 
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Table 6.22. Cost-effectiveness results (summary statistics)  
Strategy Costs (€) Benefits (QALYs) ICER 
(€/QALY) 
Total Incremental Total Incremental  
No PrEP 
programme 
3,971  10.90   
PrEP 
programme 
3,886 -85 10.93 0.03 -2,735 
(Dominant) 
Costs rounded to nearest euro 
Figure 6.10 gives the cost-effectiveness plane; ‘PrEP’ dominates ‘No PrEP’ and is cost 
saving (in the fourth quadrant). Figure 6.11 gives the cost-effectiveness scatterplot 
at a willingness-to-pay (WTP) threshold of €45,000. 
Figure 6.10. Cost-effectiveness plane 
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Figure 6.11. Incremental cost-effectiveness scatterplot 
 
Notes:  
 WTP – willingness to pay threshold (€45,000 per QALY gained).  
 Each dot represents an individual simulation of the Monte Carlo analysis.  
 Encircled is the 95% ellipse
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Figure 6.12 gives the cost-effectiveness acceptability curve (CEAC) for the 
intervention. PrEP has an 87% probability of being considered cost-effective at a 
WTP threshold of €5,000 per QALY gained, a 94% probability at a WTP of €20,000 
per QALY gained and a 95% probability of being considered cost-effective at a WTP 
of €45,000 per QALY gained, the agreed threshold by the Irish Pharmaceutical 
Healthcare Association (IPHA) and the Department of Health for pharmaeucticals to 
be reimbursed through the community drugs scheme. 
Figure 6.12. Cost-effectiveness acceptability curve 
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6.4.2 Sensitivity analysis 
6.4.2.1 Univariate sensitivity analysis 
Univariate deterministic sensitivity analysis was carried out to demonstrate how 
much uncertainty in the outcome (in this case, the ICER) is induced by uncertainty in 
individual parameters. In this type of analysis, the model is run with each of the 
input parameters held at their upper and lower bound, while all the other 
parameters were assigned their mean value, to ascertain what effect it has on the 
ICER for a given comparison. Figure 6.15 provides the Tornado plot of the findings 
(note that parameters that had less than a 5% impact on ICERs are not shown). In 
this analysis, costs are varied by 20% and the efficacy of PrEP ranges from the lower 
efficacy noted in iPrEX (44%) to the higher noted in PROUD and IPERGAY (86%). 
Also varied are the proportion eligible, incidence of HIV, transition probabilities 
between risk groups, disutility and mortality associated with HIV, and the discount 
rate . 
In Figure 6.13, most ICERs are negative – this means that they are cost saving (in 
the fourth quadrant of the cost-effectiveness plane). The efficacy of PrEP and the 
incidence of HIV among individuals at high risk (represented by the transition 
probability of moving from ‘high risk’ to ‘HIV-positive’) had the greatest impact on 
the cost-effectiveness (see Section 6.4.5 for further analysis). The results were also 
sensitive to the costs associated with the PrEP programme and the treatment of HIV. 
The effect of varying the discount rate had little impact; increasing the discount rate 
from 2% to 6% resulted in ICERs decreasing from -€2,365 to -€2,774.  
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Figure 6.13. Univariate sensitivity analysis 
 
Note – Blue indicates the effect of increasing the value of the base case and red indicates decreasing the value of the base case. 
In the base case, the ICER is cost saving. 
WTP = willingness-to-pay threshold
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6.4.2.2 Variation in eligible proportion and uptake 
As outlined in Section 6.2.1.3, provisional data from EMIS 2017 indicate that the 
proportion eligible for PrEP may have increased in recent years. A sensitivity analysis 
was carried out whereby the proportion of MSM eligible for PrEP was varied, 
between 5% and 50% [in the base case, the proportion eligible is approximately 
12%, based on model calibration]. Figure 6.14 outlines these results; the 
intervention becomes more cost saving as the proportion eligible increases. 
Figure 6.14. Sensitivity analysis of increasing proportion of eligible  
MSM 
 
A two-way sensitivity analysis was also performed whereby the uptake rate and 
eligible proportion were simultaneously varied, between 5% and 50%. Figure 6.15 
demonstrates the resulting ICERs over this range; ICERs are negatively associated 
with both variables.
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Figure 6.15. Two-way sensitivity analysis: uptake and proportion at high risk 
ICERs 
High risk 
5% 10% 15% 20% 25% 30% 35% 40% 45% 50% 
Uptake 
5% -€170 -€812 -€1,341 -€1,785 -€2,162 -€2,488 -€2,771 -€3,019 -€3,239 -€3,435 
10% -€329 -€1,080 -€1,687 -€2,188 -€2,609 -€2,967 -€3,275 -€3,544 -€3,780 -€3,988 
15% -€483 -€1,335 -€2,011 -€2,560 -€3,015 -€3,399 -€3,726 -€4,009 -€4,256 -€4,473 
20% -€633 -€1,578 -€2,315 -€2,905 -€3,388 -€3,791 -€4,132 -€4,425 -€4,679 -€4,901 
25% -€780 -€1,811 -€2,601 -€3,225 -€3,730 -€4,148 -€4,500 -€4,799 -€5,057 -€5,283 
30% -€922 -€2,033 -€2,870 -€3,522 -€4,046 -€4,475 -€4,834 -€5,137 -€5,398 -€5,624 
35% -€1,061 -€2,245 -€3,123 -€3,800 -€4,338 -€4,775 -€5,138 -€5,444 -€5,706 -€5,932 
40% -€1,197 -€2,449 -€3,363 -€4,060 -€4,609 -€5,052 -€5,418 -€5,724 -€5,985 -€6,210 
45% -€1,329 -€2,644 -€3,590 -€4,304 -€4,861 -€5,308 -€5,675 -€5,981 -€6,241 -€6,464 
50% -€1,458 -€2,831 -€3,805 -€4,533 -€5,096 -€5,545 -€5,912 -€6,217 -€6,475 -€6,695 
 
ICER – incremental cost-effectiveness ratio 
Note – negative values indicate cost saving (less costly and more effective) relative to standard care  
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6.4.2.3 Efficacy 
As the efficacy of PrEP was a significant driver in the model, a range of efficacy 
values was investigated to investigate their effect on the cost-effectiveness of PrEP. 
In Figure 6.16 below, efficacy values ranging from 40% to 95% are presented. PrEP 
is cost saving at all efficacy values above 60%. At an efficacy of 44% (the lowest 
recorded efficacy in MSM [iPrEX trial]), the ICER is €4,711/QALY. This ICER would be 
considered highly cost-effective and is far below the WTP threshold for 
pharmaceuticals in Ireland (€45,000/QALY). 
Figure 6.16. Sensitivity analysis: efficacy of PrEP 
ICER – incremental cost-effectiveness ratio 
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6.4.3 Scenario analysis 
6.4.3.1 EMIS Ireland 2017 provisional data 
In the preceding sections, sensitivity analysis on both the uptake and proportion at 
high risk demonstrated that, intuitively, PrEP becomes more cost saving as these 
parameters increase in value.  
A scenario analysis incorporating provisional EMIS Ireland 2017 data, the most 
recent data collected on the risk behaviour profile of sexually active MSM in Ireland, 
was undertaken. In this scenario, parameter calibration was not performed and the 
high risk group followed the responses of participants in the EMIS Ireland 2017 
report. As described in Section 6.2.1.3, 647 of 2083 respondents fulfilled Irish 
eligibility criteria for PrEP in this survey (31% of total). Monte Carlo analysis was 
carried out over 10,000 simulations whereby the high risk group is defined by the 
parameter distribution beta (647, 1436). 
The ICER decreases to -€5,288 (95% CI: -€12,535 to €7,289) in this scenario, that 
is, it becomes even more cost saving relative to usual care.  
However, while the EMIS 2017 survey provided useful information on the sexual 
behaviour of its respondents, it is unknown how representative this sample is of the 
overall MSM group in Ireland. To investigate how plausible this scenario is, the ‘No 
PrEP’ group was followed for five years. Table 6.23 provides these results and 
compares them to the base case analysis. By the end of the first year an estimated 
630 cases of HIV would be expected to occur. This falls well outside the calibration 
range for HIV cases previously described (150 to 400 cases maximum). 
Table 6.23. Markov cohort tracing (‘No PrEP’ group) 
Stage All 
MSM 
Sexually 
Active HIV-
negative 
MSM 
EMIS-2017 data Base case analysis 
MSM at 
high risk 
Cumulative 
HIV cases 
MSM at 
high risk 
Cumulative 
HIV cases 
Outset 77,755 48,986 15,216 0 5,904 0 
Year 1 76,623 48,272 10,979 630 5,705 302 
Year 2 75,545 47,593 8,552 1,131 5,563 592 
Year 3 74,432 46,892 7,145 1,545 5,450 868 
Year 4 73,244 46,144 6,312 1,894 5,349 1,125 
Year 5 71,949 45,328 5,798 2,187 5,249 1,358 
6.4.3.2 Event-based dosing 
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A scenario analysis was performed where the PrEP regimen followed ‘event-based’ 
dosing. In the only trial that investigated the efficacy of event-based oral PrEP in 
MSM (IPERGAY(29), with an identical efficacy as daily PrEP trials with correspondingly 
high adherence), a median of 15 pills per month were taken by participants. 
Monte Carlo simulation was performed for three scenarios: 
 50% of PrEP users follow event-based and 50% follow daily dosing 
 75% of PrEP users follow event-based and 25% follow daily dosing 
 100% follow event-based dosing. 
Table 6.24 outlines the ICERs and 95% CI’s associated with these scenarios. As 
expected, event-based dosing is associated with a lower ICER, that is, it is more cost 
saving. 
Table 6.24. Event-based PrEP 
Scenario ICER 95% CI Lower 95% CI Higher 
50% event-based, 50% daily -€4,594 -€20,158 €14,150 
75% event-based, 25% daily -€5,562 -€20,665 €11,012 
100% event-based -€6,258 -€22,245 €8,052 
6.4.3.3 Delay in HIV treatment costs 
Due to the long time horizon, average lifetime treatment costs were applied 
uniformly in the ‘PrEP’ and ‘No PrEP’ groups (modelled costs are applied immediately 
after infection). In reality, there is a delay between infection, diagnosis and 
treatment. In the budget impact analysis (next section), the delay between infection 
and diagnosis was incorporated in the model due to the short (five year) time 
horizon, according to the proportions described in Section 6.2.3.3 (see Table 6.16). 
If this delay were included in the cost-effectiveness model, the ICER would increase 
to €1,226, which has a 95% probability of being considered cost-effective at a 
willingness to pay threshold of €20,000/QALY. With heightened focus on early 
diagnosis and treatment, however, the delay between infection, diagnosis and 
initiation of ART is likely to decrease in future years. 
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6.5  Budget impact analysis  
6.5.1 Methods 
Whereas an economic analysis addresses the additional health benefit gained from 
investment in a technology, such as the cost per QALY gained, budget impact 
analysis (BIA) addresses the affordability of the technology. For example, it outlines 
the net annual financial cost of adopting the technology over a defined period, 
typically five years. Although BIA and cost-effectiveness analysis have many similar 
data and methodological requirements, there are some important distinctions 
between the two approaches.  
Budget impact analysis: 
 reports costs only  
 reports the costs for each year in which they occur  
 is concerned with costs over a short time horizon  
 incorporates Value Added Tax (VAT) where it applies  
 does not incorporate discounting 
 calculates net costs for the entire patient population.  
In general, the BIA model used the same approach as the cost-effectiveness model, 
however it adopted a shorter time horizon (five years), allowed new entrants to join 
the initial cohort after the first year (it was an open as opposed to closed model), 
and took the delay between HIV infection and diagnosis into account (see Section 
6.2.3.3). The incremental costs in the BIA include medication costs and all staff and 
resource use costs associated with PrEP clinic visits that are additional to ‘usual care’ 
(as described in Section 6.2.3.2). Not included in the incremental costs are staff 
shortages and infrastructural issues relating to current STI service demand that is 
currently unmet, unrelated to PrEP. The model incorporated the potential increase in 
STI diagnoses and cost offsets: the reduction in PEPSE use in PrEP users and the 
reduction in HIV care costs associated with averted HIV cases due to PrEP. 
Scotland’s first year of a national PrEP programme enrolled 1,872 individuals.(127) 
This number of PrEP participants was used to guide our estimates of the number of 
individuals who are likely to enroll in an Irish programme (note that Ireland’s 
population is approximately 10% smaller than Scotland’s; 4.8 versus 5.4 million). 
The model was therefore calibrated to assume a plausible range of 1,000 to 3,000 
individuals joining the programme in Year 1 (the calibration process is described in 
Section 6.3). The same care pathway and distribution parameters outlined in the 
cost-effectiveness analysis were applied. Note that the total number of MSM was 
Draft: Health technology assessment of a PrEP programme for populations at substantial risk of 
sexual acquisition of HIV 
Health Information and Quality Authority 
Page 173 of 244   
decreased by 5% to obtain the HIV-negative population (as 5% of respondents in 
MISI 2015 were noted to be HIV-positive), which was balanced by an arbitrary 
increase of 5% to capture all individuals who are not MSM but who would be 
considered eligible for PrEP (in the absence of Irish data on this group).  
The number of participants likely to enroll in the programme was therefore 
determined by the following parameters: 
 Proportion of men who are MSM  
 Proportion of MSM who are sexually active 
 Proportion of sexually active MSM who are at substantial risk (eligible) 
 Uptake rate among eligible MSM. 
Following calibration, the mean number of people who are estimated to join the 
programme in Year 1 is 1,705 people (95% CI: 617 to 3,452). The distribution 
parameters are described previously (see Table 6.21). 
This initial cohort of participants is followed according to the same pathway outlined 
in the state transition Markov model used in the cost-effectiveness analysis, whereby 
individuals may discontinue and resume PrEP over time (see Figure 6.1). In contrast 
to the closed cohort modelled as part of the cost-effectiveness analysis, the budget 
impact model is an open model in the sense that new entrants can enter the model 
after Year 1. New entrants consist of migrants entering the system and 16 year olds 
coming of age. The net inward male migration was 18,200 individuals in the year 
ending April 2018. Additionally, there were 32,550 males who became 16 years of 
age in 2018.(129) Applying the same four distribution parameters as before, a mean 
of 48 new migrants/16-year olds coming of age join the PrEP programme each year 
(95% CI: 17 to 98). The cycle length was set at one year intervals for convenience. 
As per the cost-effectiveness analysis, all BIA results are based on probabilistic 
sensitivity analysis, with each parameter being defined as a distribution based on the 
plausible range of values. These parameters are sampled over the course of 10,000 
Monte Carlo replications to take account of the uncertainty associated with the 
model outputs. Due to the short (five year) time horizon, the delay between 
infection and diagnosis/treatment with ART was incorporated in the model, 
according to the proportions previously described (see Table 6.16). 
Sensitivity and scenario analyses were also carried out. First, a deterministic 
univariate sensitivity analysis was performed where all distribution parameters were 
varied between their lower and upper limits (Section 6.6.3). Second, the proportion 
eligible for PrEP was increased to that recorded in the EMIS Ireland 2017 dataset 
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(Section 6.6.4). Third, due to the fact that efficacy was found to be the main driver 
of cost-effectiveness, scenarios were carried out where the efficacy values noted in 
iPrEX and PROUD (the lowest and highest efficacy values recorded among daily MSM 
oral PrEP users) (Section 6.6.5). Fourth, a two-way sensitivity analysis was 
performed, simultaneously varying PrEP uptake and the eligible proportion of MSM 
and assessing the effect on the budget impact. 
6.5.2 Results of base case analysis 
The mean number of people who are estimated to join the programme in Year 1 is 
1,705 people (95% CI: 617 to 3,452). The number of individuals on PrEP over the 
first five years is provided in Table 6.26. 
Table 6.26. PrEP participants over time 
Year Mean 95% CI Lower 95% CI Higher 
Year 1 1,705 617 3,452 
Year 2 1,654 602 3,326 
Year 3 1,634 689 3,121 
Year 4 1,628 709 3,055 
Year 5 1,635 688 3,123 
The incremental budget impact of the PrEP programme is almost€1.5m in the first 
year (95% CI: €0.5m to €3m) and €5.4m over five years (95% CI: €1.8m to 
€11.5m). The incremental cost takes into consideration the potential increase in STIs 
[rectal chlamydia] and cost savings due to averted HIV infections and the reduction 
in PEPSE use in PrEP users. Table 6.27 and Figure 6.17 provide the incremental cost 
in each year following the introduction of the programme. Note that approximately 
71% of total PrEP programme costs relate to PrEP medication costs. 
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Table 6.27. Incremental budget impact by year 
Year Incremental cost of PrEP 
(programme+drug costs) 
95% CI 
Lower 
95% CI 
Higher 
Year 1 €1.48 €0.52 €2.98 
Year 2 €1.29 €0.49 €2.65 
Year 3 €1.11 €0.31 €2.42 
Year 4 €0.90 -€0.03 €2.31 
Year 5 €0.65 -€0.48 €2.16 
5-year total €5.44 €1.77 €11.46 
All costs in millions 
In terms of incremental programme-only costs (excluding drug costs), the mean cost 
associated with STI clinic visits in the first year is €451,075 (95% CI: €163,234 to 
€913,261).Also modelled was the number of HIV infections estimated to occur with 
and without a PrEP programme in place (see Table 6.28). Overall, 173 HIV infections 
are estimated to be averted over the course of five years. 
Table 6.28. HIV cases averted by PrEP programme 
 PrEP programme No PrEP  Cases averted 
New 
cases 
Cumulative 
cases 
New 
cases 
Cumulative 
cases 
Annually Cumulative 
Outset - - - - - - 
End-Year 1 286 286 323 323 38 38 
End-Year 2 276 561 311 634 35 73 
End-Year 3 277 839 311 945 34 106 
End-Year 4 279 1,118 313 1,258 33 140 
End-Year 5 282 1,400 315 1,573 33 173 
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Figure 6.17. Incremental budget impact by year 
 
Note – overlapping bars indicate the 95% confidence interval associated with incremental costs
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6.5.6 Sensitivity analysis 
6.5.6.1 Univariate sensitivity analysis 
A deterministic sensitivity analysis was performed where all distribution parameters 
were varied between their lower and upper limits. Figure 6.18 illustrates these 
results in the form of a Tornado diagram (only parameters that had a 5% or greater 
impact on the incremental budget impact are listed). The parameters that had the 
greatest impact on the budget were those that influenced the number of participants 
in the programme, such as the proportion eligible for PrEP and the transition 
probabilities between health states that favoured a larger proportion in the PrEP 
group. Also influential were the efficacy of PrEP and the cost associated with the 
PrEP programme and in the treatment of HIV, similar to that noted in the cost-
effectiveness sensitivity analysis (see Section 6.4.2). 
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Figure 6.18. Tornado diagram 
3 4 5 6 7 8 9
Transition probability: No PrEP at high risk to med/low risk [0.24;0.50]
Cost associated with one episode of rectal chlamydia [69.77;192.96]
Transition probability: PrEP high risk to No PrEP high risk [0.05;0.16]
Transition probability: No PrEP high risk to No PrEP high risk [0.22;0.77]
Transition probability: PrEP high risk to PrEP high risk [0.43;0.62]
Cost associated with treatment of HIV (annual per patient) [8224.21;12331.87]
Transition probability: No PrEP high risk to HIV [0.02;0.04]
Transition probability: PrEP high risk to med/low risk [0.28;0.47]
Proprotion of male population who are MSM [0.04;0.06]
Proportion of MSM who are sexually active [0.47;0.74]
Cost associated with PrEP medications + Programme (annual per patient)
[731.99;1091.96]
Proportion of MSM who are at high risk of HIV [0.05;0.22]
Efficacy of PrEP (Relative Risk) [0.10;0.63]
Transition probability: Med/low risk to no PrEP high risk [0.02;0.10]
Transition probability: No PrEP high risk to PrEP high risk [0.08;0.28]
Five year budget impact (€ million) 
Parameter at upper bound
Parameter at lower bound
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6.5.6.2 Two-way sensitivity analysis (uptake and proportion 
eligible) 
As previously discussed, there is evidence to suggest that high risk behavior may be 
increasing in the MSM group. Any increasing trend of risky sexual behavior is of 
concern and will influence future cost estimates. In tandem with the proportion 
eligible, the uptake rate similarly affects the budgetary requirements and 
affordability of PrEP. A two-way sensitivity analysis was carried out whereby the 
proportion of MSM eligible for PrEP and the uptake rate were varied, up to 50% 
eligible and 40% uptake rate (in the base case, the proportion eligible is 
approximately 12.4% and uptake is 27.4%, based on model calibration). Figure 6.19 
illustrates these results. 
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Figure 6.19. Two-way uptake/eligible proportion sensitivity analysis 
Incremental 
BIA  
(5-year) 
High risk 
5% 10% 15% 20% 25% 30% 35% 40% 45% 50% 
Uptake 
5% €4.00 €4.90 €5.80 €6.70 €7.60 €8.50 €9.40 €10.30 €11.20 €12.10 
10% €4.00 €5.00 €5.90 €6.80 €7.70 €8.60 €9.60 €10.50 €11.40 €12.30 
15% €4.10 €5.00 €6.00 €6.90 €7.80 €8.80 €9.70 €10.70 €11.60 €12.60 
20% €4.10 €5.10 €6.00 €7.00 €8.00 €9.00 €9.90 €10.90 €11.90 €12.80 
25% €4.10 €5.10 €6.10 €7.10 €8.10 €9.10 €10.10 €11.10 €12.10 €13.10 
30% €4.10 €5.20 €6.20 €7.20 €8.20 €9.30 €10.30 €11.30 €12.30 €13.40 
35% €4.20 €5.20 €6.30 €7.30 €8.40 €9.40 €10.50 €11.50 €12.60 €13.60 
40% €4.20 €5.30 €6.30 €7.40 €8.50 €9.60 €10.70 €11.70 €12.80 €13.90 
45% €4.20 €5.30 €6.40 €7.50 €8.60 €9.70 €10.90 €12.00 €13.10 €14.20 
50% €4.20 €5.40 €6.50 €7.60 €8.80 €9.90 €11.00 €12.20 €13.30 €14.40 
All costs in millions
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6.5.7 Scenario analysis 
6.5.7.1 EMIS Ireland 2017 provisional data 
Provisional data from EMIS Ireland 2017 is described in detail in Section 6.2.1.3. 
Briefly, the number eligible for PrEP based on overlapping survey responses was 647 
out of 2,083 respondents, or 31%. 
Monte Carlo analysis was carried out over 10,000 simulations whereby the group at 
high risk is defined by the parameter distribution beta (647,1436). Under this 
scenario, an estimated 4,253 individuals (95% CI: 2,633 to 6,301) join the 
programme in Year 1. Unsurprisingly, this scenario is significantly more costly. The 
5-year incremental budget impact is €7.6m (95% CI: €3m to €15m). Table 6.29 lists 
the yearly incremental costs under this scenario. 
 Table 6.29. Incremental budget impact – EMIS 2017 data 
Year Incremental cost of PrEP 
(programme+drug costs) 
95% CI 
Lower 
95% CI 
Higher 
Year 1 €1.56 €0.54 €3.16 
Year 2 €1.59 €0.62 €3.16 
Year 3 €1.56 €0.59 €3.15 
Year 4 €1.49 €0.44 €3.18 
Year 5 €1.38 €0.23 €3.24 
5-year total €7.58 €2.97 €15.05 
All costs in millions 
6.5.7.2 Efficacy 
Due to the fact that efficacy was the major driver of cost-effectiveness, probabilistic 
scenario analyses where the lowest and highest efficacy values for PrEP among MSM 
were undertaken to investigate the difference in results. From Chapter 4, Section 
4.3.4.1, the range of efficacy values for daily oral PrEP in MSM was as follows: 
 Lowest (iPrEX study): Relative risk of HIV acquisition = 0.56, SD 0.12, 95% CI 
0.37 to 0.84 
 Highest (PROUD study): Relative risk of HIV acquisition = 0.14, SD 0.11, 95% 
CI: 0.04 to 0.47 
Table 6.30 compares these results. The difference in the incremental budget impact 
is modest in the first year (€1.5m in PROUD versus €1.6m in iPrEX). The five-year 
total incremental BIA is €4.7m (PROUD scenario) compared with €7.6m (iPrEX 
scenario). 
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Table 6.30. Highest and lowest efficacy scenarios 
  PROUD study (86% effectiveness) iPrEX study (44% effectiveness)  
Year Incremental cost  95% CI Lower 
95% CI 
Higher 
Incremental 
cost 
95% CI 
Lower 
95% CI 
Higher 
Year 1 €1.46 €0.51 €3.00 €1.56 €0.54 €3.16 
Year 2 €1.19 €0.44 €2.50 €1.59 €0.62 €3.16 
Year 3 €0.96 €0.22 €2.20 €1.56 €0.59 €3.15 
Year 4 €0.70 -€0.22 €2.04 €1.49 €0.44 €3.18 
Year 5 €0.40 -€0.78 €1.80 €1.38 €0.23 €3.24 
5-year total €4.72 €1.38 €10.34 €7.58 €2.97 €15.05 
All costs in millions 
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6.5.8 Years to budget neutrality 
As demonstrated in the cost-effectiveness analysis, PrEP was found to be cost saving 
over the modelled cohort’s lifetime. Budget impact analysis typically reports costs 
over a much shorter time period, however, which overcomes much of the 
uncertainties relating to future changes in epidemiological and cost parameters. 
However, if the budget impact model is continued beyond five years according to the 
methods previously described, the yearly incremental budget impact becomes 
negative (cost saving) by Year 8 (-€0.2m; 95% CI: -€2m to €1.7m). In terms of the 
aggregate budget impact, the ‘break even’ point is reached in Year 14 (all 
programme and medication costs will have been recuperated). It must be stressed, 
however, that changes in epidemiological parameters (such as changing patterns of 
migration) may significantly alter these findings. Table 6.31 provides the incremental 
budget impact and its probability of being budget neutral by year. 
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Table 6.31. Budget impact over 25 years and probability of cost saving 
Year Mean 95% CI 
lower 
95% CI 
upper 
Probability cost 
saving 
Aggregate BIA 
1 €1.5 €0.5 €3.0 0 €1.5 
2 €1.3 €0.5 €2.6 0 €2.8 
3 €1.1 €0.3 €2.4 0 €3.9 
4 €0.9 -€0.1 €2.3 0.03 €4.8 
5 €0.7 -€0.5 €2.2 0.14 €5.4 
6 €0.4 -€1.0 €2.1 0.29 €5.8 
7 €0.1 -€1.5 €1.9 0.45 €5.9 
8 -€0.2 -€2.1 €1.7 0.59 €5.7 
9 -€0.5 -€2.6 €1.5 0.71 €5.3 
10 -€0.8 -€3.2 €1.4 0.79 €4.5 
11 -€1.1 -€3.9 €1.2 0.85 €3.4 
12 -€1.4 -€4.5 €1.1 0.89 €2.1 
13 -€1.7 -€5.2 €0.9 0.92 €0.4 
14 -€2.0 -€5.9 €0.8 0.94 -€1.6 
15 -€2.3 -€6.6 €0.7 0.95 -€4.0 
16 -€2.7 -€7.4 €0.5 0.95 -€6.6 
17 -€3.0 -€8.1 €0.4 0.96 -€9.6 
18 -€3.3 -€8.9 €0.3 0.97 -€12.9 
19 -€3.6 -€9.7 €0.2 0.97 -€16.6 
20 -€4.0 -€10.4 €0.1 0.97 -€20.6 
21 -€4.3 -€11.2 -€0.0 0.98 -€24.9 
22 -€4.6 -€12.1 -€0.1 0.98 -€29.5 
23 -€5.0 -€12.9 -€0.2 0.98 -€34.5 
24 -€5.3 -€13.7 -€0.3 0.98 -€39.8 
25 -€5.6 -€14.5 -€0.5 0.98 -€45.4 
All costs in millions 
BIA – budget impact analysis; CI – confidence interval
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6.6  Discussion 
Discussion of main findings 
PrEP was found to be cost saving in the first cost-effectiveness and budget impact 
analysis of a targeted PrEP programme tailored to the Irish HIV epidemic. Modelling 
the entire HIV-negative MSM population of Ireland in 2018 over a lifetime horizon, a 
national PrEP programme is expected to provide significant health benefits associated 
with a substantial reduction in HIV incidence and lead to cost savings in as little as 
eight years.  
The movement of individuals between risk groups was tracked in an economic model 
and the time horizon (60 years) was adequate to capture all costs and consequences 
accrued over the cohort’s lifetime. The key strength of this analysis was its simplicity 
of design requiring relatively fewer assumptions, transparency and ease of 
interpretation for decision makers. Consistent with national HTA guidelines, a 
conservative approach was adopted that would bias against PrEP. The results are 
robust to considerable variations in the main assumptions and variation of parameter 
values within plausible ranges. The model  assumes adequate adherence and 
correspondingly high clinical effectiveness, as PrEP effectiveness was the main driver 
of cost-effectiveness in the model. The ICERs were also sensitive to the incidence of 
HIV in MSM at high risk of sexual acquisition. Nonetheless, the ICER did not exceed 
€5,000/QALY gained in any scenario investigated. ICERs were less sensitive to 
variations in key cost parameters, including the cost of HIV care and the cost of PrEP 
(PrEP remained cost saving over a range of plausible values).  
Despite the strength of the evidence, one of the residual concerns about the 
introduction of PrEP is risk compensation and the potential spread of other STIs and 
the cost of their treatment. Trial evidence to date has not demonstrated an increase 
in STIs while on PrEP. Observational data is typically subject to confounding, such as 
differences in the frequency of testing between pre- and post-PrEP time periods, so 
that limited conclusions can be made. One meta-analysis of 18 observational studies 
noted an increased odds of rectal chlamydia,(154) but not of any other pathogen or 
chlamydia at other anatomic sites. Conservatively, it was decided to incorporate this 
increase in rectal chlamydia cases in analyses. It was found to have a negligible 
impact on the cost-effectiveness of PrEP. In any case, the early detection and 
treatment of STIs minimises the consequences and onward transmission, and the 
cost of treatment is low due to the availability of low-cost generic antimicrobials 
relative to the cost of HIV treatment. Even if there is a substantial increase in STIs, it 
would be unlikely to impact the findings of cost effectiveness analysis. 
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It is important to note that the comparator used in the model is all HIV-negative 
MSM in 2018, followed for their lifetime, without access to a PrEP programme. The 
assumption here is that PrEP is not available, whereas in reality it is known that there 
are individuals who pay for PrEP out-of-pocket at pharmacies, and others who buy 
PrEP online in Ireland. Including these individuals in the comparator (‘No PrEP’ 
group) was not considered appropriate, as the HSE does not incur medication costs 
for these people. Due to the fact that the perspective is all direct costs to the public 
health and social care system (HSE), this comparison would bias the cost-
effectiveness analysis in favour of the ‘No PrEP’ group. In any case, there is little 
data on the actual number of individuals taking PrEP, and in the case of online 
ordering of PrEP, it is unknown if the eligibility criteria are met, ongoing monitoring is 
in place, and there is no data on adherence in this group.  
A number of other economic evaluations of PrEP have been conducted in other 
countries employing a range of economic models. Few investigated PrEP as part of a 
holistic programme, and fewer still assessed the budget impact of a national 
programme that would provide PrEP to all eligible individuals. Most prior studies 
modelled PrEP over a short time horizon, failing to capture the lifelong consequences 
of HIV infection. In general our findings are consistent with published studies that 
modelled generic priced PrEP and used HIV treatment cost estimates similar to those 
seen in Ireland, that is, that PrEP is cost-effective or cost-saving relative to usual 
care. Similar to other economic evaluations, ICERs were found to be to be highly 
sensitive to PrEP adherence-related effectiveness, incidence of HIV and costs of 
antiretroviral drugs. On the other hand, ICERs in this analysis were not very sensitive 
to the discount rate used, unlike other analyses.  
Scenario and sensitivity analyses 
Scenario and sensitivity analyses were used to explore the impact of different 
assumptions in the model, particularly in relation to parameter uncertainty. Scenario 
analyses facilitate the incorporation of an alternative set of assumptions to determine 
the impact on the estimated cost-effectiveness and budget impact. An important 
feature of scenario analyses is to consider whether the decision-maker has any 
control over the underlying assumption. For example, a decision-maker may be 
unable to influence the effectiveness of PrEP, but they may be in a position to 
negotiate a lower price and implement strategies that increase PrEP uptake and 
improve medication adherence. As such, some scenario analyses illustrate the impact 
a different set of assumptions has on decision-making, while others may give 
practical guidance on the scope to improve the cost-effectiveness. 
The effectiveness of PrEP was the main driver of cost-effectiveness and was varied 
extensively through sensitivity analysis. Effectiveness estimates were derived from a 
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systematic review of the international evidence (Chapter 4) and were considered 
applicable to Ireland. PrEP was found to be cost saving at all effectiveness values 
above 60%. At an effectiveness of 44%, the lowest recorded value in MSM where 
adherence was sub-optimal (the iPrEX trial), the ICER was €4,711/QALY. This ICER 
would still be considered highly cost-effective and is far below willingness to pay 
thresholds used for pharmaceuticals in Ireland (e.g., €45,000/QALY). 
From a health policy and decision-making perspective, the scenario where the PrEP 
regimen followed event-based dosing is of interest. Assuming event-based PrEP 
remains as effective as daily PrEP in future studies, the cost would reduce 
substantially if participants adopted this dosing schedule. If all participants took 
event-based PrEP, it is estimated that the ICER would decrease from -€2,735 to -
€6,258/QALY gained, that is, treatment would become even more cost saving 
relative to usual care. However, as PrEP is only licensed for daily use, event-based 
dosing cannot yet be recommended as first line treatment. 
The proportion of MSM eligible for PrEP and the uptake of PrEP in these individuals, 
and hence the size of the PrEP programme, are both crucial parameters and were 
subject to significant uncertainty. Two-way sensitivity analysis investigated both the 
cost-effectiveness and budgetary requirements across a range of these parameter 
values. Intuitively, PrEP is more cost saving as the size of the programme increases. 
Due to the lag between programme implementation and cost savings, however, 
promotion of PrEP and programme scale-up must be balanced with budgetary 
constraints. 
Limitations 
The present study was subject to a number of limitations. As with any economic 
modelling exercise, the applicability of the findings is dependent on the assumptions 
underpinning the model structure and on the quality of the parameter values used. 
Model structure 
As with all mathematical models, this discrete-time transition Markov model is a 
simplification of reality, whereby individuals are stratified by risk status and all 
individuals within a particular health state are assumed to behave the same. While 
movement between risk groups is permitted in the model, individuals in any 
particular health state are treated as a homogenous group regardless of prior risk 
status. Also, for the association between behavioural risk and incidence of HIV to be 
valid, the assumption must hold that PrEP eligible individuals are correctly identified, 
as PrEP use in medium/low risk individuals would reduce the effectiveness and cost-
effectiveness of the programme.  
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A limitation of the model’s design is that it does not incorporate dynamic 
transmission elements, which would allow the quantification of the benefit of PrEP on 
the wider HIV epidemic in Ireland, including the benefits for those not given PrEP. 
Therefore, there is an underestimation of the total benefit. Nevertheless, as only 2% 
of Irish MSM were given PrEP in this model, the likely indirect impact of the PrEP 
programme would be limited. Dynamic transmission models typically note that the 
indirect impact of PrEP is relatively modest. One analysis of Dutch MSM using a 
dynamic model showed only a 13 to 16% decrease in the ICER when indirect effects 
were included.(159) However, while the effects on ICERs are typically small, the 
indirect health benefits can be large if PrEP coverage over a long period is 
maintained. A UK dynamic transmission analysis noted that 58% of averted 
infections over 80 years following PrEP introduction would be due to the indirect 
prevention of onward transmission.(131) Overall, while the addition of a dynamic 
component to the model would enhance PrEP’s health benefits and cost savings 
through capturing the indirect effects of PrEP, it would introduce uncertainty and 
require simplifying assumptions that would reduce confidence in our findings. As with 
other assumptions in the model, and consistent with best practice, a conservative 
approach was adopted, biasing the results against PrEP, so that the model will have 
underestimated rather than overestimated the cost-effectiveness of PrEP 
A cohort model was adopted for the cost-effectiveness analysis, unlike the BIA, and 
fluctuations in population parameters such as the birth rate and migration were not 
accounted for. Certain model parameters could be significantly altered by migration. 
It was decided a priori not to model long-term migration patterns as they are highly 
unpredictable. The very significant uncertainty associated with changes relating to 
migration would, if included in the model, dwarf the uncertainty in relation to our 
knowledge of the existing situation. In other words, the model reflects the best 
estimate of what is known currently rather than what might be known in the future. 
If migration patterns were to result in a higher proportion of MSM eligible for PrEP, 
however, this would likely make PrEP even more cost saving, as evidenced by the 
sensitivity analysis in which the size of the programme was increased. However, an 
increase in the size of the programme would increase in the BIA in the short-term. 
Parameter uncertainty 
There was substantial uncertainty around a number of the key parameters used in 
the probabilistic sensitivity analyses. The parameters used in the model were derived 
from a wide variety of sources based on Irish and international data, and in 
situations where reliable data were lacking, calibration to observed data was 
necessary to produce plausible estimates.  
Draft: Health technology assessment of a PrEP programme for populations at substantial risk of sexual 
acquisition of HIV 
Health Information and Quality Authority 
Page 189 of 244 
A key limitation relating to epidemiological parameters used was the reliance on 
sources outside Ireland, such as HIV incidence data. While the HPSC accurately 
reports HIV notifications in Ireland, it is not possible to ascertain the overall 
incidence of HIV or the incidence of HIV by risk category. UK epidemiological data 
were extensively used,(130) due to broadly comparable HIV prevalence, completeness 
and accuracy of data collected (through electronic GUM clinic records) and 
similarities in risk stratification in both jurisdictions (for example, similar eligibility 
criteria for the provision of PrEP). 
In terms of quantifying the eligible population, it is not yet possible to estimate these 
parameters with any degree of certainty. A calibration approach was undertaken to 
retrieve plausible estimates for parameters relating to the eligible proportion and 
uptake. While sexual behaviour data has been gathered in convenience surveys, the 
extent to which they represent the overall MSM group in unknown. Provisional data 
from the European Men who have sex with men Internet Survey (EMIS) 2017, based 
on 2,083 Irish responses, reported a high proportion of MSM eligible for PrEP. While 
the estimates of the number of individuals eligible for PrEP do not alter the cost-
effectiveness conclusions, they affect the budget impact. Additionally, many factors 
will undoubtedly influence the eventual PrEP uptake rate in the eligible population. In 
the absence of reliable data on future uptake, published data from Scotland’s first 
year of their national PrEP programme were relied upon to guide our estimates. 
Uncertainty also exists relating to HIV care costs. A reduction in the cost of HIV-
related care would reduce the cost-effectiveness of PrEP. Future reductions in the 
cost of antiretroviral therapy may occur if additional generic medications enter the 
market, however this is impossible to predict. Also, in line with national guidelines, 
this evaluation did not incorporate any indirect costs relating to HIV care. Other 
evaluations have included indirect costs, particularly in relation to lost productivity 
due to HIV. In the Irish setting, a societal perspective would also entail including out-
of-pocket treatment costs that accrue to patients. If the societal cost of HIV were 
included, however, PrEP would only be considered more cost saving. 
Conclusion 
Taking into account the model assumptions and data uncertainty, our analysis has 
shown that the introduction of a publicly funded national PrEP programme would be 
cost saving over the medium to long-term and provide significant health benefits 
relative to current care, with a high likelihood of becoming budget neutral over a 
relatively short time period.   
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Future directions 
There are a number of questions that cost-effectiveness analysis cannot answer. If 
implementated, ongoing programme monitoring and evaluation should aim to answer 
the following questions: 
 how many enrolled in the programme, and how many started PrEP? 
 what proportion of PrEP users were new to STI services? 
 how many people interrupted or discontinued PrEP once started? 
 will was PrEP be taken up by those in whom PrEP is clinically recommended?  
 what was their level of adherence, and how was this be measured? 
 will did PrEP affect STI rates? 
The finding that PrEP is cost saving is in the context of the model assumptions that 
underpinned this analysis. Going forward, there are two model assumptions that 
must be borne in mind. First, it was assumed that PrEP will be taken by eligible 
participants. If access to a PrEP programme is provided to individuals at medium or 
low risk, the population-level effectiveness and resulting cost-effectiveness of the 
programme will decrease, possibly substantially. Regular clinical risk assessment to 
ensure only those at continuing substantial risk stay on PrEP is required to maintain 
cost-effectiveness and ensure equitable access based on clinical need. 
Second, the model assumed a HIV incidence based on clinical risk of HIV that was 
static over time, and that the PrEP programme would continue for the cohort’s 
lifetime. Once incidence declines sufficiently, PrEP may no longer be necessary and 
would be unlikely to be considered a cost-effective public health intervention. To 
maintain cost effectiveness, a practical way to pause PrEP initiation when the HIV 
incidence drops sufficiently should be explored. While HIV incidence is not monitored 
in Ireland, the HIV notification rate may serve as an acceptable proxy for secular 
trends in HIV transmission. While only a very modest uptake of PrEP was modelled in 
this analysis (2% of all MSM), a myriad of HIV prevention strategies are available 
and a combination approach may decrease or halt transmission in the medium to 
long term. For example, the recommendation that all newly infected individuals 
immediately start ART is underpinned by very strong evidence that viral suppression 
prevents onward HIV transmission. Major unforeseen changes occurring in HIV 
treatment or prevention will likely affect the presented results. 
On a final note, a range of scenarios were explored that highlight areas for potential 
cost savings. While not currently a licensed indication, event-based PrEP may be 
preferentially used to minimise costs and toxic effects, assuming that the 
effectiveness of daily versus event-based PrEP remains the same in future studies. 
Additionally, the finding that high PrEP uptake results in additional health benefits 
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and increases cost savings in the long run highlights the importance of promoting 
PrEP to eligible individuals, within current budgetary constraints. 
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7 Organisational issues  
Key Points  
 PrEP is available in at least 49 countries worldwide, with 12 countries providing 
PrEP through national programmes. 
 Scotland was the first country to publish data from a national PrEP programme. 
In the first year of the Scottish programme, which commenced in July 2017 and 
provides free access through sexual health clinics, 1,872 individuals were 
prescribed PrEP at least once of which 99% were gay, bisexual and other men 
who have sex with men (MSM). 
 In Ireland, there is no formal national PrEP programme. Access to components of 
the proposed programme is currently provided on an ad hoc basis through public 
sexually transmitted infection (STI) clinics and primary care providers. PrEP 
medications are paid for out of pocket and sourced through community 
pharmacies or online. 
 There are 23 public STI clinics in 16 counties in Ireland. The Gay Men’s Health 
Service (GMHS) is responsible for the majority of PrEP prescriptions and 
subsequent monitoring to date in Ireland. Current demand at GMHS exceeds the 
available capacity. 
 The primary barriers to introducing a PrEP programme are staffing and 
infrastructural issues. Staff shortages were cited by all 18 public STI clinics that 
responded to a PrEP preparedness survey. Many services also cited time 
limitations and a lack of clinical space. 
 A significant investment in STI services is required for a national PrEP programme 
to ensure a safe, sustainable and holistic service. STI services are needed to 
assess PrEP eligibility and to provide screening and ongoing monitoring. These 
are outlined in the national standards and monitoring framework. 
 PrEP medication could be dispensed through community pharmacies, hospital 
pharmacies or on-site at STI clinics. These options differ in the level of 
infrastructure investment required to support a PrEP programme and in the 
accessibility of the services, with the widest geographical access provided by 
community pharmacies. 
 Without investment in STI services, sub-optimal delivery of a PrEP programme 
could result in inequitable access to care and poor medication adherence and 
monitoring, as well as disruption of core STI clinic services and increased wait 
time for non-PrEP attendees. 
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7.1 Introduction 
This chapter outlines the expected organisational requirements of a PrEP programme 
in Ireland.  
A number of countries have initiated PrEP programmes, which are outlined in Section 
7.2. Details of pilot studies and regional and national PrEP programmes are 
presented in Section 7.3. These sections provide an insight into the acceptability and 
feasibility of PrEP in other countries and regions. In particular, uptake and retention 
rates provide valuable information for a prospective programme in Ireland, such as 
the number of individuals likely to enrol.  
Section 7.4 outlines current access to PrEP in Ireland, including existing access 
through sexually transmitted infection (STI) clinics. An overview of locations with 
potential capacity to provide PrEP is also provided.  
Information on current services was used to inform Section 7.5, which discusses 
specifications for a potential national programme. This section outlines organisational 
options for a PrEP programme that provides equitable access to a quality service, 
including PrEP medications. The potential impact of a PrEP programme on other STI 
services is discussed in Section 7.6. The requirements for an information and 
awareness campaign, should a decision be made to provide a national programme, 
are outlined in Section 7.7. 
7.2 International PrEP programmes 
PrEP is licensed in all EU/EEA member states by the European Commission (2016) 
and in the US by the FDA (2012).(160, 161) Many countries have offered PrEP through 
dedicated programmes, such as national programmes, or through initial 
demonstration projects, implementation projects and clinical trials. At the time of 
writing of this HTA, PrEP is available in at least 49 countries worldwide through one 
or more of these initiatives.  
Twelve countries provide PrEP through national programmes and, at the time of 
writing, four countries were planning to introduce national programmes (see Table 
7.1 and Figure 7.1). France became the first country in Europe to offer PrEP through 
its public health system in 2015. This was done through an ‘emergency 
recommendation for temporary use’, which became permanent in April 2017. Other 
European countries with national programmes in place include Belgium, Norway, 
Portugal and Scotland. Northern Ireland introduced a pilot PrEP clinic based in the 
Belfast Trust in August 2018. 
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Figure 7.1. Worldwide national PrEP programmes 
 
National programmes include ongoing or pilot programmes. Countries are: Belgium, Brazil, Canada, 
France, Kenya, Norway, New Zealand, Thailand, Portugal, Uganda, Scotland & Northern Ireland (UK), 
and USA  
Table 7.1. Countries with ongoing or planned national PrEP 
programmes  
Country Guideline or policy document 
Belgium HIV plan 2014–2019 Belgium(16) 
Botswana Planned 
Brazil Clinical Protocol and Therapeutic Guidelines for Management of HIV Infection 
in Adults (2018)(17)  
Canada Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational 
post-exposure prophylaxis(18) 
Guidance for the use of PrEP in British Columbia (2016)(19) 
France ANSM Pre-exposure Prophylaxis Guidelines (2017)(162) 
Kenya Framework for the Implementation of Pre-Exposure Prophylaxis of HIV In 
Kenya (2017)(21) 
New 
Zealand 
Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV 
pre-exposure prophylaxis: clinical guidelines(22) 
Northern 
Ireland 
Pilot clinic commenced August 2018 
Norway No guideline documents identified 
Portugal No guideline documents identified 
Scotland Scottish NHS Programme(127) 
Thailand Thailand National Guidelines on HIV/AIDS Treatment and Prevention 2017(24) 
Uganda National HIV AND AIDS Strategic Plan 2015/2016 - 2019/2020(25) 
Consolidated Guidelines for Prevention and Treatment of HIV in Uganda 
(2016)(26) 
USA National HIV/AIDS Strategy for the United States: Updated to 2020(163) 
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Wales Preparing for PrEP full report 2017(28) 
Vietnam No guideline documents available 
Scotland was the first country to publish data from a national PrEP programme. 
Results were based on data from the National Sexual Health System (NaSH) a 
dataset of all specialist sexual health services provided in genitourinary medicine 
(GUM) clinics in Scotland.(127) Free-of-charge access to PrEP was introduced by the 
NHS in Scotland in July 2017. In the first year of the programme, 1,872 individuals 
were prescribed PrEP at least once, of which 1,855 (99%) were gay, bisexual and 
other men who have sex with men (MSM). This represents 16% of the total MSM 
(n=11,472) that attended sexual health services for any reason during the analysed 
time period. In terms of eligibility, 78% of participants were eligible due to a history 
of condomless anal sex with two or more partners, 18% had a documented bacterial 
rectal STI in the previous 12 months and 2% had a partner who was HIV-positive 
with a detectable viral load. 
The majority of participants (74%) were prescribed a daily rather than event-based 
regimen. Over a quarter (28%; n=531) of those prescribed PrEP in the period 
analysed had not attended a GUM clinic in the two years before the PrEP programme 
became available. Furthermore, almost one fifth (19%; n=356) of those prescribed 
PrEP had no previous record on NaSH, indicating that these individuals had not 
attended any Scottish sexual health services since completion of the dataset’s roll out 
in 2011. 
7.3 PrEP programme performance 
The results of pilot studies and regional and national PrEP programmes provide 
valuable information regarding acceptance and feasibility of these programmes. This 
information includes uptake or retention rates which may be useful to inform the 
implementation and organisation of a prospective national PrEP programme in 
Ireland. 
To identify acceptability and feasibility studies for PrEP, a systematic search of the 
literature was conducted. The search was limited to studies published post 2010 
(prior to PrEP licensure in the EU and the US). A total of 1,171 study titles were 
screened and 38 potentially relevant studies were identified. After screening, nine 
studies were found to be relevant for inclusion. These nine studies were combined 
with the results of a grey literature search, which identified six additional studies 
(Figure 7.2).  
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Figure 7.2. Flow chart for studies included in review of PrEP programme 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The studies identified are presented in Table 7.2. Only four studies reported the 
dosing regimen used, with daily dosing the most common (range 57 to 100%). PrEP 
uptake varied from 55 to 90%. Analysis of retention rates, which ranged from 39% 
to 88%, was complicated by differences in the length of follow up between studies. 
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Table 7.2. Uptake, retention and dosing schedules in published PrEP 
pilot studies, and from regional and national programmes 
Country Participants Uptake Retention Dosing 
regimen 
Australia (PrELUDE)(164)  363 90% (n=327) 67% (n=243) Daily 
(88.5%) 
Australia (EPIC-NSW)(132)  3,700* N/R 76% 
(n=2,804) 
N/R 
Belgium(165) 1,385 N/R N/R Daily 
(57%) 
Brazil(166) 738 61% (n=450) 83% (n=375) N/R 
Canada(167) 86 60% (n=52) 88% (n=46) N/R 
France(168) 5,352 N/R N/R N/R 
 
 
United 
Kingdom 
England(169) 7,000+ N/R N/R N/R 
Scotland(127) 1,872 N/R N/R Daily 
(74%) 
Wales(170) 516 57% (n=296) 66% (n=203) Daily 
(100%) 
United 
States of 
America 
Atlanta(171) 367 55% (n=201) 39% (n=78) N/R 
Chicago(172) 197 N/R 67% (n=132) N/R 
Detroit(173) 34 N/R 50% (n=17) N/R 
Los Angeles(174) 1721 N/R 47% 
(n-809) 
N/R 
Rhode Island 
Mississippi 
St. Louis(175) 
267 N/R 60% (n=160) N/R 
San Francisco(176) 344 78% (n=268) 62% (n=213) N/R 
*Enrolment ended 31 October 2016, but recruitment continued during 12-month follow-up. Total 
participants 7,621 by October 2017.  
Differences in healthcare funding may limit the relevance of a number of these 
studies to the Irish healthcare setting. Access to PrEP in the US is influenced both by 
access to health insurance and coverage of PrEP by the insurer; these factors were 
noted to affect both PrEP uptake and retention rates.(177) A cost barrier was not an 
issue in other countries where PrEP is provided for free-of-charge or at a minimal 
cost (for example, Belgium where there is maximum charge of €11.90 for 30 
tablets).(165) The identified programmes that are most similar to the proposed PrEP 
programme in Ireland are those implemented in Scotland and Australia (New South 
Wales), both of which provide universal access to free HIV screening and testing 
through STI clinics along with the provision of PrEP medications free of charge. 
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7.4 Current service delivery 
In Ireland, there is currently no defined national PrEP programme through which HIV 
negative individuals can access PrEP services. As part of their existing service, a 
number of STI clinics provide free initial screening and subsequent monitoring to 
individuals who are attending for STI services or who present for the purpose of 
accessing PrEP medications.  
STI clinics do not dispense PrEP, rather individuals are provided with a prescription 
which can be redeemed in a community pharmacy. As with any other licensed 
medication, a prescription for PrEP can also be obtained from other registered 
medical doctors, including general practitioners (GPs). In primary care, unless the 
patient is a Medical Card or GP Visit Card holder, the patient is responsible for the 
cost of the appointment. If subsequent screening and monitoring is undertaken in a 
GP’s surgery, this would also be paid for by the patient. 
No medication indicated for use as PrEP is listed as a reimbursable item through the 
HSE Primary Care Reimbursement Service (PCRS). Therefore, PrEP cannot currently 
be dispensed through any of the existing PCRS schemes. Patients attending for PrEP 
through primary or secondary care present prescriptions to community pharmacies 
and pay for the medication privately. As noted in Chapter 2, there are also reports 
that patients are sourcing PrEP through online sites. 
In 2018, the HSE Sexual Health and Crisis Pregnancy Programme (SHCPP) published 
a report of the current STI and contraception services in Ireland.(178) The survey 
collated information about service provision by public and private STI clinics, non-
governmental organisations, private contraception services and student health 
clinics. While not specific to PrEP, this survey provides useful background information 
on the location, capacity and constraints of the current STI services in Ireland.  
Twenty three public STI clinics in 16 counties were identified (Figure 7.3). These 
clinics were based in hospital, community and primary-care settings. Details on the 
number of patients seen per week and the annual capacity are shown in Table 7.3. 
The survey responses suggest that a total of 80,000 patients are seen each year in 
public clinics through, on average, a total of 53 clinic sessions per week.   
Table 7.3. Access and service availability of public STI services, by 
county 
Clinic Number of 
clinic 
sessions/ 
week 
Estimated 
number of 
patients seen per 
clinic session 
Estimated 
annual 
capacity 
Are clinics 
cancelled due 
to annual 
leave? 
Carlow 0.5 18 465 Yes 
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Clare 1 14 728 No 
Cork A 5 50 13,000 No 
Cork B 2 20 2,080 No 
Donegal 1 20 1,039 Yes 
Dublin A 7 75 16,380 No 
Dublin B 4 62 12,896 No 
Dublin C 3 12 1,872 N/A 
Dublin D 3 16 2,496 No 
Galway A 1 8 415 Yes 
Galway B 5 30 7,800 No 
Kerry 0.5 20 520 No 
Laois 1 25 1,300 No 
Limerick 4 25 5,200 No 
Louth A 2 18 1,872 No 
Louth B 0.5 14 364 No 
Mayo 1 12 624 No 
Monaghan 1 16 832 No 
Sligo 2 25 2,596 Yes 
Tipperary A 0.5 17 440 Yes 
Tipperary B 1 10 517 Yes 
Waterford 6 19 5,916 Yes 
Westmeath 1 12 624 No 
Source: Extracted from: Sexual Health Services in Ireland: A Survey of STI and Contraception 
Services(178) 
Key: N/A = Not applicable. 
As noted, not all counties have a public STI clinic. Based on the survey results, the 
ten counties without public STI clinics are Cavan, Kildare, Kilkenny, Leitrim, Longford, 
Meath, Offaly, Roscommon, Wexford and Wicklow.  
These public STI services, which receive direct public funding, are provided at no 
cost to patients. Public STI services are not funded from a single budget; some 
receive funding from primary care, some from public health and some from the acute 
hospitals division. There are no validated national STI clinic data that capture the 
number of patients attending public STI clinics. 
A “Preparedness for PrEP” report is currently being undertaken by researchers at the 
Royal College of Surgeons in Ireland (RCSI).(179) The preliminary finding of the report 
is that all clinics identified issues with current staffing and or resources at STI clinics. 
These constraints impact service provision to varying degrees and potentially 
represent a major barrier to meeting the proposed national standards for a PrEP 
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programme.(180) Staff shortage was cited by all 18 clinics interviewed, with a 
particular focus on the shortage of specially qualified staff. There was feedback that 
positions had been advertised for a significant period of time with no applicants. 
Similar to that noted in the 2018 survey,(178) the inability of some clinics to find 
suitably qualified personnel led to temporary closure when a member of staff was on 
annual leave. The inability of recruit staff is a critical factor as it means that, even 
with an increase in funding, it may still be difficult to provide the necessary resources 
for a PrEP programme at certain clinics. 
Many services are limited due to the lack of availability of clinic space and time. The 
operation of some clinics is determined by the availability of rooms in outpatient 
departments. The survey highlighted that there are instances where there are 
sufficient staff to see additional patients but clinics are unable to do so due to a lack 
of space for consultations.  
Administrative constraints were identified as an issue for some clinics which operate 
without dedicated clerical cover. In those instances, the administrative work burden 
added to the workload of clinical staff. The introduction of a PrEP programme would 
increase administrative work, putting a strain on current resources and ultimately 
impacting on service provision. 
Clinics with limited resources had concerns about the additional clinical care that 
PrEP patients would require. They identified that the additional support and time 
required for PrEP patients would likely put a substantial strain on current resources, 
noting that  providing PrEP within a general STI clinic would have a detrimental 
impact on existing services. 
It is clear from the feedback from the clinics that in the event of a decision to 
provide a national PrEP programme, additional staffing and resources will be required 
to ensure that it is safe and sustainable. Adequate numbers of appropriately trained 
staff is critical not only in the initiation but also in the monitoring and surveillance of 
PrEP as outlined in the national standards and monitoring framework.(181) Staffing 
issues were not confined to clinical members of STI clinics, and increased funding 
may be required for clerical staff, particularly with the increased workload required 
for PrEP patients. 
There was a willingness of staff to provide PrEP, with all but three clinics responding 
to the RCSI survey that they would be ‘very willing’ to provide PrEP. Half of the 
clinics interviewed (9/18) also stated they would like more support from the HSE. 
This included topics such as training, policies and procedures, standardised 
databases, patient information leaflets, pro formas and patient survey templates. 
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The willingness of clinical staff to provide PrEP is substantiated by results of a cross-
sectional survey on the attitudes and practice among healthcare providers in HIV and 
STI care in Ireland.(182) This work was undertaken to inform the work of the HSE 
Sexual Health and Crisis Pregnancy Programme (SHCPP). There was a high 
awareness of PrEP (100%); 83% agreed, or strongly agreed, with a statement that 
PrEP should be available in Ireland to individuals at high risk for HIV with 91% noting 
that they were likely or very likely to recommend PrEP to individuals at high risk of 
HIV acquisition. However, there was a strong agreement (>90%) that PrEP should 
only be provided as part of an overall HIV prevention programme. Concern was also 
expressed that access to PrEP could cause patients to engage in riskier behaviours 
(approximately 60% agreement), contribute to ART resistance (approximately 35% 
agreement) and result in less funding for general health services (approximately 
35% agreement).  
As noted earlier, elements of the proposed PrEP programme are offered on an ad 
hoc basis in current STI clinics. Specifically, clinicians may discuss PrEP and provide 
screening and monitoring consistent with the requirements of the proposed 
programme for eligible patients that present at STI clinics (for example, those 
treated with post-exposure prophylaxis following sexual exposure [PEPSE]).  
Currently the majority of PrEP patients attending through public services are thought 
to access care through the Gay Men’s Health Service (GMHS) in Dublin. It runs a 
dedicated PrEP monitoring clinic  which operates every Thursday from 10am until 
noon.(183) The GMHS initially screens patients using a rapid HIV test (in addition to 
the gold standard fourth generation HIV test, which take up to five working days to 
report). Those meeting the eligibility criteria for PrEP and whose rapid test is 
negative are provided a prescription for three months of PrEP that they can redeem 
at a community pharmacy. 
7.5 National PrEP programme specifications and funding 
The HSE Sexual Health and Crisis Pregnancy Programme (SHCPP) has responsibility 
for implementing PrEP in Ireland. To inform its work, the SHCPP convened a 
multisectoral working group to develop recommendations in relation to the use of 
HIV PrEP in Ireland (the PrEP Working Group). This group, with community 
representation, developed clinical guidance documents and national standards in 
relation to the use of PrEP in Ireland. The standards represent best practice and 
outline the responsibilities of services, service managers, service providers and 
healthcare professionals, as well as establishing the expectations of service users. 
The standards are in line with the goals of the National Sexual Health Strategy 
regarding sexual health services, specifically ‘Equitable, accessible and high quality 
sexual health services, which are targeted and tailored to need’. The PrEP Working 
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Group has also developed a PrEP monitoring framework document that fulfills PrEP 
Standard 2.3: Surveillance, monitoring and evaluation. Further details of the national 
standards set out by the SHCPP are provided in Chapter 2. 
It is proposed that a national PrEP programme would be delivered at any site that 
has the expertise and capacity to deliver PrEP in line with the national standards. It is 
anticipated that, conditional on there being adequate resources, this would include 
delivery through established public STI services. Certain STI clinics, such as the Gay 
Men’s Health Service, have already introduced targeted services for PrEP users. The 
roll-out of PrEP services to other STI clinics should take into consideration the 
geographical need for PrEP and the capacity of these clinics to provide all essential 
components of the monitoring programme.   
From the budget impact analysis (Chapter 6, Section 6.5), an estimated 1,705 people 
(95% confidence interval [CI]: 617 to 3,452) may access PrEP in the first year of a 
national programme in Ireland. As indicated in Section 7.4, a proportion of these are 
already receiving care through STI services. In the first year of the PrEP monitoring 
clinic operating at the Gay Men’s Health Service, there were 950 attendances; 431 
were first visits and the remainder follow-up visits.  
As highlighted in Section 7.2, 28% of individuals prescribed PrEP in the first year of 
the Scottish NHS PrEP programme had not previously attended any public Scottish 
STI clinic in at least two years, while 19% had not attended in more than 10 years, 
and perhaps never before. The potential increase in numbers attending STI clinics in 
Ireland would need to be considered in the context of the results of the 2018 survey 
of current STI and contraception services in Ireland undertaken by SHCPP.(178) This 
suggests that, on average, approximately 80,000 patients are seen each year in 
public STI clinics. These public STI clinics are located in 16 counties and are reported 
to provide, on average, 53 public STI clinics each week (see Table 7.3). These clinics 
are noted to be already overstretched with constraints in staffing levels and 
resources noted to be the primary barriers to the implementation of a national PrEP 
programme (as outlined in Section 7.4). 
The results of Chapter 4 highlighted the strong correlation between adherence and 
efficacy. Any national PrEP programme must provide patients with levels of support 
and access to treatment that ensures an environment that promotes high adherence 
to PrEP. The implementation of a national programme would present a good 
opportunity to restructure how PrEP is currently provided.  
A possible solution to staff shortages, particularly in rural areas, would be to develop 
and use an integrative system based on a ‘hub-and-spoke’ model which would create 
collaboration with regional teams. In this approach, the initial eligibility assessment, 
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screening and testing would be provided by a designated hub, that is, a larger STI 
service or possibly a dedicated PrEP clinic. Once initiated, subsequent quarterly 
monitoring and screening would be provided by the patient’s local STI clinic. Such an 
approach could provide a patient-centred, efficient and sustainable means to improve 
access to PrEP. However, as with any integrated care model, clearly defined 
protocols would be required to facilitate seamless transitions and navigation for 
patients and providers and to ensure mutually understood and agreed-upon provider 
responsibilities. For example, prescriptions are legally valid for up to six months; 
however, given the requirement for quarterly screening and that patients have a 
documented negative HIV test before starting or continuing PrEP medications, 
consideration would need to be given to the logistical arrangements between the hub 
and any satellite screening clinic to minimise any disruption to care while also 
ensuring governance standards are maintained. 
Access to PrEP medication 
As noted in Section 7.4, no medication indicated for use as PrEP is currently listed as 
a reimbursable item through the PCRS. Therefore, PrEP cannot be dispensed through 
any of the existing PCRS schemes, rather patients are provided with private 
prescriptions for redemption at a community pharmacy and pay for PrEP out of 
pocket. 
A core tenet of the proposed national PrEP programme is that there would be 
equitable access to PrEP services, with PrEP medication provided free of charge. This 
would ensure consistency with current public health policy to limit onward 
transmission of infectious diseases. The Infectious Disease Regulations 1981 provide 
for the prevention, diagnosis and treatment of notifiable infectious diseases and 
removal of conditions which favour the spread of infection. The schedule of diseases 
to which the Regulations apply was amended in 2011 to include HIV. Regulation 
13(1)a states that the HSE ‘shall, if required by the Minister…purchase and keep a 
supply of such agents…as may be approved by the Minister for…increasing resistance 
or for producing immunity from infection with any infectious disease’. PrEP may meet 
these criteria on the basis of evidence from Chapter 4 that confirms it is safe and 
effective at preventing the acquisition of HIV by individuals at high risk of its sexual 
acquisition.  
Currently, treatment for a range of notifiable STIs, including HIV, is dispensed free-
of-charge to patients irrespective of their means at the point of care in hospital-
based HIV clinics and in selected STI clinics. Similarly, under the Infectious Disease 
Regulations 1981, all aspects of tuberculosis (TB) care, including medications, are 
provided free of charge. Depending on the region, TB medications are dispensed 
through satellite hospital pharmacies attached to specialist TB clinics on behalf of the 
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HSE or via community pharmacies with direct reimbursement of the pharmacy by the 
PCRS. This approach ensures timely access to medications. The National 
Immunisation Schedule also identifies vaccinations to prevent a range of infectious 
diseases which are provided free of charge to at-risk individuals in a range of primary 
and secondary care settings. 
Three potential mechanisms through which PrEP medications could be dispensed 
were identified: community pharmacies, hospital pharmacies and at STI clinics. 
These mechanisms are discussed briefly below. In all cases, it is assumed that all 
other requirements for screening and monitoring outlined in the national standards in 
the context of a holistic PrEP programme (Chapter 2.4.2) would be provided by the 
existing clinical services. The base case analysis in the economic evaluation assumed 
that PrEP would be made available free-of-charge to patients (that is, no co-pay or 
cost sharing) through community pharmacies. The method used to estimate the 
direct cost to the HSE of PrEP dispensed through community pharmacies is outlined 
in Section 6.2.3.1. Costs were varied by 20% to reflect any potential difference in 
cost to the State if the medication was dispensed instead through public hospitals or 
STI clinics. This reflects the additional staffing or extra workload affecting the 
efficiency of existing staff.  
Community pharmacy 
Dispensing through community pharmacy could be considered the optimal approach 
to facilitate timely local access to medications. The PCRS operates a number of 
schemes which allow patients access to listed medications either free of charge 
(Long Term Illness Scheme [LTI]), for a defined co-pay (Medical Card holders) or 
through cost-sharing mechanisms (Drugs Payment Scheme or High Tech Scheme). 
As HIV is not listed as one of the sixteen specified diseases or disabilities covered by 
the LTI scheme, the scheme is not relevant to this discussion. As noted in Section 
7.4, no medication indicated for use as PrEP is currently listed as a reimbursable item 
through the PCRS; therefore, in the first instance, approval would be required for 
their inclusion.  
As noted above, the 1947 Health Act provides for the diagnosis and treatment of 
infectious diseases, the prevention of infectious diseases, the prevention of the 
spread of infectious diseases and for removing conditions which favour the spread of 
infection. Under the Infectious Disease Regulations 1981, all related care and 
treatment of the condition is provided free of charge. The provision of PrEP to 
prevent the acquisition and onward spread of HIV could also be considered within 
the terms of the Regulations, although clarification of this may need to be sought by 
the Department of Health. 
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If PrEP medications are dispensed through community pharmacies, a mechanism 
would be required for integration and coordination of care with the clinical services, 
to support the requirements for quarterly screening and monitoring outlined in the 
proposed national standards for a PrEP programme. There is precedence of the PCRS 
restricting access to certain medications through online pre-authorisation systems. 
Individual patient reimbursement requests must be submitted for selected medicines, 
with the medication reimbursed subject to certain conditions being satisfied. These 
systems have included one-off initial approval for a medication and time-restricted 
approval. Consideration could be given, therefore, to linking individual patient 
reimbursement requests with quarterly monitoring appointments at PrEP clinics. 
Following review at the clinic, an approved prescriber could issue a prescription and 
at the same time submit an online request for three months of medications to be 
dispensed to eligible patients. 
Development and implementation of such a pre-authorisation system would incur 
one-off IT costs for the PCRS and would be conditional on the existing commitments 
of the PCRS ICT department in terms of scheduling any such work. Careful 
consideration of the design of the scheme would be required to minimise the 
administrative burden for prescribers and pharmacies and to ensure seamless care 
for patients. This would include consideration of the requirements and preparedness 
of the various stakeholders (including, for example, the acute services and approved 
prescribers within private or non-public health services) to engage with an electronic 
system. However, by capturing dispensing data (date and amount dispensed), use of 
such a scheme could provide a mechanism to audit national uptake and persistence 
on PrEP medications through an existing high-quality online transaction service. As 
noted, this mechanism has been used for other medications to manage access and 
reduce inappropriate prescribing.  
Irrespective of the reimbursement scheme used and or the potential use of an online 
pre-authorisation scheme by the PCRS, patients are not restricted in terms of the 
location of the pharmacy in which they choose to redeem their prescription and may, 
therefore, select the pharmacy of their choice based on convenience, desire for 
anonymity or personal preference. It is noted though, that for any medication to be 
reimbursed through the PCRS, a community identifier must be provided. That is, the 
patient must provide an assigned scheme number (for example, their General 
Medical Scheme, GP Visit Card or Drugs Payment Scheme number) or, in the 
absence of an assigned scheme number, their Personal Public Service Number is 
required.  
As noted in Chapter 2, there are a number of generic alternatives marked in Ireland 
in addition to the branded PrEP formulation. If a decision is made to list PrEP on the 
PCRS so that it can be dispensed by community pharmacies through a designated 
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PCRS scheme, there is potential for the HSE to achieve cost control and efficiencies 
through use of generic substitution and reference pricing. Products must first be 
designated as being interchangeable; if done at a national level, this assessment is 
the remit of the Health Products Regulatory Authority. Once designated as 
interchangeable, under the Health (Pricing and Supply of Medical Goods) Act 2013, 
the HSE can establish a reference price it will pay. The pharmacist can then offer a 
version of the medicine that is at or below the reference price. If the patient’s 
preference is for a specific brand rather avail of the generic or alternative version, 
they can pay the difference between the reference price and their preferred brand. 
Dispensing PrEP through community pharmacies would facilitate an efficient roll-out 
of the service for the HSE as, apart from the development of software for PCRS pre-
authorisation, substantial changes to infrastructure are not required. Finally, 
empowering patients to select where they collect their prescriptions affords 
individuals a convenient and flexible service which may promote improved adherence 
and remove barriers for accessing medication.  
Sexual health clinics 
Another potential mechanism to provide PrEP would be for STI clinics to store and 
dispense medication for patients on-site, in compliance with legal requirements and 
guidance for the storage and supply of medicines. This option would provide 
immediate access to medications to eligible patients, ensuring seamless care.  
Dispensing PrEP onsite at STI clinics would require significant infrastructural 
investment. The RCSI report highlighted issues STI clinics have in regard to both 
staffing and resources. Dispensing medication through STI clinics is dependent on 
clinics having the required storage space and facilities, including IT, to manage large 
quantities of medication. Many clinics do not have a dedicated space and use 
hospital outpatient rooms; therefore, this would not be an option at these locations. 
If a clinic does possess the clinic space for a storage facility, secure medication 
cupboards may need to be installed to ensure adherence with legal requirements for 
the storage of prescription medications. 
The recruitment of suitably qualified staff to manage and dispense medication may 
prove difficult for such a specialised role with irregular, limited or anti-social hours. If 
specialised staff were not hired to manage an onsite dispensary, additional 
administration and record keeping requirements would put a strain on current 
services and may compromise other services delivered at STI clinics.  
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Hospital pharmacy 
Some STI clinics are linked to hospital pharmacies, for example, St. James’s Hospital 
is linked to an onsite pharmacy through which medications to treat STIs and HIV are 
dispensed free of charge for patients attending its services. Medications are typically 
dispensed on the day the patient is seen at the clinic, ensuring immediate access to 
treatment. These pharmacies have staff with the necessary professional expertise 
required to dispense PrEP. In addition, hospital pharmacies have the infrastructure 
and record keeping procedures in place to ensure adherence to information 
governance standards. This option will have an opportunity cost in terms of the time 
demand on dispensary staff and pharmacists. Although a potential option through 
which PrEP could be dispensed, access would be limited to those patients attending 
hospital-based STI services with attached pharmacies. Given that there are only a 
few such hospital clinics, all in major urban areas (Dublin, Cork, Galway and 
Limerick), a PrEP service restricted to this option would provide a very limited 
national coverage.  
It was noted previously that given its electronic submission and reimbursement 
arrangements, the PCRS has a means to capture national-level data on medications 
dispensed through the schemes it operates. There is no such national equivalent for 
medications dispensed through hospital pharmacies; therefore, alternative means of 
collecting dispensing data would be required should this be considered necessary for 
audit purposes.   
7.6 STI rates and risk compensation 
In some jurisdictions, a rise in STI diagnoses has been noted following the 
introduction of a PrEP programme. This increase in STI notifications may be due to 
an actual increase in infections or simply an increase in STI detection (testing 
individuals who were previously not engaged in services or more frequent testing of 
individuals already engaged). While ‘risk compensation’ (an increase in risky sexual 
behaviour due to the knowledge of the protective effect of PrEP) has not been 
observed in clinical trials, this phenomenon cannot be excluded. 
The structure of the proposed PrEP programme is that everyone enrolled must be 
screened at three-monthly intervals. This includes testing for HIV and a range of 
other STIs, including chlamydia, gonorrhoea and syphilis. Best practice, per 
BASHH/BHIVA guidelines, is to test all individuals engaging in risky sexual behaviour 
every three months.(33) While this should represent current practice for high-risk 
individuals currently engaged with services, it is possible that not all of these would 
have attended four times a year; therefore, so there may be an increase in 
attendance and testing in those currently engaged with services. Additionally, based 
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on Scottish data, there is also evidence that some individuals not previously engaged 
with services will present for PrEP.(127) Overall, there will be a logistical burden 
associated with this additional testing. 
If risk compensation is suspected, this would have to be assessed in the context of 
underlying trends in STIs. There has been a significant rise in the notification rate of 
both gonorrhoea and chlamydia in Ireland (Figure 7.3).  
Figure 7.3. Trends in gonorrhoea and chlamydia notifications (rate per 
100,000)(156) 
 
Data specific to the MSM population show a steady rise in gonorrhoea (Figure 7.4). 
This increase is in part attributable to increased testing and improved detection in 
the last ten years. The impact of PrEP on risk compensation would, therefore, have 
to be considered within the current context of an increasing background incidence of 
STIs. 
Figure 7.4. Gonorrhoea notifications in MSM (HPSC)(156) 
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7.7 Information and awareness campaign to support PrEP 
rollout 
The success of a national PrEP programme relies on appropriately targeting 
individuals at sufficiently elevated risk. This requires a campaign to ensure individuals 
are aware of their potential eligibility and are well enough informed to attend a clinic. 
It also requires education of clinical staff both within the STI services and in other 
settings to ensure referral of patients (for example, patients presenting to the 
emergency department for PEPSE) that may meet the eligibility criteria for PrEP. 
The GMHS automatically offers PrEP to all prospective recipients (for example, those 
they treat with PEPSE). They also promote PrEP via posters and leaflets displayed in 
their clinic. Providing literature about PrEP at all STI clinics would help raise 
awareness nationally. The HSE have previously distributed leaflets for PrEP in 
Portuguese to remove the language barrier for Portuguese-speaking individuals in 
Ireland.  
A possible route of engaging high-risk MSM who have yet to engage in STI services 
in Ireland may be through liaising with advocacy groups who would further increase 
public knowledge of PrEP. Almost one in five individuals who enrolled in Scotland’s 
PrEP programme had not previously engaged in services. A partnership with 
advocacy groups could aid in the recruitment of these individuals with the 
dissemination of PrEP related material via less traditional means, such as through 
social media. 
Information to support other stakeholders involved in the provision of PrEP such as 
community pharmacies or those involved in the care of patients taking PrEP (GPs and 
community pharmacies) will be required to ensure that they have access to reliable 
information in relation to the components of the programme to facilitate high-quality 
care of these patients. 
7.8 Discussion 
The HSE SHCPP’s National Standards and Monitoring Framework provides the 
foundations and aims of a national PrEP programme. The standards focus on access, 
service configuration and structure, clinical assessment and management, managing 
results, information governance and public and patient engagement. The monitoring 
framework covers topics regarding outcomes and audit.  
The preliminary findings from RCSI’s survey ‘Preparedness for PrEP’ highlighted the 
key areas where current service provision is inadequate to support a PrEP 
programme and the resources required. The main barriers to the implementation of a 
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national PrEP programme were staff shortages and a lack of suitable training, clinic 
space and time. One of the biggest concerns among staff was the impact of 
increasing numbers of PrEP patients on current service provision. There was a widely 
held belief that once PrEP becomes subsidised the significant prohibitive barrier of 
cost to the patient would be removed and the numbers seeking PrEP would increase 
significantly. In addition to this, the increased awareness of PrEP could also drive an 
increase in patients seeking PrEP.  
Other countries have noted a rise in STI diagnoses following the introduction of PrEP 
programmes. This increase in STI notifications may be due to an actual increase in 
infections or simply an increase in STI detection (for example, testing individuals who 
were previously not engaged in services or more frequent testing of individuals 
already engaged). While ‘risk compensation’ (an increase in risky sexual behaviour 
due to the knowledge of the protective effect of PrEP) has not been observed in 
clinical trials, this phenomenon cannot be excluded. If risk compensation occurs, an 
increase in the transmission of STIs is likely. This reinforces the need for a holistic 
programme that includes safer sex counselling. The resources required to screen and 
treat these additional STIs will need to be considered in the context of an average of 
approximately 80,000 STI clinic visits currently provided each year in public STI 
clinics. 
There are a number of mechanisms through which PrEP medications could be 
provided to patients. To be consistent with the care and management of other 
infectious diseases and to prevent the acquisition and onward spread of HIV, it is 
proposed that PrEP medications provided through a PrEP programme would be 
provided free of charge. The mechanism of reimbursement of PrEP will depend on 
how patients will obtain the medication, either directly from clinicians at PrEP clinic 
appointments, from hospital pharmacies linked to PrEP clinics and or from 
community pharmacies. The feasibility of these alternatives will need to be explored 
within the context of the existing legislation. Ensuring that the system of dispensing 
PrEP is safe, sustainable and convenient for patients will promote an environment 
which supports good adherence. High adherence to PrEP was identified in Chapter 4 
as having a direct correlation to the effectiveness of PrEP in averting cases of HIV 
and is, therefore, crucial to the success of a PrEP programme.  
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8 Ethical and social issues 
Key points 
 PrEP is efficacious at preventing HIV acquisition and has a favourable safety 
profile. Due to the fact that PrEP is a prevention strategy typically used by healthy 
individuals, careful consideration of the risk/benefit profile is necessary. With 
careful selection of participants who are at substantial risk, however, the benefits 
of PrEP are thought to far outweigh the potential harms. 
 Of concern is the potential rise in sexually transmitted infections (STIs) (other 
than HIV) due to ‘risk compensation’ in PrEP users. This risk can be addressed 
within a holistic HIV prevention programme which incorporates frequent testing 
for other STIs and education of patients in relation to safer sex and adherence. 
 For some individuals, the benefits of PrEP extend beyond physical health to relief 
from the burden of fear of HIV infection and greater autonomy in relation to one’s 
sexual health. 
 Many of the individuals who stand to benefit most from PrEP are from vulnerable 
groups who have unique healthcare needs and are subject to stigma and 
discrimination. Stigmatisation of PrEP users may serve as a barrier to uptake in 
certain individuals.  
 Other barriers to PrEP uptake include a low perceived risk of contracting HIV, a 
lack of awareness of PrEP, reluctance to take medication and concerns about side 
effects and the opportunity cost and inconvenience of follow-up visits. A further 
barrier to the implementation of PrEP may be a lack of training of healthcare 
workers in relation to how to discuss sexual health with patients from sexual 
minority groups. 
 Information about PrEP needs to be available and accessible to individuals who 
are most at risk of sexual acquisition. Informed consent must be obtained prior to 
PrEP initiation and the administration of PrEP in paediatric patients in Ireland must 
comply with Children First: National Guidance for the Protection and Welfare of 
Children.  
 A recognition of the psychological dynamics of risk perception, sexual decision-
making and treatment adherence in education programmes is necessary to enable 
healthcare professionals to encourage patients to take charge of their sexual 
health. 
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8.1 Introduction 
Preceding chapters examined the epidemiology of HIV infection and established the 
clinical and cost-effectiveness of introducing a pre-exposure prophylaxis (PrEP) 
programme for populations at substantial risk of sexually acquired HIV in Ireland. 
The purpose of this chapter is to examine the ethical issues arising from the 
proposed implementation of a PrEP programme. The framework for the ethical 
analysis is based on the European Network of HTA (EUnetHTA) core model.(184) The 
following sections discuss PrEP in the context of:  
 Benefit—harm balance 
 autonomy and vulnerability 
 justice and access 
 professional values. 
8.2 Benefit—harm balance 
8.2.1  Burden of disease 
HIV infection raises significant concerns from a public health perspective. The overall 
goal of providing a PrEP programme, as part of a combination HIV prevention 
approach which includes HIV testing and post-exposure prophylaxis (PEP), is to halt 
the transmission of HIV. The eligibility criteria for PrEP and the essential components 
of a PrEP programme are summarised in Chapter 2. 
Infection with HIV results in significant morbidity (for example, reduction in health-
related quality of life(143)) and increased mortality,(141) even in resource-rich settings. 
The notification rate and prevalence of HIV in Ireland are discussed in detail in 
Chapter 3. In summary, there were 492 diagnoses of HIV notified in Ireland in 2017, 
representing a rate of 10.3 per 100,000 population. Just over half (53%) were 
among gay, bisexual and other men who have sex with men (MSM). The prevalence 
of HIV in Ireland is not known, but was estimated in 2017 to be 7,205 people. The 
notification rate has remained fairly stable in recent years (10.1 to 10.5 per 
100,000). It is, therefore, clear that the current range of HIV prevention strategies 
(promotion of barrier protection and safer sex, treatment-as-prevention [TaSP], post-
exposure prophylaxis [PEP] and prevention of mother-to-child transmission) is not 
sufficient to halt the transmission of HIV in Ireland. 
8.2.2  Benefits and harms for individuals 
Due to the fact that PrEP is a prevention strategy that is typically prescribed for 
healthy individuals, the benefit—harm balance must be considered carefully to 
ensure only those truly at risk of HIV obtain PrEP. Since the intervention, although 
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safe, is not risk-free, individuals who are not genuinely at risk may potentially be 
harmed by the intervention. 
In those at substantial risk, the evidence of efficacy is compelling. The systematic 
review and meta-analysis of efficacy and safety (Chapter 4) retrieved data from 15 
randomised controlled trials (RCTs) involving a total of 25,051 participants from four 
distinct patient populations. PrEP was found to be highly effective in preventing HIV 
acquisition when used appropriately. A meta-analysis of six studies investigating the 
efficacy of PrEP in MSM demonstrated a 75% reduction in the risk of acquiring HIV, 
rising to 86% when trial-level adherence exceeded 80%. PrEP was also found to be 
effective in preventing HIV acquisition in HIV-uninfected partners of serodifferent 
couples, with a risk reduction of 75%. In the small number of trials examining the 
efficacy of PrEP in preventing heterosexual transmission of HIV, adherence was poor, 
although PrEP was shown to be effective in participants who did adhere to 
treatment. A single study involving people who inject drugs found a 49% reduction in 
HIV acquisition. There is a clear link between PrEP efficacy and treatment adherence. 
PrEP was found to be safe: there was no statistically significant difference in ‘any’ 
adverse event, serious adverse event or death comparing PrEP with placebo across 
trials.  
Tenofovir/emtricitabine fixed dose oral combination is licensed across the EU for the 
prevention of sexually acquired HIV in adults and adolescents (see Chapter 2) and 
has a favourable safety profile. Similar to our systematic review of efficacy and safety 
(Chapter 4), another meta-analysis of 13 RCTs of combined tenofovir/embitricitabine 
published in 2018 found no evidence of an association between oral PrEP and an 
increased risk of serious adverse events.(185) The World Health Organization 
estimates that roughly 10% of people taking PrEP will have mild, short-term side 
effects, including headaches, dizziness and gastrointestinal problems, but these 
usually last only a few days and are almost always resolved within a month.(186) 
Some studies have shown a slight decrease in bone mineral density in the spine and 
hip in individuals taking PrEP in the first six months, but this is reversed after 
discontinuing PrEP. PrEP may be contraindicated in a very small number of people 
who have kidney problems. Serum creatinine levels will be elevated in approximately 
one in every 200 PrEP users; however, this will either be transient or will resolve 
after discontinuing PrEP.  
8.2.3  Benefits and harms for others and for society in general 
While early discussions of PrEP focused on clinical efficacy, safety and cost-
effectiveness, increasing attention is now being devoted to ‘normative’ issues such as 
users’ attitudes towards condom use, freedom from the fear of acquiring HIV and the 
need to strike a balance between preventing HIV infection and avoiding a rise in 
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other sexually-transmitted diseases.(187) More recently, concerns have been raised 
about a potential increase in risk compensation behaviours among people taking 
PrEP, particularly among MSM. Risk compensation behaviours may negate or 
undermine the efficacy of the PrEP programme.(188) Some fear that PrEP use will 
result in a reversal of the success of other HIV prevention strategies at a population 
level.(189) Since PrEP only prevents HIV infection, a decline in condom use may lead 
to an increase in other STIs or an increase in HIV transmission when PrEP is used 
incorrectly.  
Underlying secular trends in STI diagnoses must also be taken into consideration 
when determining changes in STI rates associated with PrEP use, and a longer run of 
data pre- and post-implementation of a PrEP programme may be required to 
determine if there is a true effect. Additionally, it must be noted that an increase in 
STI diagnoses may simply reflect increased testing as opposed to an actual increase 
in infections.  
The systematic review of efficacy (Chapter 4) concurs with other recent systematic 
reviews of PrEP trials and demonstration projects that found no conclusive evidence 
of an increase in risk compensation behaviours, that is, no significant change in 
condom use and no reported increase in sexual partners, among PrEP users 
compared with non-PrEP users.(190, 191) However, many of these early studies were 
randomised controlled trials and participants were unaware whether they were 
receiving PrEP or a placebo, resulting in continued perception of susceptibility to 
infection.(188) Additionally, data from clinical trials may not be entirely representative 
of behaviours among the wider population since recruited participants are generally 
motivated and health-conscious and often receive counselling or other supportive 
behavioural interventions during the course of participation.   
One systematic review and meta-analysis of 17 observational studies published in 
2018 found an increase in rectal chlamydia in PrEP users but no significant increase 
in gonorrhea or syphilis.(154) Additionally, chlamydia diagnoses did not increase at 
other anatomic sites (urethral/pharyngeal). It is notable that the primary study that 
reported the largest rise in chlamydia diagnoses in the meta-analysis did not 
compare pre- and post-PrEP periods but rather increases in the year following PrEP 
implementation. 
An increase in risky behavior was reported in behavioural surveillance studies carried 
out between 2013 and 2017 in Melbourne and Sydney and involving 16,827 
participants.(188) A large increase in PrEP use occurred during this period, 
accompanied by an increase in MSM reporting condomless sex with casual partners. 
Although increased use of PrEP coincided with large annual reductions in new HIV 
diagnoses in these jurisdictions, the long-term effect of an increase in PrEP use and a 
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decrease in condom use on the rate of new HIV diagnoses remains unknown. 
Although there has been a gradual decline in consistent condom use by gay and 
bisexual men in high-income countries in the last 15 years, commentators have 
found the rapid reduction in condom use reported in Sydney and Melbourne between 
2016 and 2017 notable.    
These data may indicate that the availability of PrEP may have an impact on 
community norms and behaviours, leading to ‘community-level risk 
compensation’.(188) As PrEP use increases, non-PrEP users may perceive condomless 
sex as less risky because they assume that their partner is using PrEP. A further 
concern is that individuals may no longer feel that open discussion of their HIV status 
is necessary if their partner is taking PrEP.(192) The increased prevalence of STIs 
detected in more recent studies suggest increased trust in the HIV-protective effect 
of PrEP, potentially leading to situations in which PrEP will in time become 
‘normalised’ for HIV prevention.(154)   
While it is likely that the high degree of protection provided by PrEP when taken 
appropriately will outweigh the increased risk of acquiring HIV as a result of an 
increase in risk taking, further data is needed about the actual real-world behaviours 
of PrEP users.(193) Discussions of risk compensation need to take into account users’ 
understandings of sexual risk taking and community-level changes in behaviour. It is 
possible that the introduction of PrEP in settings in which condom use is high might 
result in a decline in levels of condom use and increased rates of sexually transmitted 
infections, with an attendant additional burden on sexual health services.(188) 
However, it should be noted that an increase in STIs predated the introduction of 
PrEP(194) and risk compensation may be most pronounced among MSM who already 
engage in high-risk behaviours which place them at risk of HIV infection.(154)  
Further research is needed to examine patterns of sexual behaviour change among 
PrEP users outside of trial settings; however, policy makers should be aware that risk 
compensation fears may reinforce opposition to PrEP, thereby preventing those who 
stand to benefit from PrEP from accessing it.(193) Such fears need to be balanced 
against the significant preventative effect of PrEP and the long-term impact of 
greater PrEP coverage.(154) Risk may be further contextualised by acknowledging that 
individuals who acquire HIV infection require lifelong antiretroviral treatment and 
may suffer significant HIV-related morbidity and mortality.(141, 143) 
A final concern raised in relation to PrEP use is the possibility of medication 
resistance. A meta-analysis of five RCTs (Chapter 4) noted a significantly increased 
risk of resistance mutations developing to PrEP in patients randomised to receive 
PrEP who had acute HIV at enrolment. In most of these cases, the resistance was to 
emtricitabine. This highlights the importance of a robust screening process in 
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determining HIV status, the value of monitoring, and the need for counselling in 
relation to the association between resistance and poor adherence to PrEP. However, 
provided that PrEP is not administered to persons with an undiagnosed HIV infection, 
the potential of PrEP to prevent HIV infection ‘far exceeds the risk of resistance that 
could occur with its use’.(195) Fear of resistance should not impede the 
implementation of PrEP as a strategy to prevent HIV infection. However, PrEP 
implementation strategies should be carefully designed and should incorporate 
education and counselling for individuals considered to be at substantial risk of 
sexually acquiring HIV, not only to inform them fully of the benefits and risks 
associated with PrEP (including the potential for risk compensation behaviours) but 
also to empower them to take charge of their sexual health. 
8.3 Autonomy and vulnerability 
Many of the individuals who stand to benefit most from PrEP in terms of reduced risk 
of HIV transmission are gay, bisexual and other men who have sex with men and 
transgender women. Both of these groups are vulnerable because both groups 
experience stigma and discrimination based, respectively, on sexual orientation  and 
gender identity. While research involving transgender women is limited, some studies 
have drawn attention to stigma as a potential barrier to PrEP implementation among 
MSM. Stigma is a social process  in which particular behaviours or attitudes are 
‘devalued, treated with contempt by others or used to create a social distinction’.(196) 
The ‘societal and structural stigma’(192) which surrounds non-normative sexual 
practices can limit access to both healthcare and prevention strategies.(197)  
HIV has been stigmatised for decades, in part because of its associations with sex 
work, homosexuality, promiscuity and drug misuse, and in part due to the features of 
the disease itself.(197) Within the gay community itself, shaming and stigma are built 
on associations between PrEP use and high-risk sexual activity. Stereotypes of PrEP 
users as promiscuous, insufficiently responsible to use condoms or as concealing a 
diagnosis of HIV have been reported as deterrents to PrEP uptake.(198, 199) The 
infamous phrase ‘Truvada whores’ was coined in a Huffington Post article from 2012 
to refer to what its author referred to as “gay men who prefer to engage in unsafe 
sexual practices”.(200) Early PrEP users in a recent Canadian study associated stigma 
with both condomless sex and with sex with a person living with HIV.(192) Fear of 
rejection and stigmatisation based on negative associations between PrEP use, 
perceived promiscuity and sexual risk taking may reduce the motivation of potential 
PrEP users to seek PrEP or to continue using it, thereby serving as a barrier to access 
for those who stand to benefit most from it.(193) Stigmatisation of marginalised at-risk 
groups at a societal level may also undermine the political will to make PrEP available 
to these populations.(185) It is important to ensure that sex-negative messaging does 
not ‘cloud the judgement’ of policy-makers, healthcare professionals or potential PrEP 
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users, resulting in limited access and reduced uptake.(193)    
PrEP is not merely a pharmacological intervention, but should be viewed in 
biopsychosocial terms: social, psychological, cultural, and structural factors all 
contribute to the success or failure of the intervention.(197) Whether or not PrEP is 
seen as effective, socially acceptable or a viable tool for reducing risk of HIV infection 
depends on an understanding of the interaction between these factors. In pluralist 
societies, perceptions of risk and benefit are relative. Phenomena such as HIV 
infection or other STIs may be perceived as posing greater or lesser risk because 
one’s ‘perceptions of actions, events and phenomena are embedded in local ways of 
thinking, social conventions and practices’.(189) Individuals prioritise risk differently, 
and people will take more risks only in situations in which they have the opportunity 
to do so and perceive value in increased risk taking.(193) While some MSM adopt a 
‘moralising attitude’ towards condom use and prevention practices, others regard 
fluid exchange and condomless sex as more intimate, fulfilling and pleasurable.(198) 
For many, the benefits of PrEP extend beyond physical health to relief from the 
burden of fear of HIV infection, greater autonomy in relation to one’s sexual health 
and increased sexual pleasure.(192, 193) 
A PrEP programme incorporates antiretroviral medication and other prevention 
methods, including education about safer sex practices, risk reduction counselling 
and regular screening for HIV and other STIs, with recommended follow-up visits 
every three months (see Chapter 2). Offering PrEP to persons identified as at 
substantial risk provides an opportunity for these individuals to access sexual 
healthcare, testing, treatment and counselling which they may not have accessed 
otherwise.(190) Because there is no evidence that PrEP itself or behaviour changes 
related to PrEP use result in a significant public health harm,(194) unwillingness to 
offer PrEP to people who engage in condomless sex may be viewed as running 
counter to the goals of public health. To penalise patients for making choices based 
on their values and specific life circumstances in the interests of benefitting the 
broader population undermines patient autonomy and conflicts with the professional 
obligation of clinicians to act in the best interest of their patients.(194) 
8.4 Justice and access 
In addition to stigma, other barriers to PrEP uptake among MSM include a low 
perceived risk of contracting HIV, a lack of awareness of PrEP, reluctance to take 
medication and concerns about side effects, the cost and inconvenience of follow-up 
visits and the need for HIV testing prior to receiving a new prescription.(198) The lack 
of training of healthcare professionals in relation to how to discuss sexual health with 
patients from sexual minority groups may be a further barrier to the implementation 
of PrEP. In a survey commissioned by the Kaiser Family Foundation in 2014, of the 7 
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in 10 MSM in the US who had a regular GP, 61% reported that they rarely or never 
discussed HIV with their doctor and 56% reported that their doctor had never 
recommended a HIV test.(201) Only one third of respondents were aware that HIV 
infections were on the rise.(201) Almost half of respondents admitted that they had 
never discussed their sexual orientation with a doctor. Similarly, participants in a 
recent Canadian survey reported feelings of discomfort related to discussing PrEP, 
gay sexuality or sexual risk with doctors.(192) Lack of communication between patient 
and doctor may, therefore, be a barrier to both HIV testing and effective prescribing 
of PrEP.   
8.5 Professional values  
Given the significant burden of HIV in Ireland, information about PrEP needs to be 
available and accessible to individuals who are most at risk of sexual acquisition, 
including those from other jurisdictions whose first language is not English. In 2017, 
a PrEP information leaflet has been published in Portuguese by the HSE.(202)   
While there is international evidence that awareness of and access to PrEP are 
currently limited among members of socially marginalised groups and reluctance to 
promote PrEP to members of these groups may in part be value-driven,(194) there is 
no evidence for a reluctance to promote PrEP in marginalised groups in Ireland. In 
terms of HIV testing, inequalities were noted in Ireland in the MSM Internet Survey 
Ireland 2015 survey: untested men were more likely to be aged 18–24 years, live 
outside Dublin, have a lower level of education, be born in Ireland, identify as 
bisexual, be out to fewer people and not have had sex with a man in the previous 12 
months.(203) If the levels of engagement with services for  PrEP is similar to that of 
HIV testing, it may be the case that young, Irish-born MSM outside Dublin will be an 
under-served group. 
Primary care providers have an important role to play in promoting access to and 
uptake of PrEP.(197) Clinicians need to be knowledgeable about PrEP as a tool for 
preventing sexually-transmitted HIV infection and be able to identify individuals who 
would be likely to benefit from it.  
It is crucial that healthcare professionals obtain informed consent from prospective 
users prior to PrEP initiation. Informed consent is the authorisation of an intervention 
or the agreement to receive a service, following a process of communication about 
the proposed intervention or service. For consent to be valid, the service user must 
have decision-making capacity, must have received sufficient information about the 
nature, purpose, risks and benefits associated with the intervention/ service, must 
have understood the information provided and must have voluntarily agreed to 
receive the intervention or service.(204) 
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Since PrEP is licensed for adolescent use from the age of 13 upwards, special 
consideration should be given to the question of the treatment of minors, particularly 
in relation to issues of consent and assent.  When a child is under 16, a parent or 
legal guardian is required to provide consent to treatment (excluding treatment for 
mental illness). However, the capacity of minors to participate in healthcare decision-
making develops as they grow older and they should be involved in decision-making 
to the fullest extent possible.(205)  In exceptional cases, a minor may wish to make a 
decision without the consent of a parent or guardian and in such situations 
healthcare providers may decide to provide the intervention without the knowledge 
of parents or guardians, depending on a number of factors, such as the level of 
maturity of the child, the stability of his or her values, his or her best interests and 
other considerations relating to his or her welfare.(206) 
In Ireland, the principle that the welfare of the child is paramount informs the 
constitution and is reflected in a number of statutory instruments.  Under the 
Children First Act (2015),(207) if any mandated health professional believes that a 
child is at risk of harm or has a concern about a child’s welfare they must make a 
report to Tusla, the Child and Family Agency, in accordance with the National 
Guidance for the Protection and Welfare of Children (2017).(208) 
The effectiveness of PrEP at both individual and public health levels is contingent 
upon adherence, and adherence may be compromised in situations where PrEP users 
feel the need to conceal their PrEP use.(197) Clinicians have a responsibility to educate 
potential candidates for PrEP about the importance of taking the medication 
appropriately. While healthcare professionals may perceive prescribing PrEP as 
enabling sexual disinhibition and increased risk taking, their obligations are ‘to their 
patients’ health, not to their own sexual morality’.(209) Although public health 
concerns about an increase in sexual risk taking and the rising prevalence of STIs are 
legitimate, these may be offset by the recognition that limiting access to PrEP could 
prevent a net reduction in HIV risk even in individuals who increase sexual risk 
taking.(193) An understanding of the stigma experienced by MSM and members of 
other sexual minority groups should inform a sensitive approach to communication 
relating to sexual practices and risky behaviours. Healthcare providers should provide 
patients with comprehensive information relating to the relative effectiveness of PrEP 
and condoms so that they can make conscious and informed decisions about their 
sexual health based on their own evaluation of harms and benefits.(194) 
Education programmes which integrate epidemiological evidence with a recognition 
of the ‘psychological dynamics of risk perception, sexual decision-making, and 
treatment adherence’ are necessary to enable healthcare professionals to engage 
patients in taking charge of their sexual health.(210)  Important factors to take into 
account in designing and implementing these programmes include cultural 
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perspectives, socioeconomic diversity among individuals at risk and experienced 
health disparities among members of sexual minority communities.(210) 
8.6 Discussion 
As with any new technology, there are many ethical issues to consider prior to the 
implementation of a PrEP programme.  
Based on RCT and observational data, the benefits of PrEP to reduce sexual 
acquisition of HIV in populations at substantial risk are thought to far outweigh the 
potential harms when participants are correctly identified. However, as this is a 
prevention tool for uninfected and typically healthy individuals, the benefit/harm 
considerations are slightly different. Without careful screening of eligible participants, 
certain individuals will only suffer the harms of PrEP without gaining a benefit.  
Of concern to clinicians and public health professionals is the potential rise in STIs 
(other than HIV) due to risk compensation (increases in risky behaviours such as 
condomless sex based on a decreased perception of the likelihood of acquiring HIV) 
in PrEP users. Risk compensation behaviours may have an impact on the efficacy of 
PrEP and may lead to a rise in other STIs due to the fact that PrEP offers no 
protection to STIs other than HIV. Although the trial evidence to date (Chapter 4) 
does not suggest PrEP induces risk compensation; however, observational studies 
have suggested otherwise. Also of concern is the development of resistance 
mutations in individuals who start PrEP with unrecognised HIV infection at baseline 
or in those who acquire HIV while not properly adherent to PrEP. The risks of 
increasing STI rates and drug resistant mutations can be mitigated by careful 
screening for HIV at baseline and follow-up, frequent testing for other STIs and 
advice on safer sex.  
Many of the individuals who stand to benefit most from PrEP are from vulnerable 
groups who have unique healthcare needs and are subject to stigma and 
discrimination. Stigmatisation of PrEP users may serve as a barrier to uptake in 
certain individuals. Other barriers to PrEP uptake include a low perceived risk of 
contracting HIV, a lack of awareness of PrEP, reluctance to take medication and 
concerns about side effects and the opportunity cost and inconvenience of follow-up 
visits. 
A further barrier to the implementation of PrEP may be a lack of training of 
healthcare workers in relation to how to discuss sexual health with patients from 
sexual minority groups. A recognition of the psychological dynamics of risk 
perception, sexual decision-making and treatment adherence in education 
programmes are necessary to enable healthcare professionals to engage patients in 
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taking charge of their sexual health. Important factors to take into account in 
designing and implementing these programmes include cultural perspectives, 
socioeconomic diversity among individuals at risk and experienced health disparities 
among members of sexual minority communities. Finally, information about PrEP 
needs to be available and accessible to individuals who are most at risk of sexual 
acquisition, including those from other jurisdictions whose first language is not 
English. 
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9 Summary and conclusions 
9.1 Key findings 
9.1.1 Description of technology 
Pre-exposure prophylaxis (PrEP) is a biomedical HIV prevention strategy that uses 
antiretroviral medications to protect HIV-negative people from acquiring HIV. Once-
daily oral tenofovir/emtricitabine, as a fixed dose combination tablet, has been 
licensed and available for use as PrEP in Ireland since 2016. Clinical guidance 
documents and national standards for PrEP use in Ireland were subsequently 
developed. These recommend that PrEP medications should be provided as part of a 
holistic programme that includes frequent monitoring for adherence and side effects, 
testing for HIV and other sexually transmitted infections (STIs), and counselling and 
advice on safer sex practices. 
In this assessment, all populations who are at substantial risk of sexual acquisition of 
HIV and, therefore, eligible for PrEP are considered. In the cost-effectiveness 
analysis, the modelled cohort comprises only MSM due to the fact that this group is 
expected to make up more than 95% of programme participants and due to the lack 
of data on other groups. In the budget impact analysis, the size of the cohort is 
increased by 5% to account for non-MSM participants. 
9.1.2 Epidemiology 
HIV infection remains a significant public health threat in Ireland. HIV is a notifiable 
disease and all new diagnoses notified in Ireland are reported nationally by the 
Health Protection Surveillance Centre (HPSC). There were 492 diagnoses of HIV 
notified in 2017, representing a rate of 10.3 per 100,000 population. Following a 
large increase between 2014 and 2015, the HIV notification rate remained relatively 
stable between 2015 and 2017. A change in the case definition used by the HPSC 
(whereby confirmatory HIV testing required only one sample as opposed to two) and 
a rise in HIV testing may partly explain the increase in 2014 and 2015. Gay, bisexual 
and other men who have sex with men (MSM) are disproportionately affected: just 
over half of diagnoses in 2017 were in this group. 
Migration plays an important role in the changing epidemiology of HIV in Ireland. 
Overall, 63% of the notifications to the HPSC in 2017 were for individuals born 
outside Ireland (compared with 26% born in Ireland and 11% with an unknown 
country of birth). In the MSM group, 61% of the notifications received in 2017 were 
for individuals born outside Ireland, with the highest number from Latin America. 
Additionally, there has been an increase in the proportion of notifications in people 
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who were previously diagnosed HIV positive abroad: in 2017, these comprised 39% 
of all notifications. A majority of these had transferred their care to Ireland (88%). 
The proportion of MSM previously diagnosed HIV positive before arrival in Ireland 
has increased from 16% of cases in 2012 to 42% in 2017. Of those previously 
diagnosed HIV positive abroad in 2017, 91% were transferring their care to Ireland. 
Significant work was undertaken in 2018 to estimate the prevalence of HIV in 
Ireland, which included modelling undertaken by UNAIDS (in collaboration with the 
HPSC and HSE’s Sexual Health and Crisis Pregnancy Programme) and a 
comprehensive national treatment audit. In summary, 7,205 (95% confidence 
interval [CI]: 6,456 to 8,056) people are estimated to be living with HIV in Ireland; 
87.1% of whom are aware of their HIV status and 83.3% have initiated ART 
(UNAIDS 2018 data). Of these, 95.4% are virally suppressed (2018 treatment audit). 
UNAIDS has set a target of 90% for each of these three measures. While not 
achieving this target for the first two goals, Ireland compares favourably to the WHO 
Europe region as a whole.  
9.1.3 Clinical effectiveness and safety 
A systematic review undertaken to assess the clinical effectiveness and safety of oral 
PrEP retrieved 15 randomised controlled trials (RCTs) that compared PrEP with 
placebo, delayed PrEP or another PrEP medication or dosing schedule. Four distinct 
patient populations were assessed: six RCTs enrolled MSM, five enrolled heterosexual 
participants, three enrolled serodifferent couples and one enrolled people who inject 
drugs. Included studies involved 25,051 participants encompassing 38,289 person-
years of follow-up data. Of the 15,062 participants that received active drug in the 
intervention arms of trials, 8,239 (55%) received combination tenofovir/emtricitabine 
fixed dose combination and 6,823 (45%) received single agent tenofovir.  
PrEP was found to be highly effective in preventing HIV acquisition in MSM with a 
risk reduction of 75% across all trials (RR 0.25, 95% CI: 0.1 to 0.61). In trials with 
adherence above 80%, risk was reduced by 86% (RR 0.14, 95% CI: 0.06 to 0.35). 
Included in this analysis was one trial that investigated event-based dosing (also 
known as ‘on demand’ dosing; here, PrEP is taken during high-risk periods as 
opposed to daily use). Risk was reduced by 86% in this trial.  
PrEP was also found to be effective in preventing HIV acquisition in HIV-uninfected 
partners of serodifferent couples, with a risk reduction of 75% (RR 0.25, 95% CI: 
0.14 to 0.46). Evidence for effectiveness was not demonstrated in a meta-analysis of 
all trials that enrolled heterosexuals, likely due to poor adherence. Evidence of effect 
was found, however, in one trial where adherence was more than 80% (RR 0.39, 
95% CI 0.18 to 0.83).  
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PrEP was found to be effective in preventing HIV transmission in people who inject 
drugs in the only trial retrieved that enrolled drug users, which was conducted in 
Bangkok. Risk was reduced by 49% (RR 0.51, 95% CI: 0.29 to 0.92). This trial may 
not be directly applicable to the Irish context due demographic differences and the 
high prevalence of HIV in people who inject drugs in Thailand. Additionally, it is 
difficult to separate the impact of PrEP on parenteral HIV transmission from sexual 
transmission in people who inject with drugs, and the authors of the study 
acknowledge that, although the study was designed to measure the impact on 
parenteral transmission, participants may have become infected sexually. 
Overall, the RCTs were judged to have a low risk of bias. Adherence varied greatly 
across studies. Plasma drug monitoring was considered the most objective 
measurement for adherence assessment; adherence by this measurement ranged 
from 25% to 88%. Trial-level adherence greater than 80% was selected a priori as 
‘high’ adherence for the purpose of analyses. A meta-regression found that efficacy 
was strongly associated with trial-level adherence (p<0.001). On average, an 
increase in adherence of 10% increased efficacy by 13%. 
PrEP was found to be safe. PrEP did not increase the risk of ‘any’ adverse event (RR 
1.01, 95% CI: 0.99 to 1.03), serious adverse events (RR 0.91, 95% CI 0.74 to 1.13) 
or death (RR 0.83, 95% CI: 0.6 to 1.15) compared with placebo. Minor adverse 
events were common in trials (78% of patients reporting 'any' adverse event), while 
serious adverse events and deaths were rare. A reduction in creatinine clearance was 
noted in some trials that returned to baseline upon discontinuation of study drug. No 
deaths occurred that were attributable to PrEP. 
Eleven trials measured changes in sexual behaviour. Studies showed either no 
change in condom use throughout the duration of the study (n=4 studies) or 
increases in condom use (n=4 studies). There was no difference in condom use 
between intervention and control arms. Six studies showed no change in the number 
of sexual partners throughout the duration of the study, four studies showed a slight 
reduction in number of sexual partners and one showed an increase. There was no 
difference between intervention and control arms. 
Five studies recorded changes in the incidence of STIs; no studies reported an 
increase in STIs or a between-group difference in STI diagnoses. Therefore, it cannot 
be concluded from RCT evidence to date that PrEP is associated with an increased 
risk of STIs. Of note, findings from placebo-controlled trials of PrEP do not permit 
conclusions to be drawn regarding the effect of PrEP on sexual behaviour. One open-
label trial demonstrated no difference between the immediate and deferred arms in 
total number of sexual partners or the incidence of STIs, which were high in both 
groups prior to enrolment and during the trial. 
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In a meta-analysis of five trials, patients randomised to receive PrEP who had an 
unrecognised acute HIV infection at enrolment were at increased risk of developing 
resistance mutations to the study drug (RR 3.3, 95% CI: 1.17 to 8.27). Most 
conferred resistance to emtricitabine. This finding highlights the need for careful 
screening of PrEP participants at baseline, with a requirement for a negative 4th 
generation HIV test prior to PrEP initiation. 
9.1.4 Cost-effectiveness and budget impact  
A systematic review was conducted to gather the available evidence on previous 
cost-effectiveness studies. Seventeen studies were identified. Overall, the evidence 
demonstrated that when PrEP is targeted at MSM at substantial sexual risk of HIV 
acquisition, it has the potential to be cost-effective and potentially cost-saving, 
provided medication adherence is high. In general, estimates of cost-effectiveness 
were dependent on the efficacy of PrEP, incidence of HIV, the cost of PrEP and 
lifetime cost of HIV. Due to substantial sociodemographic and cost differences 
between countries, no study was directly applicable to the Irish setting. Additionally, 
many studies investigated the cost-effectiveness of PrEP medication alone and not as 
part of an overall holistic programme. Therefore, a de novo economic evaluation was 
necessary to estimate the cost-effectiveness and budget impact of introducing a PrEP 
programme in Ireland. 
An original state transition Markov model was developed to compare the costs and 
consequences of providing a PrEP programme in Ireland compared with no PrEP 
being available. The model is a closed cross-sectional population model that tracks 
the entire population of Irish HIV-uninfected MSM at the outset of the simulation 
(2018) and follows these men for their lifetime. 
Monte Carlo simulation was performed over the course of 10,000 replications to 
derive estimates of the costs and consequences of implementing a PrEP programme, 
with parameters sampled from their range of plausible values in each replication. In 
the base case, PrEP is cost saving, with an incremental cost-effectiveness ratio 
(ICER) of -€2,735 (95% CI: -€16,486 to €21,585) per quality-adjusted life year 
(QALYs) gained over the cohort’s lifetime. A PrEP programme dominates not having a 
PrEP programme; that is, it is more effective and less costly. The negative value 
arises due to PrEP being cost saving relative to not having a PrEP programme.  
Univariate deterministic sensitivity analysis was carried out to identify how sensitive 
these results are to changes in the input parameters. The results are robust to 
considerable variations in the main assumptions and plausible parameter values. 
PrEP effectiveness was the main driver of cost-effectiveness in the model. PrEP is 
cost saving when adherence-related effectiveness is 60% or more. At an 
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effectiveness of 44% (reported in the iPrEX RCT, the lowest effectiveness recorded 
among MSM), the ICER is €4,711/QALY (highly cost-effective).The ICERs were also 
sensitive to key cost parameters, including the cost of HIV care and the cost of PrEP. 
However, PrEP was still considered cost saving over a range of plausible costs. 
Two-way sensitivity analysis was carried out on the proportion of MSM at high risk 
and the uptake rate for PrEP. PrEP becomes more cost saving as either parameter 
increases. PrEP also becomes more cost saving when event-based dosing is used. In 
the scenario where 50% of PrEP recipients follow event-based dosing, the ICER 
decreases to -€4,594 (95% CI: -€20,158 to €14,150). 
The key strength of this analysis was its simplicity in design, transparency and ease 
of interpretation by decision-makers. Additionally, the movement of individuals 
between risk groups was tracked, and the time horizon (60 years) was adequate to 
capture all costs and benefits accrued over the cohort’s lifetime. Extensive sensitivity 
and scenario analyses were used to test a range of model assumptions and 
parameter uncertainties; in no case did the uncertainty alter the interpretation of the 
findings. In general, consistent with the approach advocated in HTA guidelines, 
conservative values were adopted for parameters, that is, values that bias against 
PrEP. It is, therefore, likely that the ICER may be lower than estimated here. 
However, a limitation of this design is that it does not incorporate dynamic 
transmission elements, which would allow the quantification of the benefit of PrEP on 
the wider HIV epidemic in Ireland, including the benefits for those not given PrEP 
(the reduction of onward transmission of HIV). Therefore, there is an 
underestimation of the total benefit. Nevertheless, as only 2% of Irish MSM were 
given PrEP in this model, the likely indirect impact of the PrEP programme would be 
limited. 
An open Markov cohort model was developed to assess the incremental budget 
impact of introducing a national PrEP programme over a time horizon of five years. 
The mean number of people estimated to join the programme in year one is 1,705 
people (95% CI: 617 to 3,452) based on model calibration to the observed number 
who enrolled in Scotland’s national programme. The incremental budget impact of 
the PrEP programme is €1.5m in the first year (95% CI: €0.5m to €3m) and €5.4m 
over five years (95% CI: €1.8m to €11.5m).  
Approximately 71% of the total programme costs relate to PrEP medication costs. On 
average, 173 HIV infections are estimated to be averted over the course of the first 
five years in the base case analysis. Deterministic sensitivity analysis revealed that 
the parameters that determined the number of participants in the programme (such 
as PrEP eligibility and uptake rate) had the greatest impact on the incremental 
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budget.  
Extending the budget impact analysis beyond five years, the yearly incremental 
budget impact becomes cost saving by Year 8 and the aggregate budget impact 
becomes cost saving (‘break even’ point) by Year 14 (all programme and medication 
costs will have been recouped) relative to no PrEP. 
9.1.5 Organisational and ethical issues 
PrEP is available in at least 49 countries worldwide, with 12 countries providing PrEP 
through national programmes. In Ireland, there is no formal national PrEP 
programme. Access to components of the proposed programme (that is, screening, 
testing and counseling) is currently provided on an ad hoc basis through public STI 
clinics and primary care providers. PrEP medications are paid for out-of-pocket and 
sourced through community pharmacies or online. 
There are a number of mechanisms through which PrEP medications could be 
provided to patients. To be consistent with the care and management of other 
infectious diseases and to prevent the acquisition and onward spread of HIV, it is 
proposed that PrEP medications provided through a PrEP programme would be 
provided free of charge. The mechanism of reimbursement of PrEP will depend on 
how patients will obtain the medication, either directly from clinicians at PrEP clinic 
appointments, from hospital pharmacies linked to PrEP clinics and or from 
community pharmacies. The feasibility of these alternatives will need to be explored 
within the context of the existing legislation. Ensuring that the system of dispensing 
PrEP is safe, sustainable and convenient for patients will promote an environment 
which supports good adherence. 
There are 23 public STI clinics in 16 counties in Ireland. The primary barriers to 
introducing a PrEP programme are staffing and infrastructural issues. Staff shortages 
were cited by all 18 public STI clinics in a recent survey, with many services also 
limited due to the lack of availability of clinic space and time. A significant investment 
in STI services is required for a national PrEP programme to ensure a safe and 
sustainable service. Without investment in STI services, sub-optimal delivery of a 
PrEP programme could result in inequitable access to care and poor medication 
adherence and monitoring, leading to treatment-resistant HIV infections and 
disruption of core STI clinic services with increased wait time for non-PrEP attendees.  
As with any new technology, there are many ethical issues to consider prior to the 
implementation of a PrEP programme. Of concern to clinicians and public health 
professionals is the potential rise in STIs (other than HIV) due to ‘risk compensation’ 
(an increase in condomless sex based on a decreased perception of the likelihood of 
acquiring HIV) in PrEP users. Also of concern is the development of resistance 
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mutations in individuals who start PrEP with unrecognised HIV infection at baseline 
or in those who acquire HIV while not properly adherent to PrEP. The risk and impact 
of increasing STI rates and drug resistance mutations can be mitigated by careful 
screening for HIV at baseline and follow-up and frequent testing for other STIs along 
with advice on safer sex. 
Many of the individuals who stand to benefit most from PrEP are from vulnerable 
groups who have unique healthcare needs and are subject to stigma and 
discrimination. Stigmatisation of PrEP users may serve as a barrier to uptake in 
certain individuals. Additionally, stigmatisation of marginalised at-risk groups at a 
societal level may also undermine the political will to make PrEP available to these 
populations. Other barriers to PrEP uptake include a low perceived risk of contracting 
HIV, a lack of awareness of PrEP, reluctance to take medication and concerns about 
side effects and the opportunity cost and inconvenience of follow-up visits. A further 
barrier to the implementation of PrEP may be a lack of training of healthcare workers 
in relation to how to discuss sexual health with patients from sexual minority groups. 
Recognition of the psychological dynamics of risk perception, sexual decision-making, 
and treatment adherence in education programmes are necessary to enable 
healthcare professionals to engage patients in taking charge of their sexual health. 
9.2 Summary 
 High quality RCT evidence was retrieved that demonstrated PrEP is safe and 
highly effective at preventing HIV infection in MSM and in HIV-uninfected 
partners of serodifferent couples. PrEP effectiveness is highly dependent on 
adherence. 
 Trial evidence does not suggest that PrEP alters sexual behaviour or leads to a 
rise in STI diagnoses. Findings from placebo-controlled trials of PrEP do not 
permit conclusions to be drawn regarding the effect of PrEP on sexual 
behaviour, however. One open-label trial demonstrated no difference between 
the immediate and deferred arms in total number of sexual partners or the 
incidence of STIs, which were high in both groups prior to enrolment and 
during the trial. 
 An original economic model was developed to estimate the costs and 
consequences of providing a holistic national PrEP programme comprising 
daily oral PrEP administration. PrEP was found to be more effective and less 
costly than not providing PrEP. The results are robust to considerable 
variations in the main assumptions and plausible parameter values. 
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 The mean number of people estimated to join a potential PrEP programme in 
Year 1 is 1,705 people (95% CI: 617 to 3,452).  
 The incremental budget impact of a national PrEP programme is €1.5m in the 
first year (95% CI: €0.5m to €3m) and €5.4m over five years (95% CI: €1.8m 
to €11.5m). Approximately 71% of the total programme costs relate to PrEP 
medication costs. In the base case analysis, 173 HIV infections are estimated 
to be averted over the course of the first five years. 
 Extending the BIA beyond five years, the yearly incremental budget impact 
becomes cost saving by Year 8 and the aggregate budget impact becomes 
cost saving (‘break even’ point) by Year 14. 
 The primary barriers to introducing a PrEP programme are staffing and 
infrastructural issues. Staff shortages were cited by all 18 public STI clinics in 
a recent survey with many services also limited due to the lack of availability 
of clinic space and time.  
 A significant investment in STI services is required for a national PrEP 
programme to ensure a safe, sustainable and equitable service. 
9.3 Conclusion 
The successful implementation of a national PrEP programme would be safe, 
effective and cost-saving over the medium to long term in Ireland.   
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